MDMA : binge use and functional outcomes in the rat by Rodsiri, Ratchanee
Rodsiri, Ratchanee (2009) MDMA : binge use and 
functional outcomes in the rat. PhD thesis, University of 
Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/13386/1/508246.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
MDMA - BINGE USE AND FUNCTIONAL 
OUTCOMES IN THE RAT 
RATCHANEE RODSIRI 
BSc. Pharm. (Hons.) 
Institute of Neuroscience 
School of Biomedical Sciences 
University of Nottingham 
MED1CAL L ' B R A R ~ ~
QUEENS MEDICAl CENTRE 
Thesis submitted to the University of Nottingham for the degree 
of Doctor of Philosophy 
MAY 2009 
CONTENTS 
PAGE 
Acknowledgement 
Publications 
Abstract 
Abbreviations 
List of figures 
List of tables 
CHAPTER 1: General introduction 
1.1 S-Hydroxytryptamine (S-HT; Serotonin) 
1.1.1 Synthesis and metabolism of 5-HT 
1.1.2 5-HT receptors 
1.1.3 5-HT pathways in the eNS 
1.2 Dopamine 
1.2.1 Synthesis and metabolism of dopamine 
1.2.2 Dopamine receptors 
1.2.3 Dopaminergic pathways in the CNS 
1.3 3,4-Metbylenedioxymetbampbetamine (MDMA or 'ecstasy') 
1.3.1 The acute effects of MDMA in experimental animals 
1.3.2 The acute effects ofMDMA in humans 
1.3.3 The long-term effects of MDMA in experimental animals 
1.3.4 The long-term effects of MDMA in humans 
1.3.5 Possible mechanisms ofMDMA-induced neurotoxicity 
1.4 Learning and memory 
1.5 Involvement of S-HT in learning and memory 
1.6 Involvement of dopamine in learning and memory 
1.7 Effects of MDMA on learning and memory 
1.7.1 Evidence from human studies 
1.7.2 Evidence from animal studies 
1.8 Novel object discrimination 
1.9 Objectives 
ii 
iii 
v 
vii 
xi 
2 
3 
7 
9 
11 
13 
16 
20 
29 
32 
34 
36 
46 
47 
50 
52 
53 
55 
58 
CHAPTER 2: The acute effect of single low doses of MDMA 
on novel object discrimination 
PAGE 
2.1 
2.2 
2.3 
2.4 
Introduction 
Materials and methods 
Results 
Discussion 
CHAPTER 3: The acute effects of repeated administration of 
low doses of MDMA on locomotion, body temperature 
and extracellular 5-HT in the hippocampus 
3.1 Introduction 
3.2 Materials and methods 
3.3 Results 
3.4 Discussion 
CHAPTER 4: The long-term effects of repeated MDMA 
administration on memory and 5-HT neurotoxicity 
61 
62 
74 
80 
84 
86 
101 
111 
4.1 Experiment 1: Acute effects of repeated MDMA administration to 
singly housed rats on locomotion and body temperature and the 
long-term effects on novel object discrimination and neurotoxicity 
4.1.1 Introduction 118 
4.1.2 Materials and methods 
4.1.3 Results 
4.1.4 Discussion 
4.2 Experiment 2: Acute effects of group housing on the MDMA-
120 
124 
140 
induced change in body temperature and the long-term effects on 
novel object discrimination and neurotoxicity 
4.2.1 Introduction 
4.2.2 Materials and methods 
4.2.3 Results 
4.2.4 Discussion 
146 
147 
149 
160 
CHAPTER 5: Influence of brain tyrosine availability on PAGE 
MDMA-induced 5-HT neurotoxicity 
5.1 Introduction 164 
5.2 Acute effects of tyrosine depletion on brain tyrosine, 
dopamine, 5-HT and their metabolite levels 
5.2.1 Materials and methods 166 
5.2.2 Results 174 
5.3 Effects of tyrosine depletion on MDMA-induced 5-HT 
neurotoxicity 
5.3.1 Materials and methods 183 
5.3.2 Results 185 
5.4 Discussion 193 
CHAPTER 6: General discussion 
6.1 Introduction 198 
6.2 The interpretation of animal data to humans 200 
6.3 Does low dose MDMA administration produce long-term 
5-HT neurotoxicity? 201 
6.4 Mechanisms for memory impairments produced 
byMDMA 203 
6.5 Summary 204 
References 206 
Appendix I 247 
Appendix II 248 
Appendix III 249 
Appendix IV 250 
ACKNOWLEDGEMENTS 
I would like to thank my supervisors Professor Charles Marsden and Professor 
Kevin Fone for their kindly support throughout my PhD; without their help and 
patience much of what I have achieved would not have been possible. I also 
wish to thank Professor Richard Green for his knowledge of MDMA and his 
kindly guidance during my study. Thanks to the School of Biomedical Sciences 
for allowing me to use the department facilities. 
I also wish to thank many people within School of Biomedical Sciences, Karen 
Swift for her HPLC expertise, Clare Spicer for her help with microdialysis 
technique, Professor Fran Ebling for radiotelemetry technique, Ian Topham for 
helping with all behavioural tests and all the staff who have been a great help 
during my study. 
Special thanks to my family especially my parents for their understanding and 
support and my sister who inspired me to always do my best. Thanks to all 
academic staff in The Faculty of Pharmaceutical Sciences, Chulalongkom 
University especially Associate Professor Boonyong and Associate Professor 
Mayuri Tantisira for their kindly advice and support before and during my 
PhD. 
Finally thanks to the Royal Thai Government under the program "Strategic 
Scholarships for Frontier Research Network" for funding and opportunity. 
PUBLICATIONS 
Abstract 
Rodsiri R, Fone K.C.F., Green A.R, Marsden C.A. (2007) Tyrosine depletion 
fails to alter MDMA-induced loss of serotonin in the rat brain. Journal of 
Psychopharmacology, 21 (7) (Supplement), MG09, A31. 
Rodsiri R, Marsden C.A., Fone K.C.F., Green A.R (2008) Changes in activity 
and temperature fail to correlate with 5-HT release following repeated MDMA 
administration in rats. Journal of Psychopharmacology, 22(5) (Supplement), 
A65, A81. 
Rodsiri R., Marsden C.A., Fone K.C.F., Green A.R. (2008) Changes in activity 
and temperature fail to correlate with 5-HT release following repeated MDMA 
administration in rats. Fundamental and Clinical Pharmacology, 22 
(Supplement 2), SCP028, P 124. 
Papers 
Rodsiri R., Green A.R., Marsden C.A., Fone K.C.F. (2009) Effect of acute 
brain tyrosine depletion on MDMA-induced changes in brain 5-HT (Journal of 
Psychopharmacology accepted with minor correction) 
ii 
ABSTRACT 
3,4-Methylenedioxymethamphetamine (MDMA) use has increased 
dramatically and more intensive patterns of use such as binging have become 
common. This thesis pays particular attention to the translation of animal data 
to humans by examining low doses and binge type repeated regimen of 
MDMA in the rat. The functional effects especially acute and long-term effects 
on memory have been investigated together with the measurement of changes 
in 5-HT and dopamine to investigate the possible link of these 
neurotransmitters and the functional effects of MDMA. 
The acute effect of single low doses of MDMA on memory was initially 
examined and it was shown that MDMA (3 mg/kg) acutely disrupted novel 
object discrimination when given 30 min before the test. However there was no 
change in 5-HT and dopamine in the hippocampus, striatum and frontal cortex 
150 min after MDMA administration. The combined techniques of 
radiotelemetry and in vivo microdialysis were used to examine effects of 
'binge-type' repeated low dose MDMA administration (3 or 6 mglkg i.p. x 3 
every 2 h). Locomotor activity, body temperature and 5-HT release in the 
hippocampus were simultaneously measured in the same animal during 
MDMA administration. MDMA (3 x 6 mglkg) increased locomotor activity 
after each injection. In addition MDMA (3 x 3 mg/kg) produced hypothermia 
following each injection while MDMA (3 x 6 mg/kg) changed 
thermoregulation as it decreased body temperature after the fIrst injection and 
then increased body temperature after the second to a maximum of + 1.3 °C 
after the third injection. Both 'binge' doses of MDMA however increased 
extracellular 5-HT in the hippocampus after each injection and there was no 
correlation between 5-HT release in the hippocampus and changes either in 
locomotor activity or body temperature. 
The long-term effect of repeated administration oflow doses ofMDMA (3 or 6 
mg/kg i.p. x 3 every 2 h) on memory was investigated using novel object 
discrimination 2 weeks after treatment. To imitate the single housing condition 
III 
used in radiotelemetry experiments, rats were individually housed during drug 
treatment. MDMA (3 x 6 mglkg) caused impairment of novel object 
discrimination but there was no change in 5-HT, dopamine and their 
metabolites in the hippocampus, striatum and frontal cortex 2 weeks after 
MDMA treatment suggesting no contribution of either 5-HT or dopamine loss 
to the MDMA-induced memory impairment. 
The effects of housing conditions on MDMA-induced changes in body 
temperature and subsequent 5-HT neurotoxicity were determined. Group 
housed rats showed a similar pattern of changes in body temperature to singly 
housed rats measured by radiotelemetry following MDMA (3 x 6 mg/kg) 
suggesting no effect of the housing condition on MDMA-induced changes in 
body temperature. MDMA (3 x 6 mg/kg) given to group housed rats however 
produced loss of hippocampal 5-HT 2 weeks after treatment indicating that 
MDMA-induced hyperthermia is not an essential factor for MDMA-induced 
neurotoxicity. 
The influence of tyrosine on MDMA-induced 5-HT neurotoxicity was 
determined by depletion of brain tyrosine availability by giving a tyrosine-free 
amino acid mixture (1 glkg twice 1 h apart) to Dark Agouti rats before and 
after MDMA administration (12.5 mglkg i.p.). A small increase of tyrosine in 
the hippocampus and striatum occurred in rats treated with MDMA alone. 
Although the tyrosine-free amino acid mixture decreased tyrosine in the 
hippocampus and striatum by more than 50% 2 h after administration, this did 
not protect against MDMA-induced acute hippocampal and striatal 5-HT 
depletion and long-term 5-HT loss in the hippocampus indicating no effect of 
tyrosine on MDMA-induced 5-HT neurotoxicity. 
Overall the results of the present study provide extensive evidence for acute 
and long-term memory impairments following single and 'binge-type' repeated 
low dose MDMA administration and that these effects may translate effectively 
to human conditions. The memory impairments appeared to have no link with 
5-HT and dopamine thus it is important to focus on other factors involved in 
the mechanism ofMDMA-induced memory impairments. 
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CHAPTER! 
GENERAL INTRODUCTION 
CHAPTER I: General introduction 
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a commonly used 
drug of abuse. MDMA produces acute 5-HT and dopamine release in 
experimental animals and causes selective 5-HT neurotoxicity in rats and 
possibly in human users. There is growing evidence for learning and memory 
impairments in MDMA users. The translation of effects of MDMA in animal 
studies to human has been widely debated as the typical doses used to produce 
neurotoxicity are much greater than those used by humans. The aim of this 
thesis is to investigate the effects of MDMA on memory with the focus on 
using doses in the rat that translate to single and 'binge type' repeated low 
doses of MDMA used by humans. In this chapter 5-HT and dopamine, the 
neurotransmitters currently most associated with MDMA, are reviewed 
followed by discussion of MDMA and its acute and long-term pharmacological 
and functional effects. This includes consideration of the possible association 
between the effects of MDMA on learning and memory and their link with 5-
HT and dopamine. Finally the method used to investigate memory in this 
thesis, novel object discrimination, is described. 
1.1. 5-Hydroxytryptamine (5-HT; Serotonin) 
1.1.1 Synthesis and metabolism of5-HT 
5-hydroxytryptamine (5-HT) or serotonin is an indoleamine neurotransmitter 
which is synthesized from the essential amino acid tryptophan. Tryptophan is 
competitively transported into the brain via the large neutral amino acid 
transporter (Fernstrom and Wurtmanm, 1972, Wurtmanm and Melamed, 1981). 
The synthesis of 5-HT occurs in two steps (Figure 1.1). Firstly, tryptophan is 
2 
CHAPTER I: General introduction 
converted to 5-hydroxytryptophan (5-HTP) by the rate-limiting enzyme 
tryptophan hydroxylase. The 5-HTP is then decarboxylated by the enzyme L-
aromatic amino acid decarboxylase (AADC) to form 5-hydroxytryptamine (5-
HT) (Figure 1.1). 5-HT is concentrated in presynaptic storage vesicles by the 
vesicular monoamine transporter protein (VMA T). Following release into the 
synaptic cleft, 5-HT may bind to 5-HT receptors or is taken up again by the 
presynaptic serotonin reuptake transporter (SERT). When returned to the 5-HT 
terminal, 5-HT is either transferred back into presynaptic storage vesicles or 
metabolized by the mitochondrial enzyme monoamine oxidase (MAO) and 
aldehyde dehydrogenase to form 5-hydroxyindole acetic acid (5-HlAA) 
(Barnes and Sharp, 1999) (Figure 1.1). 
1.1.2 5-HT receptors 
Fourteen subtypes of 5-HT receptors have been identified, each of which is 
characterized by a unique structure, pharmacology, pattern of expression and 
signal transduction pathway (see review Barnes and Sharp, 1999, Green, 2006, 
Hoyer et aI., 1994, 2002). The main subgroups of 5-HT receptors have been 
named 5-HTI, 5-HT2, 5-HT3, 5-HT4, 5-HTs, 5-HT6 and 5-HT7. The 5-HT 
receptor families are mostly G-protein coupled receptors but 5-HT3 is a ligand-
gated ion channel. The G protein coupled transmembrane receptors can be 
divided into three types; G-protein coupled to the inhibitory adenylyl cyclase 
(Gi) (5-HTIA,B,D,E,F), G-protein coupled to phosphoinositol hydrolysis (Gq) (5-
HT2A,B,c) and G-protein coupled to the excitatory adeny1y1 cyclase (Gs) (5HT4, 
5-HT6 and 5-HT7). Electrophysiological studies have demonstrated that 5-
HTIAlIB/ID/IFJIF receptor activation produces hyperpolarization whereas 5-
3 
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HT2N2BI2C, 5-HT3, 5-HT4 and 5-HT7 receptors elicit depolarization (Hoyer et al 
2002). 5-HT receptor subtypes, their distribution in the brain and functions 
summarised in Table 1.1. 
L-Tryptophan 
T"pt ..... .,..,:' .... (TPH) I 
N 
H 
5-Hydroxytryptophan (5-HTP) 
L-Aromatlc amino acid 
decarboxylase (AADCJ 
OH 
OH 
5-Hydroxytryplamlne (5-HT) 
UOIIOIf/JVne oxid_ (UAO), 1 
Aldehyde dehydrogenaae 
H 
H 
OH 
5-HydroxyIndoIe acid (5-HIM) 
Figure 1.1 The schematic diagram of the metabolic pathway for serotonin 
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Table 1.1 Serotonergic receptor subtypes, distribution in the central nervous system 
(CNS) and behavioural responses (Alex and Pehek, 2007, Barnes and Sharp, 1999, 
Hoyer et aI., 1994, 2002, King et aI., 2008, Perez-Garcia et aI., 2006). 
Subtype G- Localisation in eNS Behavioural responses 
protein (agonism) 
5-HT, 
5-HT 1A G; The raphe nuclei (autoreceptor), Serotonin syndrome 
limbic system, hippocampus, Hypothermia 
lateral septum, cortical areas, Hyperphagia 
hypothalamus, neocortex Anxiolysis 
Sexual behaviour (+) 
Autoinhibition (pre-synaptic) 
Learning and memory 
5-HT 1B G; Basal ganglia, substantia nigra Locomotor activation 
(rodent specific) Hypophagia 
Hypothermia (g.pig) 
Myoclonic jerks (g. pig) 
5-HT ID G; Basal ganglia, substantia nigra, 
nigrostriatal pathway, 
hippocampus, cortex , dorsal 
raphe nuclei (autoreceptor) 
(Guinea pig, pig, calf, monkey, 
human) 
5-htlE G; 
5-htlF G; Hippocampus, cortex (cingulate 
and entorhinal cortices), dorsal 
raphe 
5 
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Subtype G- Localisation in eNS Behavioural responses 
protein (agonism) 
5-HTz 
5-HT2A Gq Cortex, caudate nucleus, Head twitch 
nucleus accumbens, olfactory Wet-dog shake 
tubercle, hippocampus Hyperthermia 
Discriminative stimulus 
5-HT2B Gq Cerebellum, septum, dorsal 
hypothalamus, medial amygdala 
5-HT2c Gq Choroid plexus, cortex, limbic Hypolocomotion 
system (nucleus accumbens, Hypophagia 
hippocampus, amygdale), the Anxiogenesis 
basal ganglia (caudate nucleus, Penile erection 
substantia nigra) 
5-HT3 Ligand- Brain stem nuclei, spinal cord, Long-term potentiation (L TP) (-) 
gated cortex, hippocampus Antagonism: 
channel Anti-emetic 
Anxiolysis 
Cognition (+)? 
Locomotion (-) ? 
Reward (-)? 
S-HT4 G. Substantia nigra, striatum, Anxiolysis 
nucleus accurnbens, Anxiogenesis (antagonist) 
hippocampus Cognition (+) 
5-HT!I 
5-htsA G. Cerebellum, cerebral cortex, 
hippocampus, hypothalamus, 
thalamus, pons, striatum, 
medulla 
5-htsB unknown 
6 
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Subtype G- Localisation in eNS Behavioural responses 
protein (agonism) 
S-HT6 Gs Striatum, olfactory tubercle, Learning and memory 
cerebral cortex, hippocampus, 
nucleus accumbens 
S-HT, Gs Thalamus, hypothalamus, 
hippocampus Circadian rhythms 
Depression? 
Learning and memory ? 
1.1.3 5-HTpathways in the eNS 
The cell bodies of serotonin neurons originate in the raphe nuclei of the brain 
stem (Figure 1.2). The caudal raphe nuclei, including the raphe magnus, 
pallidus and raphe obscures project towards the spinal cord and brain stem and 
fonn the descending serotonergic systems. Manipulation of the descending 
serotonergic neurons may affect spinal processing of nociceptive input and 
motor functions (Berge and Ogren, 1984, Jacobs et aI., 2002). The dorsal raphe 
nucleus, median raphe nucleus and the nucleus pontis are the sources of 
serotonergic innervations of the forebrain, represent the ascending serotonergic 
systems (Azmitia and Segal, 1978, Vertes, 1991). The serotonergic neurons 
originated in the dorsal raphe mainly innervate forebrain structures with a 
lateral location such as amygdala, striatum, lateral septum, frontal cortex and 
ventral hippocampus while the projections from median raphe mainly innervate 
midline structures of forebrain including the dorsal hippocampus and the 
medial septum (Azmitia and Segal, 1978, Vertes, 1991, 1999) (Figure 1.2). 
7 
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Thalamus 
Striatum j,..\ __ -+1 ~ - - . . . . . _ _
Neocortex 
Hypothalamus 
Amygdala ----'.-
Olfactory and ./ 
entorhinal cortices /' 
Hippocampus 
To hippocampus 
- ; ; ; ~ : r - - , . ; : : : » ' - ~ , - - - - - f f Nucleus \lnearis 
~ t - - - - - ' ~ - - ' i : - - - Dorsal raphe nucleus 
~ \ - - - - - ~ : - - - - + - - Medial raphe nucleus 
, - - - l ~ - - - : - - - - ' l - " ' r r - ' ' Nucleus raphe ponlis 
. . . . . . . . , . f I f f - - - - : ~ = + - - Nucleus raphe rnagnus 
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Figure 1.2 Serotonergic pathways in A: human brain (Nestler et al ., 2001 P 195) and 
B: rat brain (Ogren et aI. , 2008). A: In human brain the cell bodies of serotonergic 
neurons originate in the brain stem nuclei which are in rostral and caudal clusters. The 
rostral nuclei, which include the nucleus Iinearis, dorsal raphe, medial raphe and raphe 
po ntis, fonn the ascending pathway to the forebrain and the cerebellum. The caudal 
nuclei , which comprise the raphe magnus, raphe pallidus and raphe obscuris, project 
the axons to the cerebellum, brain stem and spinal cord. B: The serotonin pathways in 
rat brain are similar to human. The following abbreviations were used-DRN: dorsal 
raphe nucleus, MRN: median raphe nucleus, RPN: nucleus raphe pontis, RM: nucleus 
raphe magnus, RO: nucleus raphe obscurus, RP: nucleus raphe pallidus, cx: cerebral 
cortex, hpc: hippocampus, ob: olfactory bulb, s: septum, th: thalamus, ht: 
hypothalamus, oc: optic chiasm, pit: pituitary, cb: cerebellum, sc: spinal cord. 
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1.2. Dopamine 
1.2.1 Synthesis and metabolism of dopamine 
Dopamine is one of the three established catecholamine neurotransmitters 
which are synthesized from the amino acid precursor tyrosine. Tyrosine is 
actively transported into the brain via the large neutral amino acid transporter 
(Fernstrom and Wurtmanm, 1972, Grahame-Smith and Parfitt, 1970). In 
dopaminergic neurons tyrosine is hydroxylated by the enzyme tyrosine 
hydroxylase to form dihydroxyphenylalanine (DOPA). Tyrosine hydroxylase is 
the rate-limiting enzyme in dopamine synthesis and as such controls the 
neuronal concentration of dopamine. DOPA is then decarboxylated by the 
enzyme L-aromatic amino acid decarboxylase (AADC), the same enzyme that 
converts S-HTP to 5-HT, to form dopamine (Figure 1.3). Dopamine is 
synthesized in the nerve terminal cytoplasm and is kept in storage vesicles 
following its inward transport by the vesicular monoamine transporter protein 
(VMA T). Dopamine released into the synaptic cleft may bind to dopamine 
receptors or be reuptaken into the dopaminergic terminal via the dopamine 
reuptake transporter. Dopamine is degraded by the mitochondrial monoamine 
oxidase (MAO) and catechol-o-methyl transferase (COMT) to homovanillic 
acid (HV A) (Figure 1.3). 
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Figure 1.3 The schematic diagram of the metabolic pathway for dopamine. 
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1.2.2 Dopamine receptors 
Brain dopaminergic receptors were originally divided into DJ and D2 subtypes 
on the basis of pharmacological and biochemical evidence (Kebabian and 
CaIne, 1979, Spano et ai., 1978). Following the introduction of gene cloning 
procedures, three further dopamine receptor subtypes were characterized called 
D3, D4 and Ds (see review Missale et ai., 1998, Sokoloff and Schwartz, 1995). 
The dopaminergic receptors were classified as Dt-like and D2-like based on the 
signalling events following G-protein coupling. The Dt-like receptors, which 
include Dt and D5 receptors, couple to Gs and activate adenyl cyclase. The D2-
like receptors, which comprise D2, D3 and D4 receptors are Gi-coupled 
receptors and inhibit adenyl cyclase (Missale et ai., 1998). Dopaminergic 
receptors in the brain are widely distributed and involved in the control of 
locomotion, cognition, emotion and affected neuroendocrine secretion. Table 
1.2 reviews the dopaminergic receptor SUbtypes, their distribution in the CNS 
and functions. 
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Table 1.2 Dopaminergic receptor subtypes, distribution in the CNS and behavioural 
responses (Holmes et aI., 2004, Missale et aI., 1998, Oak et aI., 2000). 
Subtypes G-
protein 
Ds 
Localisation in the eNS 
Striatum, 
tubercle, 
pallidus, 
amygdala, olfactory 
hippocampus, globus 
hypothalamus, septum, 
substantia nigra, cerebral cortex 
Behavioural responses 
Agonism: 
Locomotion (+) 
Rewarding (+) 
Learning and memory (+) 
Hippocampus, prefrontal cortex, basal DsR Knockout mice: 
ganglia, thalamic and hypothalamic Learning and memory ? 
nuclei Depression? 
The mesencephalic dopamine cell Agonism: 
body regions (autoreceptor), striatum, 
olfactory tubercle, nucleus 
Locomotion (+) 
Rewarding (+) 
accumbens, prefrontal, cingulated, Learning and memory (+) 
temporal, and enthorhinal cortex, Hypothermia 
septal, amydala, the granule cells of Mediate an impairment of 
the hippocampal formation, prepulse inhibition following 
hypothalamus, substantia nigra pars amphetamine 
compacta, ventral tegmental area 
12 
Pituitary hormone synthesis 
and secretion (-) 
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Subtypes G- Localisation in the CNS Behavioural responses 
protein 
Dz-Iike G; 
0 3 Limbic areas, nucleus accumbens, Agonism: 
olfactory tubercle, islands of Calleja, Locomotion (-) 
substantia nigra pars compacta, ventral Anxiolytic effect 
tegmentral area, hippocampus, septal Rewarding? 
Learning and memory (-) 
0 4 Prefrontal cortex, amygdala, 04R Knockout mice: 
hippocampus, hypothalamus Hyperactivity 
Anxiogenic effect? 
1.2.3 Dopaminergic pathways in the eNS 
There are three dopaminergic systems in the eNS; the nigrostriatal, 
mesolimbocortical and tuberoinfundibular dopaminergic systems (Figure 1.4). 
The three dopaminergic nuclei in the brain originate in the substantia nigra pars 
compacta, ventral tegmental area and the arcuate nucleus. The dopaminergic 
nuclei of the substantia nigra pars compacta reside in the ventral midbrain and 
project to the striatum, to form the nigrostriatal dopamine system. The 
striatum, which is a component of the basal ganglia, regulates motor control 
and the learning of motor programs and habits. Dopamine released by the 
nigrostriatal system plays a role in the complex circuitry of the basal ganglia 
and is required for voluntary movement (Figure 1.4). 
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The dopaminergic nuclei of the ventral tegmental area, found in the ventral 
midbrain, project to limbic structure including the nucleus accumbens, septum, 
olfactory tubercle and amygdala and also innervate prefrontal cortex, cingulate 
and entorhinal cortices and are known as the mesolimbocortical dopamine 
systems. The mesolimbocortical dopamine system plays an essential role in 
cognition which will be discussed later in section 1.6. In addition the 
dopaminergic connections between the ventral tegmental area and the nucleus 
accumbens appear to mediate the reinforcing or rewarding properties of drugs 
of abuse (Figure 1.4). 
Finally the dopaminergic nuclei of the hypothalamic arcuate nucleus release 
dopamine that affects the pituitary gland and constitute the tuberoinfundibular 
dopamine system which controls prolactin release from the anterior pituitary 
(Figure 1.4). 
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Dopamine system 
Striatum 
Figure 1.4 Dopaminergic systems in human brain (modified from Bear et al. , 2006 p 
682). There are three dopaminergic pathways in the brain . Firstly (1) the nigrostriatal 
dopamine system, cell bodies originate in the substantia nigra and project the axons to 
the striatum. Secondly (2) the mesolimbocorlical dopamine system, cell bodies 
originate in the ventral tegmental area and project the axons to limbic structures 
including the nucleus accumbens, prefrontal cortex and cingulate cortex. Finally (3) 
the tllberoinfundiblllar dopamine system, dopaminergic cells of the hypothalamic 
arcuate nucleus release dopamine that affects the pituitary gland. 
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1.3. 3, 4-Methylenedioxymethamphetamine (MDMA or 'ecstasy') 
3,4-Methylenedioxymethamphetamine (MDMA or 'ecstasy') is a 
methamphetamine derivative which has a methylenedioxy (-O-CH2-0-) group 
attached to the position 3 and 4 of the aromatic ring of methamphetamine 
(Figure 1.5). In this respect, MDMA shares a structural similarity with the 
hallucinogen, mescaline. MDMA, however, produces a unique psychological 
profile which includes euphoria and a feeling of closeness to people. It has 
therefore been classified as an 'entactogen' meaning 'inducing a feeling of 
touch with the world within' (Nichols, 1986). 
MDMA was first synthesized and patented in 1912 by the Gennan 
phannaceutical company Merck as a precursor for therapeutically active 
compounds and was not intended for therapeutic use (Freudenmann et aI., 
2006). The recreational uses of MDMA firstly emerged in the United States in 
the mid 1970s. MDMA became popular as a recreational drug in the UK from 
the 1980s in club dances and parties. In 1977 the UK Home Office listed 
MDMA as a Class A drug under the Misuse of Drug Act (1971), indicating that 
it had no medicinal use but serious abuse potential. 
Like other illicit drugs prepared by illegal manufacturers, ecstasy tablets come 
in different colours, shapes and sizes with doses and purities varying greatly. 
Several surveys have investigated the composition of ecstasy tablets and 
reported that most ecstasy tablets contain MDMA and often other ring-
substituted amphetamine derivatives such as 3,4-methylenedioxyamphetamine 
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(MDA) and 3,4-methylenedioxy-N-ethylamphetamine (MDEA) (Cole et aI., 
2002, Parrott, 2004) (Figure 1.5). During the late 1990s, the proportion of 
MDMA in ecstasy tablets increased to 80-100% (Cole et aI., 2002, Parrott, 
2004). In 2005, EU surveys revealed that the typical ecstasy tablet contains 
30-80 mg of MDMA (EMCDDA, 2007). 
MDMA is usually administered by the oral route in humans and often with 
multiple dosing in combination with other substances (Hammersley et aI., 
1999, Parrott et aI., 2000, Scholey et aI., 2004, Winstock et aI., 2001). The 
prevalence of the illicit use of MDMA has increased over the last decade. 
According to a UN World drug Report (2008) it is estimated that 9 million 
people worldwide have taken MDMA (UNDOC, 2008). Approximately 90% 
of young adults who attend 'raves' and nightclubs reported use of MDMA 
(Hammersley et aI., 1999, Winstock et aI., 2001). Although it is claimed that 
MDMA is safer than other drugs of abuse and that acute fatality caused by 
MDMAlecstasy is rare, these do however occur as there were 202 ecstasy-
related deaths in England and Wales between 1996 and 2002 according to the 
National Programme on Substance Abuse Deaths (Schifano et aI., 2003). 
The first descriptions of MDMA hinging in the UK. were in a Scottish study 
from 1993 to 1995 by Hammersley et al (1999). Similar studies of ecstasy use 
in Australia reported that 35% of subjects (n = 329) had 'hinged' on ecstasy in 
the preceding 6 months (Topp et aI., 1999). Winstock et aI (2001) reported the 
levels of typical and binge consumption of ecstasy tablets in the UK. which 
showed an average use of 2.8 tablets per session. A review hy Parrott (2005) 
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suggested that binge use of MDMA boosts the subjective effects of MDMA 
possibly by reducing the tolerance effects of repeated usage. Several studies 
have shown that repeated use of MDMA decreased the desired effects while 
causing an increase in the side effects of MDMA with more experienced 
ecstasy users tending to increase the amount of ecstasy taken compared to 
novice users (Fox et al., 2001, Merill, 1996, Winstock et al., 2001). For 
example Fox et al (2001) showed that the most experienced ecstasy users 
(+500 tablets/lifetime) took an average of 3.7 tablets/occasion while the less 
experienced ecstasy users took 1.8 tablets/occasion. Scholey et al (2004) 
reported that 100% of novice users took 1-2 tablets/occasion while heavy users 
generally took either 3-4 tablets (24%) or more than 4 tablets (14%) on each 
occasion. 
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Methamphetamine 3.4 ,5-Trimethoxyphenethylamine (mescaline) 
3.4-Methylenedioxymethamphetamine (MDMA) 
3.4-Methylenedioxyamphetamine (MDA) 
3,4-Methylenedioxy-N-ethylampbetamine (MDEA) 
Figure 1.5 The chemical structures of methamphetamine, 3,4,5-
trimethoxyphenethylamine (mescaline), 3,4-methylenedioxymethamphetamine 
(MDMA), 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxy-N-
ethylamphetamine (MDEA). 
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1.3.1 The acute effects of MDMA in experimental animals 
Pharmacological effects 
MDMA administration to rats induces an acute and rapid release of 5-HT in rat 
striatum, medial prefrontal cortex and hippocampus, demonstrated by in vivo 
microdialysis (Gough et a1., 1991, Meehan et a1., 2002a, Shankaran and 
Gudelsky, 1999, Yamamoto et a1., 1995) followed by a marked decrease of 5-
HT levels during the fIrst few hours following MDMA administration (Colado 
and Green, 1994, Gough et a1., 1991, Schmidt, 1987). It was suggested that 
MDMA-induced 5-HT release is caused by binding ofMDMA to the serotonin 
reuptake transporter (SERT) with consequent transport into the cytoplasm 
leading to reverse transport of 5-HT into the synapse combined with inhibition 
of 5-HT reuptake (Berger et a1., 1992, Gudelsky and Nash, 1996). Pretreatment 
with the serotonin reuptake inhibitor, fluoxetine, attenuated MDMA-induced 5-
HT release in rat striatum and hippocampus indicating that MDMA-induced 5-
HT release involves a carrier-mediated mechanism (Gudelskyand Nash, 1996). 
In addition MDMA depletes vesicular 5-HT storage by reverse transport of 5-
HT from storage vesicles to the cytoplasm via the vesicular monoamine 
transporter (VMA T) (Partilla et al., 2006). Extracellular 5-HT is further 
elevated by an inhibition of monoamine oxidase (MAO), the enzyme used to 
catabolise 5-HT, by MDMA (Leonardi and Azmitia, 1994). Brain 5-HT levels 
in rats then decrease as MDMA inhibits tryptophan hydroxylase (TPH), the 
rate-limiting enzyme required for 5-HT synthesis (Johnson et aI., 1992, O'Shea 
et aI., 2006, Stone et aI., 1987b). Stone et al (1987) demonstrated that TPH 
activity started to decline in the neostriatum, frontal cortex, hippocampus and 
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hypothalamus within 15 min of MDMA administration. 5-HT levels however 
recover within 24 h after MDMA administration (Schmidt 1987). Figure 1.6 
summarises the effects ofMDMA on 5-HT neurons. 
MDMA exposure also causes an acute release of dopamine in the striatum, 
nucleus accumbens, caudate and hippocampus in rats (Nash and Brodkin, 
1991, Nash and Yamamoto, 1992, Yamamoto and Spanos, 1988) and mice 
(Camarero et aI., 2002, Colado et aI., 2001). It is possible that the increase in 
dopamine release results from MOMA-induced 5-HT release which then 
activates the 5-HT 2A receptor to cause an increase in dopamine synthesis and 
release (Gudelsky and Nash, 1996, Koch and Galloway, 1997, Schmidt et at., 
1994). 
MOMA has also been demonstrated to stimulate norepinephrine (NE) release 
from rat brain slices (Fitzgerald and Reid, 1990) and synaptosomal 
preparations (Rothman et aI., 2001). Because of a lack of in vivo microdialysis 
studies measuring NE release, the effects ofMOMA on NE are unclear (Green 
et aI., 2003). MDMA also produces acute release of acetylcholine in vitro from 
striatal slices (Fischer et aI., 2000). In addition in vivo microdialysis 
demonstrated MDMA-induced acetylcholine release in the prefrontal cortex, 
striatum and hippocampus (Acquas et al., 2001, Nair and Gudelsky, 2005, Nair 
and Gudelsky, 2006). Both dopamine 0\ and 5-HT4 receptors have been shown 
to mediate MDMA-induced acetylcholine release (Nair and Gudelsky, 2005). 
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Figure 1.6 Effects ofMDMA on a serotonin neuron. (1) MDMA binds to the serotonin 
reuptake transporter (SERT) causing reverse transport of 5-HT and inhibition of 5-HT 
reuptake and consequently increases extracellular 5-HT. (2) Extracellular 5-HT is 
further elevated by inhibition of monoamine oxidase (MAO) by MDMA therefore 
decreasing 5-HT degradation. (3) MDMA then decreases 5-HT synthesis by inhibiting 
tryptophan hydroxylase, the rate-limiting enzyme required for 5-HT synthesis, causing 
a short-term decrease of 5-HT levels. 
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Effects on locomotor activity and serotonin syndrome 
MDMA-induced hyperactivity is a well established acute effect of MDMA. 
The MDMA-induced locomotor activity depends upon monoamine release 
from neurons in the brain, followed by subsequent activation of multiple 5-HT 
and dopamine receptor subtypes. Classic stimulants such as cocaine and 
amphetamine increase locomotor activity via activation of dopamine 
transmission (Fischman and Johanson, 1996, Segal and Kuczenski, 1994, 
Seiden et aI., 1993). Locomotor activity stimulated by MDMA was attenuated 
by destruction of mesoaccumbens dopamine transmission indicating a role for 
dopamine in MDMA-induced hyperactivity (Gold et aI., 1989). The dopamine 
DI receptor antagonist, SCH23390 and dopamine D2 receptor antagonists, 
haloperidol and eticlopride attenuate MDMA-induced hyperactivity (Ball et aI., 
2003). In addition Ball et al (2003) found a positive correlation between 
MDMA-induced locomotion and activation of striatal neuronal activity. These 
studies suggest that the locomotor-activating effect of MDMA and other 
stimulants may share a common underlying mechanism. 
Studies by Gold et al (1988) and Spanos and Yamamoto (1989) demonstrated 
the qualitative difference between the hyperactivity produced by amphetamine 
and MDMA in rats. Spanos and Yamamoto (1989) reported the symptoms of 
the serotonin syndrome, a pattern of stereotyped motor behaviour resulting 
from excessive serotonin release, following MDMA administration to the rats 
suggesting a role of 5-HT in MDMA-induced hyperactivity. Callaway et al 
(1990, 1991) showed that preventing MDMA-induced 5-HT release, using 
fluoxetine pretreatment to block the 5-HT transporter, attenuated the 
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locomotor-activating effects ofMDMA indicating the involvement ofMDMA-
induced 5-HT release in MDMA-induced hyperactivity. Several studies 
demonstrated that the 5-HT1B/ID receptor antagonist, GR127935 and 5-HT2A 
receptor antagonist, MI00907 reduced the effect of MDMA on locomotor 
activity (Bankson and Cunningham, 2002, Fletcher et aI., 2002, Herin et aI., 
2005, Kehne et aI., 1996, McCreary et aI., 1999) suggesting that activation of 
5-HTIB and 5-HT2A receptors by released 5-HT in part at least mediates the 
effect of MDMA on locomotor activity. In contrast the 5-HT2C receptor 
antagonist, SB242084 potentiated the activity induced by MDMA (Bankson 
and Cunningham, 2002, Fletcher et aI., 2002). 
The mechanisms of MDMA-induced hyperactivity are thus not clearly 
understood as they involve a complex interaction between the 5-HT and 
dopamine systems. Ball and Rebec (2005) suggested that the blockade of 5-
HT 2A receptors reduced MDMA-induced locomotor activity by altering 5-HT 2A 
regulation of dopamine transmission in the striatum as previous studies had 
shown that 5-HT2A receptors located on dopamine neurons, modulate basal as 
well as stimulant-induced, dopamine neurotransmission (Gobert et aI., 2000, 
Lucas and Spampinato, 2000). Conversely Fletcher et al (2006) suggested that 
5-HT 2C antagonism facilitated MDMA-induced dopamine release within the 
ventral tegmental area. 
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Effects on body temperature 
MDMA-induced changes in body temperature are markedly influenced by 
ambient temperature. Rats housed in normal experimental conditions (20-22 
°C) and high ambient temperature show hyperthermia when given MDMA 
while low ambient temperature (10, 11 °C) in association MDMA causes 
hypothermia (Broening et aI., 1995, Dafters, 1994). 
The mechanisms ofMDMA-induced hyperthermia are unclear however both 5-
HT and dopamine are likely to be involved. It was demonstrated that the 5-HT2 
receptor antagonists, ketanserin and MDLl1939, and the 5-HT2A receptor 
antagonist, MlO0907, prevent hyperthermia following MDMA indicating the 
involvement of 5-HT in MDMA-induced hyperthermia (Herin et aI., 2005, 
Schmidt et aI., 1990). However the literature is inconsistent regarding the role 
of 5-HT in hyperthermia evoked by MDMA as several studies found that 
pretreatment with fluoxetine, which inhibits MDMA-induced 5-HT release, 
had no effect on the hyperthermic response to MDMA (Berger et aI., 1992, 
Malberg et a1., 1996, Mechan et aI., 2002a, Schmidt et a1., 1990). Moreover 
several compounds that block 5-HT receptors, including the 5-HTII2 receptor 
antagonist, methysegide, 5-HT2A receptor antagonist, MDLl00907 and 5-HT2C 
receptor antagonist, SB242084, failed to prevent the MDMA-induced 
hyperthermia (Mechan et aI., 2oo2a). The dopamine D\ receptor has been 
suggested to be important in MDMA-induced hyperthermia as Benamar et aI 
(2008) and Mechan et al (2002a) showed that the dopamine D\ receptor 
antagonist, SCH23390, effectively prevented the hyperthermic response of 
MDMA while the dopamine D2 receptor antagonist, remoxipride, had no effect 
25 
CHAPTER I: General introduction 
(Meehan et aI., 2002a). Recently a study by Shioda et al (2008) demonstrated 
that the 5-HT2A receptor antagonists, ritanserin, ketanserin and R-96544 
protected against MDMA-induced hyperthermia while the 5-HTIA receptor 
antagonist, WAY-100635, 5-HT2B/2C receptor antagonist, SB206553 and 5-
HT2C receptor antagonist, SB242084 did not prevent this effect of MDMA. In 
addition the dopamine DI and O2 receptor antagonist, haloperidol, blocks 
MOMA-induced hyperthermia, but the dopamine 02 receptor antagonists, 
sulpiride and L-741626 showed no effect (Shioda et aI., 2008). In agreement 
with Benamar et al (2008) and Mechan et al (2002a), Shioda et al (2008) also 
showed that the dopamine DI receptor antagonist, SCH23390, can prevent 
MOMA-induced hyperthermia. Taken together, it is likely that MDMA-
induced hyperthermia is mediated by 5-HT2A and dopamine 01 receptors. 
Many studies showed a close correlation between MDMA-induced 
hyperthermia and subsequent neurotoxicity (Baumann et aI., 2008a, Green et 
aI., 2004, Malberg and Seiden, 1998, Sanchez et aI., 2004). Schmidt et al 
(1990) and Broening et al (1995) showed that preventing hyperthermia by 
decreasing ambient temperature can protect against MDMA-induced 
neurotoxicity. In addition there were several compounds that prevent or 
attenuate MDMA-induced hyperthermia such as a-methyl-p-tyrosine, the 
dopamine synthesis inhibitor, haloperidol, the dopamine antagonist, and MK-
801 (dizocilpine), the N-methyl-D-aspartate (NMDA) glutamate receptor 
antagonist, which can aIso protect against MDMA-induced S-HT neurotoxicity 
(Colado et al., 1993, 1999b, Farfel and Seiden, 1995, Hewitt and Green, 1994, 
Malberg et aI., 1996). 
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Colado et al (1999a) suggested that MDMA-induced hyperthermia contributes 
to subsequent S-HT neurotoxicity through the enhancement of free radical 
formation in the brain as giving clomethiazole, a gamma-aminobutyric acid A 
(GABAA) agonist, with MDMA prevented both an acute MDMA-induced 
hyperthermia and the increase of free radical formation although clomethiazole 
has no free radical scavenging effect on its own. However if the hyperthermia 
of the rats was maintained following treatment with MDMA clomethiazole 
failed to decrease free radical formation suggesting that an increase of body 
temperature plays a role in the production of free radicals in the brain of 
MDMA-treated rat (Colado et aI., 1999a). 
Although there were several studies showing a relationship between MDMA-
induced hyperthermia and subsequent 5-HT neurotoxicity, some studies 
revealed that the compounds which protected against the neurotoxicity of 
MDMA did not modify body temperature, examples are a-phenyl-N-tertbutyl 
nitrone, a free radical trapping nitrone and fluoxetine (Colado et aI., 1997, 
Sanchez et aI., 2001). Moreover while keeping the animals normothermic 
following MDMA, a-methyl-p-tyrosine then failed to protect against MDMA-
induced neurotoxicity (Yuan et aI., 2002). Taken together, MDMA-induced 
hyperthermia is one of several factors that promote MDMA-induced 
neurotoxicity. 
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Effect on cardiovascular systems 
MDMA also produces effects on the cardiovascular systems as MDMA has 
been shown to produce tachycardia, arrhythmia and vasoconstriction 
(Fitzgerald and Reid, 1994, Gordon et aI., 1991). Recently Badon et al (2002) 
reported that repeated MDMA administration altered cardiovascular function in 
rats. Effects of MDMA on cardiovascular systems have been suggested to be 
mediated by effects of MDMA on peripheral noradrenergic systems as MDMA 
can displace noradrenaline from adrenergic nerve terminals, competitively 
block the noradrenaline transporter and directly bind to peripheral and central 
<l2-adrenoceptors (AI-Sahli et aI., 2001, Fitzgerald and Reid, 1993, Lavelle et 
aI., 1999, McDaid and Docherty, 2001). 
Anxiety and memory 
There are a few studies reporting an acute effect of MDMA administration on 
anxiety-related behaviours. Morley and McGregor (2000) demonstrated that 
MDMA (1.25-5 mg/kg) produced an anxiogenic effect in the elevated plus-
maze while MDMA (5 mg/kg) had an anxiolytic effect on social interaction. 
Similarly Ho et al (2004) showed that a single dose of MDMA (7.5 mg/kg) 
caused an anxiogenic profile in the elevated plus-maze 30 min after treatment 
while the higher dose of MDMA (15 mg/kg) produced an anxiolytic effect. In 
agreement with studies in mice the lower dose of MDMA produced an 
anxiogenic effect while the higher dose of MDMA reduced anxiety in the 
elevated plus-maze test (Lin et aI., 1999, Navarro and Maldonado, 2002). 
Recently Kindlundh-Hogberg et al (2007) showed that binge administration of 
MDMA (3 x 5 mg/kg) increased the activity in the centre of the open-field 
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arena in rats indicating a decrease of anxiety following MDMA. In addition to 
the anxiety-related behaviours produced by MDMA, several studies showed 
acute memory impainnents in various cognitive models following MDMA 
administration in rats and rhesus monkeys (Braida et aI., 2002, Frederick and 
Paule, 1997, Harper et aI., 2005, Marston et aI., 1999, Taffe et aI., 2001). The 
effects of MDMA on memory will be reviewed in section 1.7. 
1.3.2 The acute effects of MDMA in humans 
In humans, serum levels of MDMA peak 2 h after administration, although 
there are detectable levels after 15 min (de la Torre et aI., 2000, Helmlin et aI., 
1996, Mas et aI., 1999). Pharmacokinetic studies in humans have shown that 
repeated administration of MDMA presents non-linear pharmacokinetics (de la 
Torre et aI., 2000). This is because MDMA is a CYP 2D6 enzyme inhibitor 
which causes an inhibition of its own metabolism (Delaforge et aI., 1999) and 
consequently increases the area under the plasma concentration-time curve 
(AUC) and maximum plasma drug concentrations (Cmax) after a second dose of 
MDMA following a 24 h interval (Farre et aI., 2004). 
Recreational ecstasy users have reported acute psychological effects of MDMA 
including euphoria, sharpened sensory perception, greater sociability, 
extraversion, heightened sense of closeness to other people, greater tolerance of 
views and feelings, increase in wakefulness, and postponement of fatigue and 
sleepiness (Cohen, 1995, Davison and Parrott, 1997, McCann et at., 1996). 
However there were subacute adverse effects of MDMA ingestion reported 
including depression, irritability, panic attacks, visual hallucinations and 
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paranoid delusion (Brown and Osterloh, 1987, Creighton et aI., 1991, Davison 
and Parrott, 1997). MDMA users reported feeling significantly more depressed, 
unpleasant, sad, abnormal and unsociable than non user controls 7 days after 
use (Parrott, 2002, Parrott and Lasky, 1998). Topp et al (1999) reported various 
problems during the post-ecstasy recovery period including energy loss, 
irritability, muscle aches and trouble sleeping. Curran (2000) also reported 
midweek low mood in 83% of 469 MDMA users using a questionnaire survey. 
These mood and other psychobiological problems in the days following 
MDMA are probably due to the acute monoaminergic depletion already 
described. 
MDMA users have also reported mild signs of the serotonin syndrome 
including hyperactivity, mental confusion, hyperthermia and jaw clenching 
(Davison and Parrott, 1997, Parrott and Lasky, 1998). The serotonin syndrome 
is caused by drug induced excess ofintrasynaptic 5-HT. The symptoms include 
agitation, hyperreflexia, fever, tachycardia, shivering, clonus, myoclonus, 
ocular oscillations and tremor plus symptoms mentioned above (Gillman, 
1999, Huether et at, 1997). The presence of the serotonin syndrome in an 
MDMA user is indicative of an acute increase in 5-HT release following 
MDMA ingestion. 
The acute adverse physiological effects of MDMA that occur during the peak 
period after MDMA ingestion in humans include an increase in tension 
manifested as muscular tension, jaw clenching, tooth grinding and constant 
restless movement of the legs (McCann et aI., 1996, Peroutka, 1987, Shulgin, 
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1986}. Moreover, MDMA also affects the sympathetic nervous system 
resulting in an acute elevation of heart rate and blood pressure (Vollenweider et 
aI., 1998). 
Acute MDMA administration also produces hyperthermia in humans. MDMA 
ingestion has been reported to increase body temperature to 43°C (Connolly 
and O'Callaghan, 1999, Irvine et aI., 2006, Mallick and Bodenham, 1997). 
Davison and Parrott (1997) showed that approximately 85-90% of 
recreationally MDMA users reported an increase in body temperature and 
increased sweating and dehydration. Recently Irvine et al (2006) reported a 
moderate increase of body temperature as well as blood pressure and heart rate 
in MDMA users at a dance party with the increase of body temperature 
associated with the highest MDMA plasma concentrations. MDMA-related 
hyperthermia should be a concern as it can lead to other fatal toxicological 
problems including acute renal, hepatic, or cardiac failure, rhabdomyolysis and 
disseminated intravascular coagulation (Cohen, 1996). Similarly to the 
mechanism in rats, the mechanism involved in MDMA-induced hyperthermia 
in humans is likely to involve the 5-HT2A receptor as pretreatment with the 5-
HT2A receptor antagonist, ketanserin (50 mg p.o.), attenuates the MDMA-
induced increase in body temperature (Liechti et aI., 2000). 
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1.3.3 The long-term effects of MDMA in experimental animals 
Long-term effects on 5-HT and other neurotransmitter systems 
MDMA has been suggested to be a selective neurotoxin of serotonergic 
neurons in rats (Gibb et aI., 1990), guinea pigs (Battaglia et aI., 1988, Saadat et 
aI., 2004) and non-human primates (Ricaurte et aI., 1988) while MDMA is a 
selective neurotoxin of dopaminergic neurons in mice (Logan et aI., 1988, 
O'Callaghan and Miller, 1994, O'Shea et aI., 2001). Single and multiple 
MDMA administration produce long-term depletion of 5-HT and 5-HIAA in 
rats (For example Baumann et aI., 2008a, Commins et aI., 1987, Ludwig et aI., 
2008, Slikker et aI., 1988). Studies using eH]paroxetine binding to measure the 
presynaptic serotonin reuptake transporter (SERT) showed that MDMA 
administration decreased SERT binding indicating a decrease in the number of 
serotonergic axon terminals (Battaglia et aI., 1987, Broening et aI., 1995, 
Hewitt and Green, 1994, O'Shea et aI., 1998). In addition, immunochemica1 
analysis showed a marked loss of fme serotonergic axons in the rat neocortex, 
striatum and hippocampus following MDMA administration while cell bodies 
and thick -beaded axonal fibers were not damaged suggesting the subsequent 
regeneration of the serotonergic neurons (O'Hearn et aI., 1988). The rate of 
neuronal recovery following neurotoxic MDMA administration was shown to 
be region-dependent. For example Scanzello et al (1993) showed that the S-HT 
content in the hypothalamus of the rat first recovered within 8 weeks while 
hippocampal and striatal 5-HT levels returned to control levels within 32 
weeks. Generally in rats, full recovery can be shown in most studies and most 
brain regions within 1 year (Battaglia et aI., 1988, Sabol et at., 1996) while in 
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non human primates MDMA-induced neurotoxicity is more sensitive and more 
persistent as neurotoxicity in most neocortical regions and the hippocampus 
persisted for 7 years after treatment (Fischer et aI., 1995, Hatzidimitriou et aI., 
1999, Ricaurte et aI., 1992). The possible mechanisms of neurotoxicity are 
reviewed later in section 1.3.5. 
It is well established that MDMA produces a specific neurotoxicity to 5-HT 
neurons in the rats but there are no long-term changes in dopamine levels or the 
number of dopamine transporters following MDMA administration (Logan et 
aI., 1988, Kindlundh-Hogberg et aI., 2007). In contrast MDMA has a selective 
dopaminergic neurotoxicity with no long-term effect on 5-HT in mice (Logan 
et al., 1988, O'Callaghan and Miller, 1994, O'Shea et ai., 200 1, Kindlundh-
Hogberg et aI., 2007). A neurotoxic regimen of MDMA also has no long-term 
effects on tissue norepinephrine levels in either rat or monkey (Battaglia et aI., 
1987, Insel et aI., 1989, Slikker et aI., 1988) and no change in the density of 
catecholamine uptake sites labeled by CH]mazindol (Battaglia et aI., 1987, 
1991). 
Long-term behavioural effects 
Morley et al (2001) showed anxiety-like behaviour in emergence, elevated plus 
maze and social interaction tests 3 months after MDMA administration to rats. 
In addition Fone et al (2002) found an increase in the anxiety response in open 
field behaviour and social interaction 29 days after MDMA administration. In 
contrast Mechan et al (2002b) reported an anxiolytic response in open field 
behaviour and the elevated plus maze 73 to 80 days after a neurotoxic dose of 
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MDMA in rats. There have been several studies reporting long-tenn effects of 
MDMA on learning and memory in various cognitive models (Broening et aI., 
2001, Piper and Meyer, 2004, Sprague et aI., 2003, Williams et aI., 2003) 
which will be reviewed in section 1. 7 
1.3.4 The long-term effects ofMDMA in humans 
Long-term effects on 5-HT and other neurotransmitter systems 
Studies of serotonergic neurotransmission in humans have relied upon indirect 
methods such as the measurement of serotonin metabolites in cerebrospinal 
fluid and the use of neuroendocrine challenge tests such as d-fenfluramine and 
L-tryptophan (Gerra et at, 1998, McCann et at, 1999a). Significantly lower 
levels of the cerebrospinal 5-HIAA have been found in abstinent MDMA users 
however there was no difference in the prolactin response to L-tryptophan 
challenge (McCann et ai., 1994). Yerkes et al (2001) found a significant 
reduction in the cortisol response to fenfluramine in both moderate and heavy 
MDMA users. In addition a study from Gerra et al (2000) demonstrated that 
the cortisol response recovered after 12 months abstinence from MDMA while 
the prolactin response remained significantly reduced. 
Neuroimaging techniques have been applied to study the serotonergic system 
in the brain of humans with a history of MDMA use. These studies have 
focused on markers of serotonergic integrity including the 5-HT reuptake 
transporter as a potential marker for axons and tenninals and the 5-HT 2A 
receptor as a potential indirect marker reflecting changes in synaptic 5-HT 
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release. Findings from positron emission tomography (PET) and single photon 
emission computed tomography (SPECT) have consistently revealed 
reductions in 5-HT reuptake transporter ligand binding in heavy and recently 
abstinent MDMA users (Buchert et aI., 2004, McCann et aI., 1998, 2005, 
Reneman et aI., 2001a, Semple et aI., 1999). Studies using [123I]R91150 
SPECT, a specific, reversible ligand of the 5-HT2A receptor, showed that 5-
HT 2A receptor binding was reduced in recent MDMA users reflecting acute 
receptor down-regulation by ongoing 5-HT release while it increased in 
abstinent users for occipital regions (Reneman et aI., 2002). 
Consistent to studies in rats, MDMA produced specific 5-HT neurotoxicity 
without depleting dopamine in humans as homo vanillic acid (HV A), a 
dopamine metabolite in cerebrospinal fluid (CSF), was found in the normal 
range in regular MDMA users (McCann et aI., 1994, 1999a). In addition 
Semple et a1. (1999) demonstrated normal dopamine transporter binding in the 
human lenticular nuclei, studied by SPECT with [12311P_CIT, in regular 
MDMA users whereas cortical 5-HT transporter binding was decreased. 
Consistent with studies in rats, evidence in humans indicates that MDMA does 
not produce dopaminergic neurotoxicity. 
Long-term behavioural effects 
Long-term psychological effects following recreational use of MDMA in 
humans are well documented and are reported to persist long after cessation of 
drug use (Bolla et aI., 1998, McCann and Ricaurte, 1991, 1992, McCann et al., 
1996, 1999b, McGuire, 2000). The serious chronic effects include psychiatric 
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disorders such as anxiety, depression, paranoid psychosis and panic disorder 
(Benazzi and Mazzoli, 1991, Curran and Travill, 1997, Henry, 1996, McCann 
et aI., 1996, Schifano, 1991). In addition there was a higher incidence of 
anxiety-related disorders among MDMA users (McCann and Ricaurte, 1991, 
Morgan, 2000, Parrott, 2001). Several studies of MDMA use in humans 
showed impairments in memory and learning and this will be discussed in 
section 1.7. 
1.3.5 Possible mechanisms ofMDMA-induced neurotoxicity 
To date, although MDMA causes selective serotonergic neurotoxicity in rats 
and possibly humans, the mechanisms of this neurotoxicity remain unclear and 
there are many hypotheses that attempt to explain how the toxicity occurs. 
These include MDMA-induced free radical formation, toxic metabolites of 
MDMA and the involvement of dopamine and tyrosine. 
MDMA-induced free radical formation 
There is a sizable amount of evidence indicating that MDMA-induced 
neurotoxicity is associated with the ability of MDMA to promote the 
production of reactive oxygen species (ROS). It has been shown that MDMA 
administration increases lipid peroxidation, a marker of free radical-induced 
damage (Colado et aI., 1997, Sprague and Nichols, 1995). Additionally, 
MDMA administration increases the conversion of salicylate to 2,3-
dihydroxybenzoic acid (2,3-DHBA), an oxidation product of salicylate 
(Colado et aI., 1997). Moreover, MDMA-induced neurotoxicity can be 
attenuated by administration of free radical scavenging drugs such as ascorbic 
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acid, sodium ascorbate, L-cysteine, a-lipoic acid and mazindol (Aguirre et aI., 
1999, Gudelsky, 1996, Shankaran et aI., 1999, 2001). The sources of ROS 
responsible for toxicity have not been clearly demonstrated. 
Metabolites of MDMA 
Neurotoxic metabolites of MDMA have been proposed to mediate the 
neurotoxic effects of MDMA as neither serotonergic nor dopaminergic 
neurotoxicity were observed after direct injection of MDMA into specific areas 
of the rat brain (Esteban et aI., 2001, Paris and Cunningham, 1992, Schmidt 
and Taylor, 1988) as well as the C57BLl6J mouse brain (Escobedo et aI., 2005) 
respectively indicating that MDMA may be metabolized outside the brain to 
neurotoxic metabolites. 
The metabolism pathways of MDMA in rats and humans are different. 3,4-
methylenedioxyamphetamine (MDA), a major metabolite in rat and mouse, has 
been suggested to be a neurotoxic metabolite and contribute to MDMA-
induced neurotoxicity (Figure 1.7). MDA increased 5-HT release in the nucleus 
accumbens (Kankaanpaa et aI., 1998) and mUltiple doses of MDA can deplete 
5-HT and 5-HIAA and inhibit tryptophan (TPH) activity (Stone et aI., 1986, 
Stone et aI., 1987a). In contrast 3,4-dihydroxymethamphetamine (HHMA or N-
methyl-a-methyldopamine) is a major metabolite in humans while MDA is 
minor (De la Torre and Farre, 2004, Pizarro et aI., 2004, Segura et a1., 2001) 
(Figure 1.7). Jones et al (2005) have recently synthesized 5-(N-acetylcytein-S-
yl)-N-methyl-a-methyldopamine (5-NAC-N-Me-a-MeDA), a likely metabolite 
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of N-Me-a-MeDA in humans, and demonstrated it to be a potent serotonergic 
toxicant in rats. 
Other potential neurotoxic metabolites are thioethers (glutathione; GSH and N-
aceylcysteine; NAC) adduct metabolites of MDMA which also have been 
shown to be neurotoxic metabolites of MDMA as long-term depletion of 5-HT 
levels occurred following direct injection of the thioether adducts into the brain 
of rats (Bai et aI., 1999, Miller et aI., 1997). Recently Easton et al (2003) have 
shown that human liver microsomes were able to produce the neurotoxic 
thioether adducts indicating mechanisms shown in rats can also occur in 
humans. The GSH adduct of the MDMA metabolite a-methyldopamine, 5-
GSH-a-MeDA also decreased cell viability in rat cortical neuronal cultures 
(Capela et aI., 2005). Easton and Marsden (2006) suggested that the neurotoxic 
effects of MDMA are likely to be a result of a combination of several 
metabolites (Figure 1.7). 
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Figure 1.7 Simplified pathways of MDMA metabolism in rats, mice and humans 
(Easton and Marsden, 2006). 
Abbreviations: (1) MDA (3,4-methylenedioxyamphetamine), (2) MDMA (3,4-
methylenedioxymethamphetamine, (3) HHA (3,4-dihydroxyamphetamine or alpha-
methyldoparnine or a-MeDA), (4) HHMA (3,4-dihydroxymethamphetamine or N-
methyl-alpha-methyldoparnine or N-Me-a-MeDA), (5) HMA (4-hydroxy-3-
methoxyampbetamine), (6) HMMA (4-hydroxy-3-methoxymethamphetamine), (7) 5-
GSH-n-MeDA (5-[glutathione-S-yl]-alpha-methyldopamine), (8) 2,5-bis-GSH-n-
MeDA (2,5-bis-[giutathione-S-yl]-alpha-methyldopamine), (9) 5-GSH-N-Me-n-
MeDA (5-[giutathione-S-yl]-N-methyl-alpha-methyldopamine), (10) 2,5-GSH- N-Me-
n-MeDA (2,5-[giutathione-S-yl]-N-methyl-alpha-methyldopamine) (11) 5-NA -n-
MeDA (5-[N-acetylcysteine]- alpha-methyl dopamine), (12) 5-NAC-N-Me-a-MeDA 
(5-[N-acetylcysteine]-N-methyl-alpha-methyldopamine), (13) 2,5-NA -(l-MeDA 
(2,5-[N-acetylcysteine]- alpha-methyldopamine), (14) 2,5-NAC-N-Me-n-MeDA (2,5-
[N -acetyl cysteine ]-N -methyl-al pha -methyldopamine) 
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Involvement of dopamine 
Dopamine has been proposed to play a key role in MDMA-induced 
neurotoxicity (Sprague et al., 1998). This hypothesis is supported by several 
compounds that decrease dopamine content such as the tyrosine hydroxylase 
inhibitor, a-methyl-p-tyrosine, the dopamine depleting agent, reserpine, the 
dopamine uptake inhibitors, GBR 12909 and mazindol, as well as the 
dopamine antagonist, haloperidol, all of which attenuate the MDMA-induced 
loss of 5- HT (Hewitt and Green, 1994, Shankaran et aI., 1999, Stone et al., 
1988). Sprague et al (1998) proposed an integrated hypothesis for the 
development of selective 5-HT terminal degeneration following MDMA 
(Figure 1.8). Firstly it has been widely demonstrated that MDMA induces an 
acute release of both 5-HT and dopamine. The release of dopamine elicited by 
MDMA involves the activation of 5-HT 2A12C receptors on GABAergic neurones 
(Cowan et aI., 1990, Kita et al., 1990, Nash, 1990, Yamamoto et aI., 1995). The 
increased dopamine is then transported into 5-HT nerve terminals via the 
serotonin reuptake transporter (SERT) as it has been observed that SERT can 
also transport dopamine (Faraj et aI., 1994, Hrometz et aI., 2004, Saldana and 
Barker, 2004). Dopamine is then metabolized by the mitochondrial enzyme 
monoamine oxidase (MAO) in the serotonergic terminals to reactive oxygen 
species (ROS) as the oxidative deamination of monoamine neurotransmitters 
by MAO produces hydrogen peroxide (H202) which is subsequently converted 
to hydroxyl radical (Alves et aI., 2007). In addition inhibition of MAOs using 
MAOs inhibitor, L-deprenyl or antisense oligonucleotide targeted at MAGs 
decreased MDMA-induced lipid peroxidation and consequently protected 
against MDMA-induced long-term 5-HT depletion (Falk et aI., 2002, Sprague 
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and Nichols, 1995). Due to the large amount of dopamine transported into 5-
HT tenninals, MAOs degradation of this dopamine leads to enhanced 
production ofROS and further damage to 5-HT tenninals. 
H20 2 & free racicaI gel aation 
1 
Selective 5-HT terminal degeneration 
Figure 1.8 An integrated hypothesis for the development of selective 5-HT tenninal 
degeneration following MDMA (Sprague et al 1998). 
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Involvement of tyrosine 
The evidence suggesting involvement of dopamine in MDMA-induced 
neurotoxicity has been discussed however the role of dopamine on this 
neurotoxicity in brain areas sparse of dopaminergic innervations, such as the 
hippocampus, remains unclear. A recent study by Brier et al (2006) suggested 
the involvement of tyrosine in MDMA-induced 5-HT neurotoxicity as it was 
demonstrated that MDMA administration markedly increased extracellular 
tyrosine in the striatum and hippocampus (Breier et at, 2006). Recently Goiii-
Allo et al (2008) reported that MDMA administration increased the serum 
tyrosine concentration suggesting that the rise of tyrosine in the brain may be 
the consequence of a preceding peripheral tyrosine elevation. Breier et al 
(2006) suggested that dopamine in brain areas with sparse dopaminergic 
innervation is produced by a tyrosine hydroxylase-independent mechanism as 
they demonstrated a conversion of L-tyrosine to DOPA in the presence of 
hydroxyl radicals using an in vitro hydroxyl radical-generating system. 
Moreover reverse dialysis of a-methyl-p-tyrosine, the tyrosine hydroxylase 
inhibitor, into the hippocampus failed to prevent MDMA-induced 5-HT 
depletion in the hippocampus indicating this neurotoxicity of MDMA did not 
involve tyrosine hydroxylase (Breier et ai., 2006). The DOPA formed in this 
way is then converted to dopamine by the aromatic amino acid decarboxylase 
(AADC) present in 5-HT terminals as the AADC inhibitor, NSD 1015, 
prevented MDMA-induced dopamine release in the hippocampus and protected 
against MDMA-induced 5-HT depletion (Breier et aI., 2006). 
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In summary although the precise mechanisms of MDMA-induced 5-HT 
neurotoxicity are unknown free radical formation is probably a factor. The 
toxic metabolites of MDMA have been widely demonstrated to be involved in 
MDMA-induced neurotoxicity and dopamine could be one of the sources of 
the production of reactive oxygen species (ROS) in 5-HT terminals. It has been 
suggested that excessive dopamine released by MDMA can then be transported 
into the 5-HT terminals and metabolized to reactive oxygen species (ROS) by 
the mitochondrial enzyme monoamine oxidase (MAO). An alternative 
hypothesis proposes that in brain area sparsely innervated by dopamine 
tyrosine can be converted to dopamine via a tyrosine hydroxylase-independent 
mechanism as it was shown that MDMA increased serum and brain tyrosine 
levels. In addition, as discussed in section 1.3.1, MDMA-induced hyperthermia 
is a factor that influences neurotoxicity as it promotes the production of ROS. 
The possible mechanisms of MDMA-induced 5-HT neurotoxicity are 
summarised in Figure 1.9. 
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Figure 1.9 An overall mechanism of MDMA-induced 5-HT neurotoxicity. Toxic 
metabolites produce acute release in 5-HT and dopamine in the brain. Dopamine is 
then taken up into 5-HT terminals yia the serotonin reuptake transporter (SERT) and 
metabolized by the mitochondrial enzyme monoamine oxidase B (MAOB) to produces 
reactive oxygen species (ROS). MDMA also increases plasma and brain t}Tosine 
levels. In the brain sparsely innervated by dopaminergic neurons tyrosine is converted 
to dopamine via a tyrosine hydroxylase-independent mechanism in the 5-HT tenninaJ . 
Dopamine is then metabolized by MAOB and produces ROS. Moreover MDMA 
and/or its metabolites are oxidized to ROS in the 5-HT tenninals. 
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The evidence for MDMA producing acute 5-HT and dopamine release in 
animals has been widely demonstrated. Moreover MDMA causes 
norepinephrine and acetylcholine release in vitro. The acute behavioural effects 
of MDMA mediated by MDMA-induced monoamine release include increased 
locomotor activity, changes in body temperature, altered cardiovascular 
functions, anxiety-related behaviours and impaired learning and memory. The 
acute effects of MDMA reported in humans are similar to those in animals 
suggesting an increase in monoamines also occurs in humans following 
MDMA. The mechanisms by which MDMA produces 5-HT neurotoxicity are 
unclear however they may involve toxic metabolites of MDMA, MDMA-
induced free radical formation and increased dopamine and tyrosine levels. 
MDMA clearly has its main effects on 5-HT and dopamine systems and 5-HT 
and dopamine neurons innervate the brain area associated with learning and 
memory such as the hippocampus and frontal cortex. MDMA therefore may 
affect learning and memory function by actions in these brain areas. The next 
section of this chapter reviews the concepts of learning and memory, the 
importance of 5-HT and dopamine in learning and memory and the effects of 
MDMA on learning and memory in humans and laboratory animals. The 
relationship between the effects of MDMA on 5-HT and/or dopamine and 
impairments of learning and memory in human MDMA users and in laboratory 
animals following MDMA is also discussed. 
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1.4. Learning and memory 
Leaming is the acquisition of alterations in behaviour as a result of particular 
experience. Memory is the storage of the altered behaviour over time. Memory 
can be classified, based on the capacity and duration of information storage, as 
short-term and long-term memory. Short-term memory is the temporary store 
of information that has limited capacity. Short-term memory can be 
transformed into a more permanent storage of information which is long-term 
memory. Long-term memory can be subdivided to declarative and non-
declarative (procedural) memory. Declarative memory is the acquisition, 
retention and retrieval of knowledge that can be consciously recollected 
including memory for events (episodic memory) and memory for facts 
(semantic memory). It was proposed that the medial temporal lobe system, 
including the hippocampus formation (entorhinal cortex, dentate gyrus, areas 
CAI-CA4 and subiculum), amygdala and parahippocampal cortices, involves a 
declarative memory system (see review Squire et at., 2004). Non-declarative 
memory involves the skilled behaviour and the ability to respond appropriately 
to stimuli through practice. This type of memory is dependent on different 
brain areas for example memory for skills depends on striatum and cerebellum 
while emotional learning involves amygdala (see review Milner et at., 1998). 
Baddeley and Hitch (1974) introduced the concept of 'working memory' to 
describe a more dynamic system of short-term memory and defmed working 
memory as the system for the temporary maintenance and manipulation of 
information, necessary for the performance of such complex cognitive 
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activities as comprehension, learning, and reasoning (Baddeley, 1996). 
Working memory has been demonstrated to be dependent on the hippocampus 
and prefrontal cortex (Laroche et a1., 2000). Novel object discrimination task, 
which is used in this thesis, is one of cognition models for determining working 
memory as well as recognition memory (Ennaceur and Meliani, 1992). 
Recognition memory is defmed as the ability to discriminate the familiarity of 
things previously encountered (Aggleton and Brown, 1999). The cognition 
models used to determine recognition memory include delay matching and 
nonmatching-to-sample task and novel object discrimination. It is 
demonstrated that the rhinal and parahippocampal cortices are importance for 
object-recognition while the contribution of the hippocampus is relatively 
minor (see review Mumby, 2001). 
1.5. Involvement of S-HT in learning and memory 
The ascending serotonergic systems innervate the forebrain including the 
cerebral cortex, hippocampus, septum and amygdala, all of which represent 
brain regions associated with various domains of cognition. The involvement 
of 5-HT in learning and memory has been widely investigated. Depletion of the 
5-HT precursor, L-tryptophan, and consequently reduction of brain 5-HT levels 
impair learning and memory both in humans and rodents (Lieben et aI., 2004, 
Sambeth et a1., 2007, Uchida et aI., 2007). In addition several 5-HT receptors 
have been shown to be implicated in the mechanisms of learning and memory 
(King et at, 2008, Meneses, 2003). 
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The 5-HTIA receptor has been widely demonstrated to playa role in learning 
and memory however the mechanisms remain unclear as the 5-HTIA receptor 
agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-0H-DPAT), and 5-HTIA 
partial agonists, buspirone and tandospirone, produced a range of effects on 
memory from improvement to impairment in various animal models (see 
review Meneses and Perez-Garcia, 2007, Ogren et at., 2008). In addition 
antagonism of 5-HTIA receptors reverses the cognitive impairments induced by 
5-HT IA receptor agonists, N-methyl-D-aspatate (NMDA) receptor antagonists 
and the muscarinic receptor antagonist scopolamine (Forster et at, 1995, 
Harder and Ridley, 2000, Hirst et at, 2008, Meneses, 2007). 
The functions of 5-HT1A receptors are to act as the somatodendritic inhibitory 
autoreceptor as well as an inhibitory postsynaptic heteroceptor on 
glutamatergic and cholinergic neurons in the frontal cortex, hippocampus and 
septum. Therefore stimulation or blockade of pre- or post-synaptic 5-HTIA 
receptors may produce different results on memory. For example Warburton et 
al (1997) demonstrated that systemic administration of 8-0H-DPAT, the 5-
HT IA receptor agonist, impaired delayed non-matching-to-place (DNMTP) task 
whereas central infusion of 8-0H-DPAT into the median raphe nucleus 
improved performance in this task. Considering the post-synaptic 5-HT1A 
receptors, infusion of the 5-HTIA receptor agonist, 8-0H-DPAT, and partialS-
HTIA receptor agonist, NAN-190, into the rat hippocampus caused an 
impairment of performance accuracy in DNMTP (Warburton et al., 1997). In 
addition extra-rhinal cortex infusion ofNAN-190 inhibited short-term memory 
in an inhibitory avoidance task while intra-entorhinal infusion of 8-0H-DPAT 
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impaired long-term memory (Izquierdo et at., 1998, 1999). Moreover it is 
suggested that the effects of 5-HT IA receptor antagonists on memory 
improvement might be mediated by glutamatergic and/or cholinergic systems 
(Carli et at., 2001, 2006, Luttgen et at., 2005, Madjid et at., 2006). 
As the 5-HT4 receptor is highly expressed in brain regions involved in learning 
and memory such as basal ganglia and hippocampus and moderately expressed 
in the frontal cortex and amygdala, this receptor has been suggested to be 
involved in the mechanisms of learning and memory. It was demonstrated that 
5-HT4 receptor partial agonists, RS67333 and RS17017, improved social and 
olfactory associative learning, spatial memory and novel object recognition in 
rats and improved delayed matching-to-sample in macaques (Fontana et at., 
1997, Lamirault and Simon, 2001, Marchetti et at., 2004, Terry et at., 1998) 
while the 5-HT4 receptor antagonists, SDZ205557 and GR125487, impaired 
passive avoidance memory in mice (Galeotti et aI., 1998). The effects of 5-HT4 
receptor agonists are thought to be mediated by cholinergic neurotransmission 
as 5-HT 4 receptor agonists reverse scopolamine-induced memory deficit 
(Galeotti et aI., 1998, Micale et aI., 2006) and increase acetylcholine efflux in 
the frontal cortex and hippocampus (Consolo et aI., 1994, Matsumoto et aI., 
2001). 
Recently there is a growing evidence for involvement of 5-HT6 and 5-HT7 in 
learning and memory. Woolley et al (2001) demonstrated that antisense 
oligonucleotides direct against the 5-HT6 receptor and the 5-HT6 receptor 
antagonist, Ro 04-6790, improved performance in Morris water maze. 
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Moreover several studies demonstrated the roles of 5-HT6 receptor antagonists 
in the improvements of memory in novel object recognition and an auto shaping 
conditioned-response tasks (Hirst et aI., 2006, King et ai., 2004, Mitchell et ai., 
2006, Perez-Garcia and Meneses, 2005a, Woolley et ai., 2003). In addition the 
selective 5-HT7 receptor agonist, ASI9, facilitated memory consolidation and 
modulated mRNA of 5-HT7 expression in a Pavlovian/instrumental 
auto shaping task (Perez-Garcia and Meneses, 2005b, Perez-Garcia et aI., 
2006). 
1.6. Involvement of dopamine in learning and memory 
It is well established that the mesolimbocortical dopamine system play an 
essential role in learning and memory (see review Floresco and Magyar, 2006, 
Missale et aI., 1998). Dopamine neurotransmission in the prefrontal cortex has 
been shown to mediate executive functions such as working memory in 
primates and rats. Brozowski et al (1979) demonstrated that lesions of 
dopamine terminals in the prefrontal cortex impaired delayed responding task 
performance in primates. In addition local administration of the dopamine 01 
receptor antagonists, SCH23390 and SCH39166, into the dorsolateral 
prefrontal cortex induced a deficit in an oculomotor delay response task in 
rhesus monkeys while local administration of the dopamine D2 receptor 
antagonists, sulpiride and raclopride, had no effect in this task (Sawaguchi and 
Goldman-Rakic, 1991, 1994). In contrast systemic administration of the 
dopamine D2 receptor antagonists impaired working memory in both humans 
and primates in other studies (Mehta et aI., 2004, Von Huben et aI., 2006). 
50 
CHAPTER I: General introduction 
In rats lesions to the medial prefrontal cortex, using the selective neurotoxin 6-
hydroxydopamine, produced impairment of delayed alternation in T -maze and 
radial maze performances (Bubser and Schmidt, 1990). In addition Broersen et 
al (1995) showed that infusion of either the nonselective dopamine antagonist, 
flupentixol, or the dopamine D\ receptor antagonist, SCH23390, into the 
medial prefrontal cortex produced a delayed-independent impairment of 
delayed matching-to-position in rats. Although blockade of dopamine D\ 
receptors in the prefrontal cortex has been shown to impair working memory, 
several studies have demonstrated that excessive stimulation of the prefrontal 
cortex dopamine D\ receptors may also impair performance in a delayed 
response task in both primates and rats (Bauer and Fuster, 1978, Kesner et al., 
1981, Zahrt et aI., 1997). 
With the extensive evidence for the involvement of serotonergic and 
dopaminergic systems in learning and memory, short-term and long-term 
alterations of serotonergic and/or dopaminergic functions caused by MDMA in 
animals and possibly humans would be predicted to result in learning and 
memory impairments. The following section reviews the evidence for such 
impairments in MDMA users and the effects of MDMA administration on 
learning and memory in the experimental animals. In addition the contribution 
of changes in 5-HT and/or dopamine produced by MDMA to these 
impairments is discussed. 
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1.7. Effects ofMDMA on learning and memory 
1.7.1 Evidencefrom human studies 
The memory deficit in humans was first described by McCann and Ricaurte 
(1991) in an individual case study of regular MDMA user who reported poor 
short- and long-term memory, hallucinations, depression, anxiety and sleep 
disturbance after ingestion of MDMA for more than 2 years. There is growing 
evidence for selective impairments of memory associated with chronic and 
heavy recreational use of MDMA. The most consistent fmdings of memory 
deficits in MDMA users are impairments of episodic memory and learning 
abilities (Gouzoulis-Mayfrank et aI., 2000, McCardle et aI., 2004, Montgomery 
et aI., 2005, Morgan, 1999, 2002, Parrott and Lasky, 1998, Schifano et aI., 
1998). Some studies reported deficits in working memory, complex attention, 
problem solving and test of frontal executive function as well as elevated 
cognitive impulsivity (Fox et aI., 2001, 2002, Gouzoulis-Mayfrank et aI., 2000, 
McCann et aI., 1999b, Morgan, 1998,2002, von Geusau et aI., 2004, Wareing 
et aI., 2000, Zakzanis and Young, 2001). Many studies have shown memory 
impairments related to the reduction of brain 5-HT. For example Bolla et al 
(1998) found the impairment in verbal and visual memory in MDMA users 
correlated with the reduction in brain 5-HT as indexed by cerebrospinal 5-
HIAA. Renemann et al (2001b) reported an impairment in verbal memory in 
both recent and ex-MDMA users associated with a decrease of cortical [123I]f3_ 
CIT-labelled SERT density in recent but not in ex-MDMA users suggesting 
that there was a recovery of 5-HT in abstinent users but memory impairments 
were persistent. 
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Although the association of MDMA use and memory deficits in humans has 
been a consistent finding in most studies, the utility of those data is limited by 
several factors including incomplete history of drug use of the subjects, 
inappropriate control groups, small group sizes and the difficulty in assessing 
brain pathology in living human subjects. In addition it is widely reported that 
MDMA users also consume a variety of other drugs, most notably cannabis, 
alcohol and cocaine which also caused memory impairments (Rogers and 
Robbins, 2001, Scholey et aI., 2004). It is likely that cognitive impairments 
reported in MDMA users might be related to other drug use. Studies of the 
effects of MDMA administration in laboratory animals are important to 
determine effects of MDMA on learning and memory. 
1.7.2 Evidence/rom animal studies 
There is increasing evidence for effects of MDMA on learning and memory in 
laboratory animals. Marston et at (1999) reported an acute disruption of the 
delayed non matching-to-place (DNMTP) when MDMA was given twice daily 
to rats over 3 days in ascending doses (10, 15 and 20 mglkg). In addition 
Braida et al (2002) showed an acute effect of single low doses ofMDMA (1, 2 
or 3 mg/kg) on short-term working memory and impairment of long-term 
working memory in the eight-arm radial maze task. Harper et al (2005) found 
that MDMA (2 and 3 mglkg) impaired the delayed matching-to-sample 
accuracy when given 10 min before the task. In rhesus monkeys, Frederick and 
Paule (1997) suggested that MDMA (0.1-1.0 mglkg) disrupted performance in 
learning and time estimation more than short-term memory and visual 
discrimination. However with a higher dose of MDMA (10 mg/kg i.m. twice 
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daily for 4 days) rhesus monkeys showed impairment of self-ordered spatial 
search (SOSS) and delayed non-matching-to-sample task (Taffe et aI., 2001). 
To date no study has investigated the neurotransmitters relevant to the acute 
memory impairments caused by MDMA. 
The long-term effects of MDMA on memory in laboratory animals are more 
controversial and additionally the relationship between impairments in memory 
and long-term 5-HT depletion caused by MDMA remains unclear. MDMA 
exposure to very young rats has been reported to cause impainnents of 
sequential and spatial reference memory-based learning using the multiple-T 
water maze and the Morris water maze while there was little change in 5-HT, 
dopamine and norepinephrine levels in the hippocampus and frontal cortex 
(8roening et aI., 2001, Williams et al., 2003). On the other hand MDMA 
administration to adult rats affected spatial learning in the Morris water maze 
and significantly decreased 5-HT levels in the hippocampus (Sprague et al., 
2003). Piper and Meyer (2004) found an impairment of object recognition 
memory in rats given repeated intermittent MDMA treatment during the 
periadolescent period, but only a small decrease of 5-HT uptake transporter 
density in the cortex and hippocampus. In addition, high dose regimen of 
MDMA also produced a long-lasting disruption of rat memory in the object 
recognition task (Morley et aI., 2001). Other studies have found long-term 
cognitive impainnents caused by MDMA as determined by the delayed non 
match-to-position task (Marston et aI., 1999) and a social memory test (Pompei 
et aI., 2002). Recently Able et aI (2006) and Skelton et al (2008) reported an 
impairment of path integration learning in the Cincinnati water maze in rat 
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treated with MDMA (4x15 mg/kg) together with long-term brain 5-HT 
depletion. However, studies in rhesus monkeys suggest that MDMA produces 
no long-lasting alteration in cognitive performance on several tasks such as 
SOSS and DMTS even though there is a decrease in 5-HIAA levels in 
cerebrospinal fluid (CSF) (Frederick et aI., 1998, Taffe et aI., 2001). 
In summary many studies have demonstrated impairments of episodic memory, 
working memory, executive function as well as learning abilities and attention 
in recent and abstinent MDMA users. These impairments have also been 
demonstrated to correlate with a decrease in 5-HT integrity in recent MDMA 
users however loss of 5-HT was shown to recover in ex-MDMA users. In rats 
MDMA caused an acute disruption of working memory in various cognitive 
models. In addition long-term impairments of sequential, spatial and working 
memory following MDMA administration occurs in rats. The following section 
reviews the method used to study the effect of MDMA on memory in this 
thesis, the novel object discrimination task. 
1.S. Novel object discrimination 
There are various animal models used to investigate effects of MDMA 
administration on learning and memory in the rats including delayed non-
matching-to-place, delayed matching-to-sample, Morris water maze and 
Cincinnati water maze. The study in this thesis aimed to investigate the acute 
and long-term effect of MDMA on memory using the novel object 
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discrimination which tests recognition as well as working memory as these 
types of memory are impaired in MDMA users (see section 1.7). 
The novel object discrimination is a recognition memory task involving an 
innate preference of the rats for novelty. The novel object discrimination 
protocol used in this thesis is modified from Ennaceur and Delacour (1988). 
The test consists of two trials; familiarisation and choice trials with varied 
inter-trial interval (Figure 1.10). In the familiarisation trial a rat is allowed to 
explore two identical objects. Following an inter-trial interval, one of the 
identical objects is replaced by a novel object in the choice trial. The nonnal 
rats spend more time exploring the novel object, suggesting that the familiar 
object is recognized (Dix and Aggleton, 1999, Ennaceur and Delacour, 1988). 
The novel object discrimination task is a 'pure' working memory task as it is 
completely free of reference memory and reinforcements such as electric shock 
or food (Ennaceur and MeHani, 1992). In addition advantages of novel object 
discrimination task, in comparison to other animal models for cognition, are 
that the novel object discrimination requires less training and does not induce 
high levels of arousal and stress, therefore it is more closely related to 
conditions under which human recognition memory is measured (Ennaceur and 
Delacour 1988). 
Both 5-HT and dopamine neurotransmission, the neurotransmitters affected by 
MDMA, have been demonstrated to be involved in novel object discrimination. 
For example the 5-HTIA receptor antagonist, WAY 100635 improved novel 
object recognition in rats (Pitsikas et aI., 2003, Schiapparelli et aI., 2006) while 
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the 5-HT1A receptor agonist, 8-0H-DPAT caused impairment of novel object 
discrimination performance (Pitsikas et ai., 2005). In addition the novel object 
discrimination was improved following administration of the 5-HT 4 receptor 
agonist, RS67333 and the 5-HT 6 receptor antagonists, SB271046 and Ro-
046790 (King et aI ., 2004, Lamirault and Simon, 2001). Hotte et aI (2005) 
found that dopamine DI receptor activation impaired object recognition with a 
short delay while improved object recognition after long delay. In addition 
Chuhan and Taukulis (2006) showed that methylphenidate, a dopamine and 
noradrenaline reuptake transporter inhibitor impaired novel object 
discrimination using a 24 h delay between trials. 
Delay 
Familiarisation Trial Choice Trial 
Figure 1.10 The novel object discrimination used in this thesis is modified from 
Ennaceur and De1acour (1988). The test comprises of two trials: familiarisation and 
choice trials . In the familiarisation trial two identical objects are presented to the rat 
followed by a delay. In the choice trial one of the identical objects is replaced by a 
novel object. The normal rats spend more time exploring the novel object as they 
recognise the familiar object. 
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1.9. Objectives 
The review of the literature has shown that MDMA produces acute and long-
term effects on various neurotransmitter systems especially 5-HT and 
dopamine, two of the neurotransmitter systems associated with learning and 
memory. Additionally there is a growing evidence for MDMA-induced 
learning and memory impairments in experimental animals and possibly 
humans. The interpretation of effects ofMDMA in animals to humans is one of 
concern due to the fact that animal studies use high doses to produce 
neurotoxicity. Moreover the dosage regimens used in animal studies are often 
not comparable to human use patterns. This thesis focuses on using low doses 
of MDMA combined with repeated administration to imitate 'binge' use in 
human. 
This thesis therefore has the following aims: 
1. To determine the acute effects of single low doses of MDMA on working 
memory and changes in amine neurotransmitter levels relevant to the 
acute memory deficits 
2. To determine the acute effects of repeated administration of low doses of 
MDMA, which imitates 'binge' use of MDMA in humans, on locomotor 
activity, body temperature and changes in extracellular 5-HT in the 
hippocampus 
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3. To detennine the long-tenn effects of repeated low doses of MDMA on 
working memory and 5-HT neurotoxicity and investigate an influence of 
housing conditions during MDMA administration on MDMA-induced 
acute change in body temperature and consequent long-tenn 5-HT 
neurotoxicity 
4. To detennine the importance of tyrosine (and dopamine) depletion in 
MDMA-induced 5-HT neurotoxicity 
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THE ACUTE EFFECT OF SINGLE LOW DOSES OF 
MDMA ON NOVEL OBJECT DISCRIMINATION 
CHAPTER 2: Acute effect oflow doses of MOM A on memory 
2.1. Introduction 
There is growing evidence for a link between cognitive impairments and 
MDMA administration in humans and experimental animals (Morgan, 2000, 
Parrott, 2006, Piper, 2007). However the acute effects of MDMA on learning 
and memory in the rat have been relatively little investigated. Marston et al 
(1999) reported an acute disruption of the delayed non-matching to place when 
MDMA was given twice daily to rats over 3 days in ascending doses (10, 15 
and 20 mg/kg). In addition when given a single low dose ofMDMA (1, 2 or 3 
mg/kg) to rats 20 min before the eight-arm radial maze task, Braida et al (2002) 
showed a modest effect of MDMA on short-term working memory and 
impairment of long-term working memory. The more recent study by Harper et 
al (2005) showed that MDMA (2 and 3 mg/kg) impaired the delayed matching-
to-sample accuracy when given 10 min before the task. However this 
impairment was suggested to represent a disruption of attention rather than 
memory (Harper et al., 2005, 2006). To date there has not been a study 
investigating the involvement of specific neurotransmitters in the acute 
memory disruptions caused by MDMA. 
The research described in this chapter aimed to determine the acute effects of a 
single low dose of MDMA on recognition memory using novel object 
discrimination and simultaneously to investigate changes in amine 
neurotransmitters in specific brain regions which are thought to be responsible 
for the cognitive disruption. 
61 
CHAPTER 2: Acute effect oflow doses ofMDMA on memory 
2.2. Materials and methods 
2.2. J Animals 
Adult male Lister hooded rats (Biomedical Service Unit, University of 
Nottingham) weighing 250-350 g were housed in groups of 3-4 on a 12 h 
light/dark cycle (light on at 07.00 h) and given food and water ad libitum. 
Room temperature (21±2 0c) and humidity (45-65%) were kept constant. All 
experiments were performed in accordance with the UK Animals (Scientific 
Procedures) Act, 1986 under project license 40/2715 and approved by the 
University of Nottingham Local Ethical Review Committee. 
Lister hooded rats were used in the present study because this strain of rat has 
good eyesight compared to albino rat strains due to the pigmented nature of 
hooded rats. This allows Lister hooded rats to perform better in a visual 
discrimination task such as novel object discrimination. Recently Ennaceur et 
al (2005) showed that male and female Lister hooded rats had better 
performance in novel object discrimination task compared to male Wistar rats 
while female Wistar rats cannot discriminate the novel from the familiar object. 
Dark Agouti rats were used in preference in the tyrosine depletion study (see 
Chapter 5), however it has poor performance in novel discrimination task as 
preliminary study showed that Dark Agouti rats cannot discriminate the novel 
from the familiar object in the choice trial of novel object discrimination with a 
2-h inter trial interval. In addition Dark Agouti rats has less attention to the 
objects compared to Lister hooded rats as it was shown in the preliminary 
study that total time spent exploring the novel and familiar objects in the 
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choice trial of Dark Agouti rats was 8 ± 1 s compared to 34 ± 5 s of Lister 
hooded rats in this experiment. 
2.2.2 Novel object discrimination 
Novel object discrimination used in the present study was modified from 
(Ennaceur and Delacour, 1988). The apparatus comprised a clear Perspex box 
(39 x 23.5 em with 30 cm high walls) as an arena and the objects to be 
discriminated were plastic bottles (8 cm high x 5 cm diameter) covered in 
white masking tape alone (familiar object) or white and black masking tape 
(novel object). Objects were cleaned with 20% v/v ethanol prior to each 
experiment to remove any olfactory cues, and each bottle was then inverted 
and secured with Blu-tack through holes in the floor located 5 cm from the side 
and 10 cm from the end walls in opposite comers (front left and back right) of 
the arena. The weight of each bottle was such that the rats could not displace it. 
Experiments were performed in constant light (200 Lux at floor level in the 
arena) between 10.00 and 14.00 h. 
The experiment comprised of two consecutive trials; the first familiarisation 
trial (Trial I; TI) and the second choice trial (Trial 2; T2). Twenty-four hours 
prior to testing, each rat was habituated to an individual test arena for 60 min in 
the absence of any object. On the test day, each group of rats received either 
MDMA (1 mg/kg or 3 mg/kg i.p., (±)-MDMA Hel, Sigma, UK) or saline (I 
ml/kg i.p.). Thirty minutes later, each rat was habituated in the individual arena 
for 3 min in the absence of any object and then the rat was returned to its own 
home cage for 1 min. In the familiarisation trial rats were exposed to the two 
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identical objects for 3 min followed by a 2 h inter-trial interval. In previous 
studies at Nottingham it has been shown that Lister hooded rats can 
discriminate t h ~ ~ novel from the familiar object with an inter-trial interval of up 
to 3 h (King et al., 2004). In the choice trial one of the identical objects was 
replaced with a bottle of identical size and shape but with horizontal black 
stripes (novel object). The remaining object from trial 1 was left untouched 
(familiar object). During both trials the exploration of either object was defined 
as the time spent sniffing, licking, chewing or touching it with the nose or 
within 1 cm of it with moving vibrissae and was recorded separately for each 
object by stopwatches. Sitting on the object was not regarded as exploratory 
activity. 
Immediately after novel object discrimination rats were killed and the brains 
were quickly removed from the cranial cavity and dissection carried out on a 
chilled glass plate. The frontal cortex was cut 3 mm from the front of the brain. 
The hippocampus and striatum were dissected out and each half of these 
structures was kept separately in 1.5-ml eppendorf tubes. Brain regions were 
quickly frozen in liquid nitrogen immediately following dissection and stored 
at - 80°C for later analysis of 5-HT, 5-HIAA, dopamine, DOPAC and HV A. 
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'MDMA • Habituation (3 min) • Exploring novel 
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• Saline (1 mlA<g i.p.) objects (3 min) (3 min) 
Figure 2.1 Diagrammatic representation of the experimental protocol 
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Figure 2.2 Diagram representing the familiarisation trial, comprised of two identical 
objects (bottle with white masking tape), and the test trial when one of the familiar 
objects (white masking tape) was replaced by a novel object (white and black masking 
tape). 
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2.2.3 Measurement of dopamine, 5-HT and their metabolites in brain tissues 
using HPLC-ECD 
High performance liquid chromatography (HPLC) is widely used for 
quantitative analysis of components contained in solution. The method 
comprises two techniques; chromatographic separation and quantitative 
analysis using a suitable method of detection. "Reverse-phase" 
chromatography is generally used for measurement of monoamine 
neurotransmitters. The stationary phase consists of alkyl silylating reagent 
bound to the silica particles which create a hydrophobic, non-polar surface. 
The polar mobile phase, consisting of water and methanol, was pumped over 
the stationary phase at a fIxed flow rate. Components are eluted in order of 
decreasing polarity. Electrochemical detection (ECD) is used to detect the 
electroactive compounds using three electrodes; the working, reference and 
auxiliary electrodes. The working electrode, made of glassy carbon, has a 
positive fIxed potential applied to it, which for the amines is normally O.7SV. 
The reference electrode usually consists of a silver/silver chloride (AgI AgCI) 
maintained at a fIxed the potential. The components in the samples are 
separated by a silica column (according to molecular mass and charge in 
solution) and then pass through the cell, over the working electrode where the 
molecules are oxidized and electrons transferred to it thereby generating a 
current which is directly proportional to the amount of electroactive substance 
present. The current is amplifIed and converted into a signal which is recorded 
on a chart recorder or chromatography integrator. The potential is governed by 
applied potential at which the molecules undergo the redox reaction underlying 
this method (Figure 2.3). 
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Tissue sample preparation 
Tissue samples were weighed and then homogenized with 1 ml ice-cold 
solution of 0.1 M perchloric acid containing 0.1 % w/v sodium metabisulfite 
and 0.01 % w/v disodiumethylenediamine-tetraacetate (EDT A) using a 
sonicator (Soniprobe, output -20,20-30 s). The homogenate was centrifuged at 
17500 g for 20 min at 4°C (Harrier 18/80 refrigerated, MSE). The supernatant 
was filtered and then kept at -80°C for later analysis. 
HPLC-ECD 
The HPLC system consisted of a Jasco PU-980 pump, Rheodyne 7125 
injection valve and SP4290 integrator. The mobile phase; 0.05 M potassium 
dihydrogen orthophosphate (KH2P04), 0.1 mM EDTA, 0.16 mM octane 
sulfonic acid (disodium) and 13.5% methanol dissolved in HPLC grade water, 
pH adjusted to 3.0 with o-phosphoric acid, pumped at 1 mllmin through 
SphereClone column (C18, 4.6 x 150 nun, 5J.1m; Phenomenex, Macclesfield, 
OB). A 20-J.11 of 10-7 M mixed standard of 5-HT, 5-HIAA, dopamine, DOPAC 
and HV A was routinely injected onto the column. Quantification was achieved 
using Antec CU-04 controller and Antec VT-03 cell fitted with a glassy 
working carbon electrode (Antec Leyden, Zoeterwoude, The Netherlands) with 
the potential set at 0.75V versus AglAgCl reference electrode. The lower limit 
of detection was 0.1 pmol injected onto the column. The internal standard was 
not used in the present study as the process of tissue sample preparation is 
simple and does not involve multiple process of extraction. The internal 
standard used in the analysis for 5-HT, 5-HIAA, noradrenaline and dopamine 
concentrations in brain tissue is N-methyl-5-HT (Durkin et aI., 2008). 
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Figure 2.3 Diagram showing the oxidation of catecholamine and indoleamine that 
occurs at the surface of the carbon electrode. 
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Figure 2.4 The components of HPLC-ECD system used in this thesis 
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Figure 2.5 An example of the chromatographic separation of dopamine, DOPAC, 5-
HT, 5-HIAA and HV A (10.7 M each) in the mixed standard using mobile phase 0.05 
M KH2P04, 0.1 mM EDTA, 0.16 mM octane sulfonic acid and 13.5 % v/v methanol 
pH 3.0. 
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Figure 2.6 Examples of chromatograms from striatum (A) hippocampus (B) and 
frontal cortex (C). Tissue samples were weighed and then homogenized with 1 m! ice-
cold solution of 0.1 M perchloric acid containing 0.1 % w/v sodium meta bisulfite and 
0.01 % w/v EDTA using a sonicator (Soniprobe, output -20, 20-30 s). The 
homogenate was centrifuged at 17500 g for 20 min at 4 °C (Harrier 18/80 refrigerated, 
MSE). The supernatant was filtered and then kept at -80 °C for later analysis. There 
are dopamine, DOPAC, 5-HT, 5-HIAA and HVA peaks in the striatum sample (A) 
while there are 5-HT and 5-HIAA peaks in the hippocampus (B) and frontal cortex (C) 
samples. 
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Figure 2.7 Linear relation between the concentration of exogenous dopamine, 
DOPAC, HV A, 5-HT and 5-HIAA injected onto the column and the detector 
response. 
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2.2.4 Statistical analysis 
For novel object discrimination, data are presented as time (s) spent exploring 
each of the identical objects during the familiarisation trial, and time (s) spent 
exploring the novel object versus the familiar object during the choice trial (± 
SEM) and two-way ANOV A was used to analyse overall effect of treatment 
and object on time spent exploring the objects followed by Bonferroni post hoc 
test for within-group comparisons of time spent exploring each object. The 
explomtory data in the choice trial was converted to a mean preference index 
(PI). PI is a measure of the percentage time spent exploring the novel object 
compared to the total time exploring both objects in the choice trial (e.g. [novel 
object! novel object + familiar object] x 100) (Bruel-Jungerman et aI., 2005). 
The PI of each group of rats was then compared to a PI value of 50% chance 
level performance using one sample t-test. Between-group comparison of total 
time that mts spent exploring two identical objects in the familiarisation trial 
(total TI time) and the novel and the familiar object in the choice trial (total T2 
time) (s) were assessed using one-way analysis of variance (ANOVA) followed 
by Tukey's post hoc test. A significant difference was considered at p<0.05. 
For amine neurotmnsmitters analysis in the striatum, hippocampus and frontal 
cortex, between-group comparison of amine neurotmnsmitter concentrations 
(pmol/mg of tissue) was made using one-way ANOVA followed by Tukey's 
post hoc test. A significant difference was considered at p < 0.05. 
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2.3. Results 
2.3.1 The acute effect of low doses of MDMA on novel object discrimination 
To detennine the acute effect of low doses of MDMA on novel object 
discrimination rats were given either MDMA (1 mglkg or 3 mglkg) or saline 
30 min prior to the familiarisation trial followed by 2 h inter-trial interval 
before the choice trial. In the familiarisation trial when the rats were exposed to 
two identical objects, all three groups of rats showed no difference in time 
exploring the two identical objects (Figure 2.8A). In the choice trial which was 
2 h after the familiarisation trial, two-way ANOV A revealed an overall effect 
of the objects (F(I,25) = 31.91, p < 0.0001) on time spent exploring the novel 
versus familiar object, such that Bonferroni post hoc test showed that rats in the 
control group (saline injected) spent a significantly greater time exploring the 
novel versus the familiar object (p < 0.01), indicating an ability to discriminate 
between the novel and familiar objects. This ability to discriminate was also 
seen in the rats treated with MDMA (1 mglkg) as they spent significantly more 
time exploring the novel rather than the familiar object (p < 0.01) in trial 2 
(Figure 2.8B). However, the higher dose of MDMA (3 mglkg) caused an 
impainnent in novel object discrimination in trial 2, as the rats spent equivalent 
times exploring the novel and the familiar objects (p > 0.05; Bonferroni post 
hoc test) (Figure 2.8B). 
Object exploratory times in the choice trial were converted into the preference 
index (Pij shown in Figure 2.9. The PI value of either MDMA (lor 3 mglkg) 
treated rats was not significantly different from saline-treated rats (p > 0.05, 
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unpaired Student t-test). However the PI values of saline and MDMA (1 
mg/kg) treated rats were significantly greater than the PI value of 50% chance 
level (p = 0.0002 and p = 0.0004 respectively, one sample I-test) while the PI 
value of MDMA (3 mg/kg) treated rats was not significantly different from 
50% chance level (p = 0.1105, one sample I-test) (Figure 2.9). 
The total time that the rats spent exploring the objects in trial 1 (total Tl time) 
and trial 2 (total T2 time) are shown in Table 2.1. Total TI time varied between 
groups of rats but the differences were not significant. The data showed that 
total Tl time in the MDMA (1 mglkg)-treated group (47 ± 4 s) was higher than 
that of the saline-treated rats (39 ± 7 s) while total Tl time of the MDMA (3 
mg/kg)-treated rats (28 ± 4 s) was the lowest. However, there was no 
difference in the total time spent exploring the novel and the familiar object in 
trial 2 (one-way ANOVA). 
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Figure 2.8 Effects of MDMA (l and 3 mg/kg i.p.) on the time spent (s, means ± SEM) 
exploring each of the identical objects during trial 1 (A) and the novel versus the 
familiar object during trial 2 which was 2 h after trial 1 (B). The first trial was 30 min 
after drug treatment and the second trial was 150 min after treatment. ** p < 0.01 
compared with time spent at the familiar object in the same treatment group, 
Bonferroni post hoc test (n = 9 - 10). 
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Figure 2.9 Time spent exploring the novel versus the familiar objects in the choice 
trial was converted into a preference index (PI) (e.g. [novel object! novel object + 
familiar object] x 100) (Bruel-Jungennan et aI., 2005). Data are presented as means of 
PI values ± SEM (n = 9 - 10). Each experimental group was compared against a PI 
value of 50% chance level (dashed line) using one sample t-test. *** p < 0.001 
compared to a PI value of 50% chance level (one-sample t-test) 
Table 2.1 Total time spent exploring the objects in trial 1 (Total T1 time) and trial 2 
(Total T2 time) (s). The first trial was 30 min after drug treatment and the second trial 
was 150 min after treatment. Data are expressed as means ± SEM. (n = 9 - 10) 
Treatment Total Tl time Total T2 time 
(s, mean ± SEM) (s, mean ± SEM) 
sa line 39 ± 7 34 ± 5 
MDMA (1 mg/kg) 46 ± 4 33 ± 4 
MDMA (3 mglkg) 28 ± 4 36 ± 3 
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2.3.2 The acute effects of low dose MDMA on dopamine, 5-HT and their 
metabolites in rat hippocampus, frontal cortex and striatum 
Following treatment with MDMA (I mg/kg), 5-HT levels in rat hippocampus 
was not different from controls. However MDMA (3 mglkg) tended to 
decrease 5-HT levels in rat hippocampus but this was not significant compared 
to saline controls (Table 2.2). In the frontal cortex, 5-HT levels following 
MDMA (I mglkg) and MDMA (3 mglkg) were a little lower than controls but 
again this was not significant (Table 2.2). In the striatum, there was no 
significant difference between 5-HT levels following saline and MDMA (I 
mglkg and 3 mglkg) (Table 2.2). 
5-HIAA, the major 5-HT metabolite, was also measured in the hippocampus, 
frontal cortex and striatum 150 min after MDMA (1 and 3 mg/kg) 
administration. Data showed no significant different in 5-HIAA levels in the 
hippocampus between saline and MDMA (1 and 3 mg/kg) treated rats (Table 
2.2). Similar lack of drug treatment was seen in the frontal cortex and the 
striatum (Table 2.2). 
Dopamine and its metabolites, OOP AC and HV A, concentrations were 
measured only in the striatum. The results show that dopamine, DOP AC and 
HV A in the striatum of MDMA (I and 3 mg/kg) treated rats were not 
significantly different from saline controls (Table 2.3). 
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Table 2.2 5-HT and 5-HlAA levels (pmol/mg tissue) in rat hippocampus, frontal 
cortex and striatum 150 min after MDMA (1 or 3 mg/kg i.p.) or saline (1 mllkg i.p.). 
Data are presented as means ± SEM. (n = 8 - 10) 
Hippocampus Frontal cortex Striatum 
Treatment 5-HT 5-HIAA 5-HT 5-HIAA 5-HT 5-HIAA 
Saline 2.34±O.l3 2.59±O.26 2.67±O.18 1. 67±O.24 3.08±O.23 2.99±O.l9 
MDMA 2.45±O.25 2.49±O.10 2.52±O.15 1.64±O.28 3.04±O.l2 2.85±O.11 
(1 mgtkg) 
MDMA 2.l4±O.l9 2.51±O.42 2.53±O.l3 1.43±O.l9 3.25±O.20 2.69±O.20 
(3 mgtkg) 
Table 2.3 Dopamine and its metabolites, DOP AC and HV A levels in rat striatum 150 
min after MDMA (lor 3 mg/kg i.p.) or saline (1 ml/kg i.p.). Data are presented as 
means ± SEM. (n = 8 -10) 
Treatment Dopamine 
saline 35.56 ± 5.26 
MDMA (1 mgtkg) 41.28 ± 4.21 
MDMA (3 mgtkg) 38.84 ± 1.86 
OOPAC 
5.42 ± 1.06 
5.63 ±0.69 
5.69 ± 0.66 
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3.15 ± 0.57 
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3.27± 0.30 
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2.4. Discussion 
This chapter reviews studies examining the acute effect of single low doses of 
MDMA on memory assessed by using novel object discrimination in the adult 
rat. The MDMA doses used in this study (1 and 3 mglkg) were lower than the 
doses of MDMA used to induce serotonergic neurotoxicity in rats (10-40 
mglkg) (Battaglia et aI., 1987, Commins et aI., 1987, Schmidt et aI., 1987). In 
addition, the doses selected for this study more closely represent the equivalent 
dose for occasional use of the drug by humans as reviewed recently (Green et 
a1.,2009). 
The main finding was that acute injection of 3 but not 1 mglkg MDMA 
disrupted novel object discrimination without altering brain 5-HT and 5-HIAA 
levels. The fmding of memory disruption following a low dose MDMA 
administration in the present study is in agreement with studies demonstrated 
by Braida et al (2002) and Harper et al (2005) who found acute memory 
impairments in eight-arm radial maze and delayed matching-to-sample 
(DMTS) tasks respectively following single low doses ofMDMA (1-3 mglkg). 
The impairment of novel object discrimination presented in this study however 
cannot be solely interpreted as a specific disruption of cognitive function as it 
is noticeable that MDMA (3 mglkg)-treated rats have less total exploratory 
activity in the familiarisation trial, which was 30 min after drug administration 
than the other two groups (Table 2.1). A decrease of exploratory activity in the 
familiarisation trial following MDMA (3 mglkg) might be due to MDMA 
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causing either less attention, or a direct alteration of locomotor activity and 
stereotype related to induction of components of the serotonin syndrome 
observed with drug induced release of 5-HT. Harper et al (2005) suggested that 
the acute impairment of an overall delay-independent DMTS accuracy 
following MDMA reflected an impairment of the attention process rather than 
memory. In addition MDMA-induced acute 5-HT release causes hyperactivity 
and the serotonin syndrome (Callaway et aI., 1990, Spanos and Yamamoto, 
1989) and this might disrupt normal exploratory activity. However, the study 
by Braida et al (2002) there was no significant change in locomotor and 
stereotype activity after 20 min of acute low doses ofMDMA (1-3 mglkg i.p.). 
Similarly in the present study there was no change in stereotypies observed in 
MDMA-treated rats. In summary less exploration of the identical objects in the 
familiarisation trial in MDMA (3mglkg)-treated rats may result in less memory 
for the familiar object and thus influence recognition in the choice trial. 
The neurochemical data showed no change in dopamine, 5-HT and their 
metabolites in the hippocampus, frontal cortex and striatum 150 min after 
either doses of MDMA. The main limitation of the present study was the lack 
of a neurochemical profile during the novel object discrimination task thus it 
cannot be determined whether the impairment of novel object discrimination 
involved an acute change in neurotransmitter function (such as 5-HT and 
dopamine). In a comparable study by Gudelsky and Nash (1996), using in vivo 
microdialysis, MDMA (2.5 mglkg) produced a significant increase of 
extracellular 5-HT concentration 30 to 90 min after drug injection in the 
striatum and 30 to 60 min after drug injection in the median prefrontal cortex 
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5-HT levels returned to the baseline 150 min following MDMA (2.5 mg/kg) 
administration (Gudelsky and Nash, 1996). In addition a study by Baumann et 
al (2008) again using in vivo microdialysis showed acute dopamine release in 
the striatum and prefrontal cortex following two injections of MDMA (1 and 3 
mg/kg) at 1 h intervals. As 5-HT and dopamine have been suggested to be 
important in learning and memory (see review Floresco and Magyar, 2006, 
King et aI., 2008, Meneses, 2003, Missale et aI., 1998), this profile of 5-HT and 
dopamine release following low doses of MDMA suggests that the behavioural 
change during novel object discrimination in the present study may relate to 
changes in 5-HT and dopamine release. 
In conclusion, the present results add to the growing evidence of acute 
disruption of learning and memory processes following low dose 
administration of MDMA (3 mg/kg) in the rat. The limitation of the present 
study was clearly the lack of functional and neurochemical measurements 
during the behaviour as mentioned above. To address this issue in the next 
chapter the intracerebral microdialysis technique was used to measure the acute 
changes in 5-HT concomitant with behavioural assessment in response to 
systemic administration of low doses ofMDMA. 
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CHAPTER 3: Acute effects of repeated MDMA administration 
3.1. Introduction 
Over the last decade, the pattern of MDMA use in humans has been often 
characterized as repeated drug administration on a single occasion and referred 
to as 'binge use' (Hammersley et aI., 1999, Parrott, 2005, Topp et aI., 1999, 
Winstock et aI., 2001). It is claimed that binge use of MDMA boosts the 
subjective effects of MDMA possibly by reducing tolerance effects of repeated 
usage (Parrott, 2005). This pattern of use may lead to an increased risk of acute 
and long-term toxicity. Pharmacokinetic studies in humans showed that 
repeated administration of MDMA presented non-linear pharmacokinetics (de 
la Torre et aI., 2000) as MDMA is a CYP 2D6 enzyme inhibitor which thus 
causes an inhibition of its own metabolism (Delaforge et aI., 1999). 
Consequently Farre et al (2004) reported an increase of area under the plasma 
concentration-time curve (AUC) and maximum plasma drug concentrations 
(Cmax) of MDMA after a second dose following a 24 h interval and increased 
pharmacological effects such as increase in blood pressure, heart rate, 
subjective effects and cortisol levels. Similar to the effects in humans repeated 
administration of MDMA (3 and 9 mglkg twice daily for 4 days) increased 
mean arterial blood pressure, produced biphasic (decrease and increase) heart 
rate and produced cardiac toxicity in rats (Badon et aI., 2002). 
The hyperthermic response is a well established severe acute adverse effect of 
MDMA ingestion (Green et at, 2003, Liechti and Vollenweider, 2000). It can 
lead to other associated clinical problems including rhabdomyolysis, 
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intravascular coagulation and acute renal failure (Green et aI., 2003). In animal 
studies Green et al (2004) reported a dose-dependent MDMA-induced 
hyperthermia following repeated MDMA (2, 4 and 6 mg/kg x 3 every 3 h) to 
the rats. Baumann et al (2008a) also showed a marked and sustained increase 
of body temperature following MDMA (7.5 mglkg x 3 every 2 h) administered 
to rats. In addition to acute hyperthermia induced by repeated administration of 
MDMA, Kindlundh-Hogberg et al (2007) reported hyperactivity caused by 
repeated MDMA (5 mg/kg x 3 every 3 h). This pattern of MDMA 
administration also enhanced activity in the centre of the open field arena 
indicating reduced anxiety or enhanced impulsivity which is known to be 
associated with altered 5-HT activity (Kindlundh-Hogberg et at, 2007). 
Although evidence for acute effects of repeat administration of MDMA have 
been reported, no study has looked at acute functional changes, such as activity 
and body temperature, together with changes in extraneuronal neurotransmitter 
levels. The aim of the research in this chapter was to determine the acute 
effects of repeated low doses of MDMA to imitate binge use in humans on 
locomotor activity, body temperature and extracellular 5-HT in the 
hippocampus by combining the techniques of radiotelemetry and brain 
microdialysis so that body temperature, activity and 5-HT release in the 
hippocampus could be measured simultaneously in the same animal. The 
second aim was to examine whether changes in locomotor activity or body 
temperature correlated with changes in extracellular 5-HT in the hippocampus. 
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3.2. Materials and methods 
3.2.1 Animals 
Male Lister-hooded rats (Biomedical Services Unit, University of Nottingham, 
UK) were kept at a constant ambient temperature (21±2 0c) and humidity (45-
65 %) on a 12 h light/dark cycle (light on at 07.00 h) with free access to food 
and water. All experiments were performed in accordance with the UK animals 
(Scientific Procedures) Act 1986 and approved by the University of 
Nottingham Local Ethical Review Committee. 
3.2.2 Experimental procedure 
Rats weighing 100-130 g were implanted with a radio transmitter into the 
peritoneal cavity under isoflurane anaesthesia and then allowed to recover in an 
individual cage for 1 week. Seven days after surgery each individual cage was 
moved to the telemetry room and placed over a receiver where the rats were 
monitored for their normal activity and body temperature for 1 week. In the 
telemetry room temperature (21±1 °C) and humidity (45-65 %) were kept 
constant. Food and water were available ad libitum. Fourteen day after 
radiotransmitter implantation, the rat was implanted with a microdialysis probe 
into the hippocampus under isoflurane anaesthesia and then allowed to recover 
overnight. The following day each rat received either MDMA (3 or 6 mglkg) or 
saline (1 mIlkg) i.p. 3 times every 2 h (MDMA, synthesized by Department of 
Chemistry, University College Dublin, Ireland). Microdialysis samples were 
collected 1 h before the first injection until 2 h after the last injection. Body 
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temperature and locomotor activity were simultaneously recorded during 
treatment using radiotelemetry. 
Day 
o 
I 
Recovery period 
Radiotransmltter 
implantation 
7 14 
Body temperature and activity basefine 
monitoring 
• Treatment : 
- MDMA 3 mglkg I.p. or 
- MDMA 6 mglkg Lp. or 
- Saline 1 mVkg Lp. 
3 times 2 h apart 
• Simultaneously 
measurement 
- Microdialysis: 5-HT 
- Telemetry: Body 
temperature and activity 
Figure 3.1 Diagrammatic representation of the experimental protocol. 
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3.2.3 Radiotelemetry 
The radiotelemetric technique provides a tool to monitor physiological 
functions in awake and freely moving laboratory animals. The system consists 
of a miniature sensor and transmitter coated with biocompatible material used 
to detect and broadcast biological signals in animals to a remote receiver, 
which converts the analog frequency signal into a digital signal inputted into a 
computerized data acquisition system. The acquisition system stores, 
manipulates, formats, tabulates and outputs the data. A telemetric system used 
in this experiment (DataScience International, St Paul, MN, USA) consists of 
an implantable radiotransmitters (Model TAlOTA-F20 to measure body 
temperature and activity), RPC-l receiver, a consolidation matrix and 
A.R.T.v2.1 acquisition software (Figure 3.2). 
The advantages of radiotelemetry in psychopharmacological research include 
reducing animal distress compared to conventional techniques, eliminating 
animal restraint, reducing the number of animals used by increasing the 
number of parameters that can be collected from a group of animals and 
permitting virtually unrestricted continuous data collection (Kramer and 
Kinter, 2003). Since radiotelemetry permits investigation of drug effects in 
freely moving unrestrained animals, it facilitates an animal model that mimics 
the clinical conditions of drug investigation. 
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Surgical procedure 
A radio transmitter (TAIOTA-F20) was implanted into the peritoneal cavity of 
the rat under isoflurane general anaesthesia. Anaesthesia was induced using 
isoflurane (4%) in 02:N20 1:2 and maintained using isoflurane (2.5%). During 
surgery the rat was placed on a heat pad to maintain body temperature. A small 
abdominal incision was made vertically at approximately 1 em to an abdominal 
midline. A sterile radiotransmitter was inserted then subcutaneously sutured 
with absorbable suture (Fluorosorb) and skin closed by sterile clips which were 
removed 5 days after surgery. Analgesia (Rimadyl), local anaesthesic (Lignol) 
and fluid replacement (0.9% NaCl) were given and plastic wound dressing 
(Nobecutane, Astra Pharmaceutical) applied. Rat was allowed to recover in an 
individual home cage for 1 week before starting radiotelemetry recording. 
Data manipulation and statistical analysis 
When an individual cage was placed over the receiver, locomotor activity and 
body temperature were continuously sampled lOs every 2 min using 
A.R.T.v2.1 acquisition software. The data during treatment were calculated as 
means of activity (counts/min) and body temperature eC) in 20-min time bins 
for individual rats thereby enabling a mean ± SEM value for each group at each 
time point to be calculated. In addition a calculation of the overall changes over 
the observation period of 120 min after each injection (area under the curve; 
AUC) was performed for locomotor activity. This allows a comparison of the 
size of response in each group as presented graphically in the results section. 
Data from changes in activity and body temperature in 20-min time bins and 
the AUC were analysed using repeated, 2-way ANOV A with treatment and 
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time as mam factors followed by Bonferroni post hoc test. The significant 
difference was considered at p < 0.05. Differences were deemed significant at p 
<0.05. 
.1 HPLCIECD I . ~ ~
Microdialysis probe Implanted into the hippocampus 
-1 ~ ~ Radiotransmitter T A 1 OT A-F20 
RPC-1 receiver 
Consolidation Matrix 
tR.T. v 2.1 acqUisition software 
-== D I; ~ ~ ~ .. .I • BODY TEMPERATURE I r "l • ACTIVITY 
• ~ ~t , ) 
Figure 3.2 Combining radiotelemetry and microdialysis to simultaneously record 
locomotor activity, body temperature and 5-HT release in the hippocampus during 
administration of repeated low doses of MDMA. The telemetric system used in the 
present study (DataScience International, St Paul, MN, USA) consists of a 
radiotransmitter (TA lOT A-F20) implanted into th peritoneal cavity of the rat; 
detecting body temperature and activity, RP -1 receiver, a consolidation matrix and 
A.R.T. v2.1 acquisition software. A microdialysis probe was also implanted to the rat 
hippocampus under anaesthesia. Microdialysis samples were collected every 20 min 
then later analysis for 5-HT using HPLC-ECD. 
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Figure 3.3 Radiotelemetry data for baseline monitoring of A: locomotor activity 
(cowlts/min) and B: body temperature (0C). The sample data selected were from day 4 
after individual rat cages were placed over receivers in the telemetry room. Data are 
presented as mean in I-h bins over 24 hours ± SEM (n == 18). The blue bar ( _ ) 
shows when the light is off (light oIT at 19.00h and on at 07.00h) and the red bar 
( _ ) shows the experimental period on treatment day (09.00 - 16.00 h). Locomotor 
activity and body temperature were higher during the dark phase compared to those 
during the light phase. 
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3.2.4 Brain microdialysis 
Microdialysis is an in vivo bioanalytical sampling technique which allows 
continuous monitoring of relative changes in the chemical composition of 
living tissue. In brain microdialysis, a microdialysis probe consisting of a 
semipermeable membrane with a specific molecular weight cut-off is inserted 
into a specific brain region. If the molecular weight of the substances of 
interest, such as neurotransmitter, is less than the molecular weight cut-off of 
the semipermeable membrane, the substance will diffuse across the membrane. 
The fluid balance of living tissue will not alter as an isotonic perfusion fluid, 
for example artificial cerebrospinal fluid (aCSF) for brain tissue, is perfused at 
a constant flow rate. Microdialysis samples can then be analysed for the 
interested substances of interest, in this experiment 5-HT, using HPLC. 
In the present study microdialysis probes were made from semipermeable renal 
dialysis tubing (reconstituted cellulose) with a molecular weight cut off point 
of20,000. The exposed length of probes was 4 mm (220 Jim o.d., 180 Jim i.d.) 
(Figure 3.4). The microdialysis probe was connected to a Harvard 
Microinfusion pump (Harvard Scientific, USA) via the liquid swivel system 
(Harvard Scientific, USA) to allow the animal relatively unrestricted 
movement (Figure 3.6). The artificial cerebrospinal fluid (aCSF) (in mM: NaCI 
125.0, NaHC03 27.0. KCI2.5, NaH2P04 0.5 Na2HP04 1.2, NaS04 0.5, MgCh 
1.0, CaCh.2H20 1.0 adjusted to pH 7.4 with phosphoric acid) was constantly 
perfused through the probe at flow rate of 1.6 Jillmin. To determine in vitro 
recovery, microdialysis probes were immersed in a 10-7 M solution of 
dopamine, DOPAC, 5-HT, 5-HIAA and HVA and perfused with aCSF at 1.6 
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~ l / m i n n then the microdialysis samples were analysed using the HPLC-ECD. 
An internal standard is not required for this experiment as there is no extraction 
process but direct measurement of 5-HT in the microdialysis samples. The 
recovery of 5-HT through the probe was 8%. 
Surgical procedure 
The microdialysis probe was implanted into the hippocampus under general 
anaesthesia as described in 3.2.3. The rat was placed on the stereotaxic frame 
and fitted with ear bars. The rat skull was exposed and bregma located. The 
coordinates of the right hippocampus are AP -5.6, ML +4.6 relative to bregma 
and DV -8.0 below the dura using the rat brain atlas (Paxinos and Watson, 
1998). At the coordinate, a hole was drilled through the skull and the probe 
lowered to the hippocampus. The probe was fixed to the skull with two skull 
screws and dental cements. The open incision was sutured and local 
anaesthesia (Lignol) applied before spraying with plastic wound dressing 
(Nobecutane, Astra Pharmaceutical). Rats were allowed to recover in the 
recovery box for at least 6 h and food pallets were replaced by moistened mash 
to help recovery. After the recovery period, rats were moved to the telemetry 
room. The recovery boxes were placed over the individual telemetry receiver. 
Rat activity and body temperature were monitored overnight before treatment 
and sample collection. 
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Sample Collection 
On the following day, microdialysis samples were directly collected into the 
O.l-ml HPLC-inserts vials (Kinesis, Bolnhurst, UK) every 20-min. After each 
collection the inserts were put into 1.5-ml eppendorf tubes and immediately 
frozen in liquid nitrogen. The first 3 samples in the first hour before treatment 
were calculated as an individual baseline. Immediately after the third collection 
rats were given either MDMA (3 or 6 mglkg) or saline (1 ml/kg) i.p. 3 times 
every 2 h. Microdialysis samples were continuously collected every 20 min for 
2 h after the fmal dose. Rat activity and body temperature data were 
simultaneously recorded during treatment using radiotelemetry. 
Histology 
The probe placement was confirmed in all rats at the end of the experiment. 
Only the microdialysis samples from rats in which the probe was located in the 
hippocampus were used for later analysis of 5-HT. To stain the position of the 
probe dye was injected through microdialysis probe. The brain was carefully 
removed and stored in paraformaldehyde solution (PF A) at 4°C. Brains were 
then sliced into 20 ~ m m sections. The section with the probe staining was placed 
on a slide under a light microscope and photographed. 
Figure 3.5B shows a brain slice with a stained microdialysis probe in the 
hippocampus. There were 2 out of 20 probes were excluded as they were found 
to be incorrectly placed. 
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(A) (B) 
TNLET 
Dental cement 
4mm 
Figure 3.4 A: Diagram showing the basic structure of the microdialysis probe used in 
this experiment. A microdialysis probe consists of an inlet tube through which aCSF 
was continuously perfused. The outlet probe consists of a semipermeable membrane 
through which 5-HT passed from the brain into the probe for sample collection. The 
dialysis membrane was 4 mm long. B: The diagram shows a microdialysis probe 
implanted into the rat hippocampus. Three skull screws are fitted around the probe to 
ensure the dental cement effectively fixes to the skull so preventing the probe moving. 
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Figure 3.5 (A) shows the coordinates of the right hippocampus (AP -5 .6, ML +4.6 
relative to bregma and DV -8 .0 below the dura) where a microdialysis probe was 
inserted. The picture is from Paxinos and Watson (1998). (B) Brain slice showing the 
staining of a microdialysis probe ill the rat hippocampus . The probe placement was 
confirmed in all rats at the end of each experiment. Only microdialysis samples from 
rats in which the probe was correctly placed in the hippocampus were used for later 
analysis of 5-HT. 
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Figure 3.6 General arrangement of microdialysis probe perfusion set up. The probe is 
connected to a syringe pump (Harvard Microinfusion pump, Harvard Scientific, 
USA). The pump delivered aCSF to the probe at a constant flow rate (1.6 IlVmin) via 
an inlet flexible connecting tube and dialysis samples were collected via an outlet. The 
flexible connecting tube and liquid swivel allowed the rat relatively unrestricted 
movement. 
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3.2.5 Measurement of 5-HT in microdialysis samples using HP LC-ECD 
The samples were analysed for 5-HT using HPLC-ECD. 5-HT was separated 
on a 75 x 2.1 mm TARGA C18, 3-llm column (Higgins Analytical, CA, USA) 
using a mobile phase (0.05 M KH2P04, 0.1 rnM EDTA, 120 mg/L octane 
sulfonic acid, 8 mM KCI, 15 % v/v methanol adjusted to pH 3.0 with 0-
phosphoric acid) pumped at 0.3 mllmin flow-rate (Dionex P680 HPLC pump). 
Quantification was achieved using Antec VT-03 cell (Antec Leyden, 
Zoeterwoude, The Netherlands) with a glassy carbon working electrode set at a 
relative potential of +0.70 V to an in sitll AglAgCI (ISAAC) reference 
electrode. Column and electrochemical cell were kept in a constant temperature 
at 32.5 °C. A IS-Ill of samples and standard (10.8 M) were automatically 
injected onto the column using Series 200 Autosampler (perkinElmer, USA). 
The minimum level of detection of 5-HT in this system was 7.5 fmolllS III 
sample (signal/noise ratio = 3). 
(A) 10.8 M mixed standard of dopamine, DOPAC, HV A 5-HT and 5-HlAA: injected 
15 III onto column 
~ v v 51[ 2 " T ~ ~
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SOC.1XXl 
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(B) An example of 5-HT in a 15 ,.u microdialysis sample injected onto column 
RTI"*'I 
10 11 12 13 ,. IS 15 17 18 19 
(C) An overlay results of 10.8 M mixed standard and sample to identify the 5-HT peak 
in the sample (blue = standard, red = sample) 
1,100,000 Ii" 
1,000,000 
900,000 
000.000 
700,000 
600,000 
SOO,OOO 
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. ~ , O O O O, ~ ~ ~ ~ ~ ~ ~ ~ ~ ~______ ~ ~________ ~ ~____ ~ ~ ~____ ~ R ~ , l ~ I ~ ~J J
.1 10 11 12 13 14 , ~ ~ 16 17 18 
Figure 3.7 Examples of the chromatographic separation of A: dopamine, DOPAC, 5-
HT, 5-HIAA and HVA (10's M each) in the mixed standard, B: 5-HT ( ~ ) ) in tIle 
microdialysis samples using mobile phase 0.05 M K K ~ P P 4 , , 0.1 roM EDTA, 120 mglL 
octane sulfonic acid, 8 mM KCI and 15% vi'll methanol pH 3 .0: injected 15 JlL onto 
column. C: An overlay of the result from (A) and (B) to identify 5-HT peak ( ~ ~ ) in the 
microdialysis sample. 
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Figure 3.8 Linear relation between the concentration of 5-HT injected onto the column 
and the detector response. 
Data manipulation and tatistical analysis 
5-HT in each microdialysis sample was calculated as f m o V ~ 1 . . Mean of 5-HT 
levels from the first 3 samples in the first hour before treatment was used as an 
individual baseline. Data then were calculated as a percentage of an individual 
rat baseline (when the baseline of each rat was 100%) thereby providing mean 
± SEM of each group at each time point. Two-way ANOV A with time and 
treatment as main factors was used to compare the change in 5-HT levels 
followed by Bonferroni post hoc test. P < 0.05 was considered as a significant 
difference. 
100 
CHAPTER 3: Acute effects of repeated MDMA administration 
3.3. Results 
3.3.1 Effect of repeated administration of MDMA on locomotor activity 
There was no significant difference in locomotor activity between groups of 
rats 1 hour before treatment. The lower dose of MDMA (3 x 3 mg/kg) 
produced no significant difference in locomotor activity compared to controls 
at any time point (Figure 3.9A). In contrast the higher dose of MDMA (3 x 6 
mg/kg) produced a significant hyperactivity response after each injection 
(Figure 3.9A). The peak response occurred 40 min after the first (p < 0.05) and 
second (p < 0.01) injection of MDMA (3 x 6 mg/kg) and a marked and 
sustained hyperactivity was presented following the last injection (p < 0.001 at 
t = 280- 360 compared to saline (Figure 3.9A). 
Two-way ANOVA showed significant time (F(2,28) = 3.57, P = 0.04), 
treatment (F(2,28) = 16.84, P = 0.0002) and time x treatment interaction 
(F(4,28) = 4.00, p = 0.011) on the overall changes over 2 h periods after each 
injection (AUC) (Figure 3.9B). There was a significant lower locomotor 
activity response to the lower dose of MDMA (3 mg/kg) compared to the 
higher dose (6 mg/kg) after the first and the third injection (p < 0.05 and p < 
0.001 respectively) (Figure 3.9B). In addition there was a marked response 
following the third injection of MDMA (6 mg/kg) (p <0.001 compared to 
saline at the same period). 
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to N co ~ ~ 0 to 
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t t 
Time (min) 
-G- MDMA (3 mg/kg) --- MDMA (6 mg/kg) 
*** 
2nd injection 3rd injection 
C:::J Saline 
C:::J MDMA (3x3 mg/kg) 
_ MDMA (3x6 mg/kg) 
Figure 3.9 Effect of repeated administration ofMDMA (3 and 6 mglkg i.p.) and saline 
(1 ml/kg i.p.) 3 injections given at 2-h intervals on locomotor activity recorded using 
radiotelemetry. A: Data are presented as means of locomotor activity in 20-min time 
bins ± SEM (injections indicated by arrows, n=5-6 per group). There were overall 
effects of time (F(26,364) = 4.00, p<O.OOOI), treatment (F(2,364) = 16.64, p = 0.0002) 
and time x treatment interaction (F(52,364) = 3.89, p<O.OOOl) (repeated, 2-way 
ANOVA). The significant difference from Bonferroni post hoc test is not shown for 
the clarity of the figure. B: The total activity over the 2-h period after each injection 
(AUC). ***p<O.OOl compared to saline; sp<0.05, sssp<O.OOl compared to MDMA (6 
mglkg) at the same time periods (Bonferroni post hoc test). 
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3.3.2 Effect of repeated administration ofMDMA on body temperature 
Figure 3.10 shows the body temperature response following repeated 
administration of either MDMA (3 or 6 mglkg) or saline (l mllkg) i.p. 3 times 
every 2 h. There was no significant difference in body temperature between 
groups of rats 1 h before treatment. Saline treated rats exhibited a decrease of 
body temperature across the 7-h recording period which was comparable to a 
normal body temperature baseline recorded over a 1 week acclimatization 
period (Figure 3.3B). MDMA (3 mglkg) significantly decreased body 
temperature after each injection compared to saline control (p < 0.001 at t = 40, 
60, 160, 180, P < 0.01 at t = 140, P < 0.05 at t = 280) (Figure 3.10). The 
maximum decreases occurred 40 min after each injection then body 
temperature returned to saline level 1 h after the last injection. MDMA (6 
mglkg) significantly decreased body temperature after the first injection (p < 
0.001 at t = 40, P < 0.01 at t = 60) while after the second injection of MDMA 
(6 mglkg) body temperature continuously increased. The third administration 
of the higher dose of MDMA (6 mglkg) produced a marked and sustained 
increase of body temperature (p < 0.01 at t = 300, P <0.001 at t = 320-360) 
(Figure 3.10). 
The maximum change in body temperature after each injection of either 
MDMA (3 or 6 mglkg) or saline (1 mIlkg) is presented in Figure 3.11. The 
maximum change was calculated by subtraction of body temperature of an 
individual rat from the mean value 1 h before treatment then providing the 
mean of maximum change of each group ± SEM in each period after injection. 
It was shown that MDMA (3 mglkg) and MDMA (6 mglkg) produced a 
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maXimum decrease of body temperature by -0 .9 ± 0.1 and -0.8 ± 0.3 °c 
respectively following the fust injection. MDMA (3 mg/kg) further decreased 
body temperature by -1.2 ± 0.2 and -0.4 ±0.4 °c after the second and the third 
injections respectively while rats treated with MDMA (6 mg/kg i.p.) 
continuously increased body temperature following the second injection to the 
maximum increase of + 1.3 ± 0.5 °c after the last injection. 
i i i i i i i I 
0 0 0 0 0 0 0 0 c.o c.o N co '<t 0 c.o , N (") (") 
t t Time (min) t 
.-* .. Saline ~ ~ MDMA (3 mg/kg) ~ ~ MDMA (6 mg/kg) 
Figure 3.10 Effect of repeated administration of either MDMA (3 or 6 mglkg i.p.) or 
saline (1 ml/kg i.p.), 3 injections given at 2-h intervals, on body temperature recorded 
using radiotelemetry. Data are presented as means of body temperature in 20-min time 
bins ± SEM (injections indicated by arrows, n = 6 per group). Two-way ANOV A 
showed significant effects of time (F(26,390)=S.67, p<O.OOOl), treatment 
(F(2,390)=20.16, p<O.OOOl) and time x treatment interaction effects (F(S2 390)=7.91, 
p<O.OOOl). The significant difference from Bonferroni post hoc test is not shown for 
the clarity of the figure. 
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*** 
$$ 
2nd injection 3rd injection 
c:::=J Saline 
c:::=J MDMA (3x3 mg/kg) 
_ MDMA (3x6 mg/kg) 
Figure 3.11 Maximum changes in body temperature after each injection ofMDMA (3 
or 6 mglkg i.p.) or saline (I ml/kg i.p.). Data are presented as group means of the 
maximum differences between body temperature recorded in the 2-h period after each 
injection and the average of the body temperature in a 1-h baseline period before 
treatment ± SEM (n = 6 per treatment). Two-way ANOV A revealed effects of time 
(F(2,30) = 4.15 , p = 0.026), treatment (F(2,30) = 8.53, p = 0.0034) and time x 
treatment interaction (F(4,30) = 4.74, P = 0.004) on changes in body temperature. 
***p<O.OOI compared to saline control at the same period, sSp<O.OI, sssp<O.OOl 
compared to MDMA (6 mglkg) at the same time period (Bonferronipo t hoc test) 
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3.3.3 Effect of repeated administration of MDMA on extracellular 5-HT in the 
hippocampus 
Microdialysis samples were collected every 20 min. Samples from I h before 
treatment were calculated as a group baseline. Mean values for basal 
extracellular 5-HT were 0.73 ± 0.11 fmollJ.l.I (pre-saline group, n=4), 0.84 ± 
0.22 fmollJ.l.I (pre-MDMA 3 mg/kg group, n = 5) and 0.48 ± 0.11 fmollJ.l.I (pre-
MDMA 6 mg/kg group, n = 5) such that there was no significant difference 
between groups of rats (F2,\3 = 1.334, P = 0.303; one-way ANOV A). 
Figure 3.12 shows effect of repeated administration ofMDMA (3 and 6 mg/kg) 
and saline (1 mllkg) on extracellular levels of 5-HT in the hippocampus. Data 
are presented as means of % baseline calculated compared to means of the first 
three samples (see 3.2.4). Two-way ANOVA revealed time (F(21,225) = 1.87, 
P = 0.0139) and treatment effects (F(2,225) = 39.75, p < 0.0001) on 
extracellular 5-HT levels in the hippocampus (Figure 3.12). The higher dose of 
MDMA (6 mg/kg Lp.) produced a marked increase in extraneuronal 5-HT 
levels in the hippocampus 40, 60 and 80 min after the first injection (+485, 
+555 and +393% respectively compared to the 100% basal levels) while the 
lower dose of MDMA (3 mg/kg) increased 5-HT to a peak increase of + 134% 
compared to 100 % baseline 40 min after the first injection. After the second 
injection, MDMA (6 mg/kg) produced a maximum increase of +389% 
compared to 100% baseline at t = 180 while MDMA (3 mglkg) increased 5-HT 
by +284 % compared to 100% baseline at t = 180. After the third injection, the 
magnitude of increase of 5-HT following both doses of MDMA was similar as 
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the maximum increase of + 315 % and + 292 % compared to 100 % baseline 
by MDMA 6 and 3mglkg respectively at t = 300 (Figure 3.12). 
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Figure 3.12 Effect of repeated administration of MDMA on extracellular 5-IIT levels 
in the hippocampus. Each point represents % baseline calculated compared to means 
of the first three samples. Two-way ANOV A revealed time (F(2l ,226) = 1.86, P = 
0.0127) and treatment effects (F(2,226) = 39.88, p < 0.0001) on extracellular 5-RT 
levels in the hippocampus. **p < 0.01 compared to saline at the same time point, sp < 
0.05 compared to MDMA (3 x 6 mglkg) at the same time point (Bonferroni post hoc 
test) 
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3.3.4 Correlation 
Pearson correlation analysis was applied to detennine whether there was a 
relation between the functional changes (locomotor activity and body 
temperature) and extracellular 5-HT in the hippocampus. The mean of 
extracellular 5-HT at 2 h after each injection was plotted against either mean 
activity or mean body temperature at the same time point. The mean activity in 
2 h after each injection was also plotted against mean body temperature at the 
same time point. The results are shown in Table 3.1. 
There was no significant correlation between extracellular 5-HT in the 
hippocampus and either body temperature or locomotor activity after each 
injection (Table 3.1). There was no significant correlation between body 
temperature and locomotor activity after the first and second injections. 
However there was a significant positive correlation between body temperature 
and locomotor activity (Pearson correlation coefficient; r = 0.8072; p < 0.0001) 
(Table 3.1). 
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Table 3.1 Data showing lack of correlations between extracellular 5-HT in the 
hippocampus and either locomotor activity or body temperature while there was a 
correlation between locomotor activity and body temperature but only after the third 
injection of MDMA. Data were calculated from mean of extracellular levels of 5-HT 
in the hippocampus, mean activity and mean body temperature in 2 h period after each 
injection. Data are presented in Pearson correlation coefficients (r) with corresponding 
p value. 
Correlatio 1st injection 2na injection 3nl injection 
n p Sig P Sig P Sig 
Activity 0.1337 0.6951 ns 0.1420 0.6771 ns 0.06787 0.8428 ns 
vs S-HT 
Body temp -0.5696 0.0674 ns -0.3936 0.2310 ns -0. 1454 0.6698 ns 
vs S-HT 
Activity vs 0.3746 0.1256 ns 0.3634 0.1383 ns 0.8072 < ••• 
Body temp 0.0001 
(A) Correlation between activity (counts/min) and 5-HT (finoV15 Ill) after the third 
injection 
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(B) Correlation between body temperature (0C) and 5-HT (finoVI5 Ill) after the third 
injection 
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(C) Correlation between activity (counts/min) and body temperature (0C) after the 
third injection 
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Figure 3.13 Examples of correlation between A: activity (counts/min) and 5-HT 
(finoI/I5 Ill), B: body temperature (0C) and 5-HT (finoV15 Ill) and C: activity 
(counts/min) and body temperature (0 ) following the third injection of either MDMA 
(3 or 6 mg/kg) or saline (1 mVkg) 
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3.4. Discussion 
The research in this chapter aimed to detennine the acute effects of repeated 
administration of low doses of MDMA, which imitates binge use of the drug in 
humans. The effects of MDMA on locomotor activity, body temperature and 
extracellular S-HT levels in the hippocampus were detennined by combining 
the techniques of radiotelemetry and microdialysis to allow measurement of 
these effects of MDMA in the same animal. The pattern and doses used in this 
experiment represent binge use in humans. A review by Green et al (2009) 
comparing MDMA dose-plasma concentration response in rats and human has 
suggested that "a fourfold higher dose is required in rats to produce a similar 
peak plasma MDMA concentration in humans". Therefore doses used in this 
experiment, which are 3 and 6 mg/kg, are equivalent to 0.75 and 1.5 mglkg in 
human respectively which are in the range of dose use in humans (0.75-4 
mglkg) (Morgan, 2000). 
The first fmding was that repeated administration of 6 but not 3 mglkg MDMA 
induced hyperactivity. MDMA-induced hyperactivity in the present study 
supported this well documented effect of MDMA (for example Kindlundh-
Hogberg et aI., 2007, Spanos and Yamamoto, 1989). Additionally the present 
study provided evidence of marked and sustained hyperlocomotor activity 
when MDMA was given repeatedly. In addition to the acute effect on 
locomotor activity, it was demonstrated in the present study that both doses of 
MDMA produced different body temperature responses. The lower dose of 
MDMA (3 mglkg) decreased body temperature following each injection while 
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the higher dose of MDMA (6 mg/kg) produced hypothermia after the first 
injection then continuously increased body temperature after the second 
injection to the peak increase of + 1.3 °c after the last injection. 
MDMA-induced change in body temperature depends mainly on an ambient 
room temperature (Dafters and Lynch, 1998, Green et aI., 2004, Malberg and 
Seiden, 1998). The ambient temperature in this experiment was set at 21±1 °C 
and the body temperature response to MDMA reported at this ambient 
temperature range is controversial as some studies reported MDMA-indueed 
hyperthermia (Dafters and Lynch, 1998, Meehan et aI., 2002a) while others 
found hypothermia (Jaehne et aI., 2005, Malberg and Seiden, 1998). It is 
noticeable that all of these previous experiments used a single high dose of 
MDMA (10 - 40 mg/kg) while in the present study, using repeated low doses 
(3 or 6 mg/kg), there was hypothennia after the first administration. 
Following repeated injection, the lower dose of MDMA (3 mg/kg) decreased 
body temperature after the second and third injections. This result is in contrast 
to the study by Green et al (2004) in which they reported a dose-dependent 
hyperthermia in rats housed at 19 °c following repeated administration of low 
doses of MDMA (2, 4 and 6 mg/kg, 3 injections every 3 h). It is noteworthy 
that this study by Green et a1 (2004) was conducted in group housed rats 
whereas rats in the present study were singly housed as this is required for the 
radiotelemetry measurement. Housing condition is a factor that influence 
MDMA-induced changes in body temperature. It has been demonstrated that 
amphetamines including MDMA produced more marked behavioural effects in 
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group than single housed animals an effect called 'aggregate toxicity' (Chance, 
1947, Fantegrossi et at, 2003, Morton et at., 2001). Group housing of the rats 
also well represents a crowded dance club condition where MDMA is nonnaUy 
used in humans. Therefore not only ambient temperature but also the single 
housing condition in the present study possibly influenced the hypothennia 
caused by the lower dose of MDMA (3 mglkg). 
In contrast to the lower dose of MDMA, changes in thermQregulation were 
found after repeated administration of the higher dose of MDMA (6 mglkg). 
This effect of repeated higher dose MDMA might involve the impairment of 
central thennoregulation in the hypothalamus as well as other heat loss 
mechanisms. It has been previously shown that MDMA inhibited the rat tail 
vasodilatory heat loss mechanism (Blessing et at, 2003, Green et al., 2005) and 
also affected other physiological mechanisms associated with thermoregulation 
(Gordon et aI., 1991). 
It has been suggested previously that changes in body temperature observed 
after MDMA administration might result from MDMA-induced hyperactivity; 
however, some studies have shown dissociation between MDMA·induced 
hyperthermia and hyperlocomotion (Dafters, 1994, 1995). The present study 
found no correlation of changes in body temperature and locomotor activity 
following the first and second injections of MDMA while there was significant 
positive correlation between changes in body temperature and locomotor 
activity after the third injection. This result indicates that MDMA-induced 
hyperthermia is partly influenced by an increase of locomotor activity. 
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MDMA administration to rats has been shown to induce an acute and rapid 
release of 5-HT in various brain regions including striatum, prefrontal cortex, 
nucleus accumbens and hippocampus (Baumann et aI., 2008b, Meehan et aI., 
2002a, Stanley et aI., 2007). Meehan et al (2002a) showed an increase of 5-HT 
in the hippocampus following a single dose of MDMA (15 mg/kg). This is in 
agreement with the present study which demonstrated an increase of 
extracellular 5-HT in the hippocampus using low doses of MDMA (3 and 6 
mg/kg). The higher dose ofMDMA (6 mg/kg) produced a greater release of 5-
HT in the hippocampus after the ftrst injection compared to the lower dose of 
MDMA (3 mg/kg) but then the magnitude of 5-HT release was similar after the 
second and third administration. The lesser release of 5-HT following repeated 
administration of the higher dose of MDMA might be due to an inhibition of 
tryptophan hydroxylase activity in various brain regions including the 
hippocampus (Che et aI., 1995, Johnson et aI., 1992, O'Shea et 81.,2006, Stone 
et aI., 1987b) which occurs in the rat 15 min after MDMA administration 
(Stone et aI., 1987b) together with depletion of 5-HT within synaptic vesicles 
as MDMA (6 mg/kg) produced a greater release of 5-HT after the ftrst 
injection. Inhibition of 5-HT synthesis and depletion of 5-HT storage caused by 
the higher dose ofMDMA (6 mg/kg) may account for the consequent decrease 
in the magnitude of 5-HT release after repeated dosing. 
There was no correlation between extracellular 5-HT in the hippocampus and 
locomotor activity in this study. MDMA-induced hyperactivity has been 
suggested to be involved in a complex interaction of 5-HT and dopamine 
release following MDMA administration (Bankson and Cunningham, 200 1). 
114 
CHAPTER 3: Acute effects of repeated MDMA administration 
Recently Baumann et al (2008) showed a direct correlation between locomotor 
activity with dialysate 5-HT and dopamine with a positive correlation between 
ambulation and dialysate dopamine levels in the nucleus accumbens, striatum 
and prefrontal cortex and with dialysate 5-HT levels in the striatum and 
prefrontal cortex. Therefore the determination of extracellular 5-HT levels in 
the hippocampus in the present study indicates that hippocampal 5-HT release 
is not involved in MDMA-induced locomotor activity. 
There was also no correlation between extracellular 5-HT in the hippocampus 
and body temperature. The mechanism underlying MDMA-induced 
hyperthermia remains unclear however 5-HT and dopamine systems have been 
suggested to mediate this effect of MDMA as the 5-HT 2A antagonists, ritanseri, 
ketanserin, MlO0907 and R-96544 as well as the dopamine 0\ antagonist, SCH 
23390 can protect against MDMA-induced hyperthermia (Benamar et aI., 
2008, Herin et aI., 2005, Mechan et aI., 2002a, Shioda et aI., 2008). MOMA-
induced 5-HT release in the hypothalamus might mediate this effect of MOMA 
as 5-HT is suggested to mediate thermoregulatory function in the 
hypothalamus (see review Bligh, 1979). Therefore it is unlikely that the 
hippocampus is the locus of any 5-HT mediated thermoregulatory response. 
In summary, the research in this chapter provides evidence for acute effects of 
repeated administration of low doses of MDMA. The present study shows that 
repeated administration of MDMA increases the risk of thermoregulatory 
impairment especially when using the higher dose (6 mglkg). In addition the 
present study also demonstrated an increase of extracellular 5-HT in the 
115 
CHAPTER 3: Acute effects of repeated MDMA administration 
hippocampus following low doses of MDMA. Although this increase in 5-HT 
released failed to correlate with locomotor activity and body temperature, the 
increase of extracellular 5-HT in the hippocampus, the brain region related to 
learning and memory (Mumby, 2001), might explain the impairment of novel 
objection discrimination following acute MDMA (3 mg/kg) administration 
demonstrated in the previous chapter. In addition to the acute effects, long-term 
clinical complications including impairments of learning and memory have 
been widely reported especially in frequent and heavy MDMA users (see 
review Gouzoulis-Mayfrank: et aI., 2000). Therefore the consequence of acute 
5-HT release in the hippocampus and change in body temperature following 
repeated administration of MDMA was further investigated in the following 
chapter in terms of its effects on 5-HT neurotoxicity and impairment of 
learning and memory. 
116 
CHAPTER 4 
THE LONG-TERM EFFECTS OF REPEATED 
MDMAADMINISTRATION ON MEMORY AND 
S-HT NEUROTOXICITY 
CHAPTER 4: Long-tenn effects of repeated MDMA administration 
4.1. Experiment 1: Acute effects of repeated MDMA administration to 
singly housed rats on locomotion and body temperature and the long-term 
effects on novel object discrimination and neurotoxicity 
4.1.1 Introduction 
In the previous chapter it was demonstrated that repeated administration of low 
doses of MDMA (3 and 6 mglkg 3 times every 2 h) increased extracellular 5-
HT in the hippocampus. The first experiment in this chapter consequently 
investigated the long-term effects of repeated MDMA administration on 
recognition memory and 5-HT neurotoxicity. 
In adult rats, MDMA administration has been shown to produce long-term 
cognitive deficits using various cognition models. For example, MDMA 
treatment produced long-term spatial memory deficits in the Morris water maze 
(MWM) (Able et at, 2006, Sprague et at., 2003). Able et al (2006) and 
Skelton et al (2008) also reported an impairment of path integration learning in 
the Cincinnati water maze (CWM) following repeated MDMA treatment in 
rats. In addition MDMA-treated rats showed deficiencies in a test of novel 
object recognition (McGregor et at., 2003, Morley et at, 2001). 
MDMA-induced long-term 5-HT depletion has been reported in rats especially 
after high dosage regimens (see review Capela et at., 2009, Green et al., 2003). 
The relevance of the 5-HT neurotoxicity to the memory impairments remains 
unclear. Sprague et al (2003) showed that MDMA (2x20 mglkg) treatment 
resulted in decreased hippocampal S-HT 2 weeks after treatment together with 
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an impainnent of spatial memory using the MWM. McGregor et al (2003) 
found an impainnent of novel object recognition and a decrease 5-HT levels in 
the hippocampus, amygdala, striatum and cortex. Able et al (2005) and Skelton 
et al (2008) reported a decrease of 5-HT in hippocampus, neostriatum and 
prefrontal cortex associated with an impainnent of path integration learning in 
the CWM but no change in novel object recognition perfonnance. Overall 
these results indicate a possible link between 5-HT loss and memory 
impainnent. 
The aim of the first experiment in this chapter was to investigate the long-tenn 
effect of repeated administration of low doses MDMA on memory using novel 
object discrimination. Rats were individually housed in the activity monitor 
chamber during MDMA treatment to imitate the singly housing conditions 
described in the previous chapter. Locomotor activity, using a non telemetric 
system, and rectal temperature were also monitored during MDMA 
administration. In addition changes in 5-HT, dopamine and their metabolites 
were determined 2 weeks after MDMA administration in specific brain regions 
considered to be involved in cognitive processes. 
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Adult male Lister hooded rats (Charles River, UK) weighing 300-350 g were 
housed on a 12 h light/dark cycle (light on at 07.00h) in constant room 
temperature (21±2 °C) and humidity (45-65%). Rats had free access to food 
and water. All experiments were performed in accordance with the UK 
Animals (Scientific Procedures) Act, 1986 under project license 40/2715 and 
approved by the University of Nottingham Local Ethical Review Committee. 
Experimental procedure 
Rats were housed in groups of 4 for 1 week before treatment. On the day 
before treatment, each rat was habituated in an individually computer-
controlled infra-red activity monitor chamber (a 39 x 23 cm with 30 cm high 
clear Perspex box) for 1 h (Figure 4.2). The locomotor activity was recorded 
during this period to determine whether each group of rats showed a level of 
normal activity before treatment. On the treatment day each rat was singly 
placed in an individual infra-red activity monitor chamber during treatment in 
order to measure the acute effects of repeated low doses of MDMA on 
locomotor activity. Rats had free access to water during this period. Rats were 
given either MDMA (3 mg/kg or 6 mg/kg i.p.) or saline (1 mllkg i.p.) 3 times 
every 2 h (n = 8 per treatment). MDMA was synthesized by Department of 
Chemistry, University College Dublin, Ireland. Activity was recorded from 1 h 
before treatment until 2 h after the last injection. Before the rats were returned 
to their own home cages rectal temperature was measured using a digital 
thermocouple probe thermometer (Portee Instrumentation Ltd, POOOS) inserted 
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6-8 cm into the rectum using light restraint. On day 14 each rat was habituated 
in an individual infra-red activity monitor chamber for 1 h and locomotor 
activity recorded. On the following day the novel object discrimination task 
was performed as described in chapter 2 with an inter-trial interval of 2 h. Rats 
were killed immediately after the novel object discrimination task. Three brain 
regions; frontal cortex, hippocampus and striatum, were dissected and later 
analysed for 5-HT, dopamine and their metabolites using HPLC-ECD as 
described in chapter 2. (Experimental design summarised in Figure 4.1) 
Day 
r 
1 
I Habituation(lh) I 
• Treatment : 
- MDMA 3 mgJkg Lp. or 
- MDMA 6 mgJkg Lp. or 
- Saline 1 mUkg Lp. 
3 injections 2 h apart 
Experiment 4.1 
• Activity recorded in activity 
chamber during treatment (Single 
housed) 
• Body temperature measure 2 h 
after the third injection 
14 
I 
I Habituation(lh) I 
• Novel object discrimination (2 h 
inter-trial interval) 
• Brain dissected (fronlal cortex, 
hippocampus, striatum) 
1 
Analysis for 5-HT, dopamine 
and their rnelabolites 
using HPLC-ECD 
15 
I 
Figure 4.1 Experimental procedure to determine the effects of repeated administration 
of low doses of MDMA to singly housed rats on novel object discrimination, and 
brain region 5-HT, dopamine and their metabolites levels. 
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Locomotor activity 
To record activity each rat was placed in a computer-controlled infra-red 
activity monitor chamber (SOl's photobeam activity system, San Diego 
Instruments, San Diego, USA) which consisted of a clear Perspex box (39 x 23 
cm with 30 cm high), with solid Perspex floor and a wire mesh lid. Four 
parallel infra-red beams, 4-cm apart, cross the chamber referred as X-beams 
and 8 parallel infra-red beams, 5-cm apart, cross the chamber referred as Y-
beams at 3.5-cm above floor level recorded locomotion. The upper layer beam, 
set at 15.5-cm above floor levels with 8 beams 2.5-cm apart, recorded rearing. 
Only the lower beams were used to calculate locomotor activity. A computer-
controlled infra-red activity monitor chamber is shown in Figure 4.2. 
Interruption of the beams caused by rat movement was recorded in 5-min time 
bins using PAS software. The results were reported as 'ambulatory' or 'fine' 
movements. To distinguish the fme and ambulatory movements, the first beam 
break was not counted. If the same beam was later interrupted, it was counted 
as a 'fme' movement. If any other beam was later interrupted, it was counted as 
an 'ambulatory' movement. 
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D PAS software • Ambulatory movements • Roo movements 
rearing beams 
Y beams 
Figure 4.2 A computer-controlled infra-red activity monitor chamber (SDI 's 
photobeam activity system, San Diego Instruments, San Diego, USA). The system 
consisted of a clear Perspex box (39 x 23 em with 30 em high), 4-paral1el infra-red X 
beam and 8-parallel infra-red Y beam at 3.S-cm above floor level recorded 
locomotions and 4-infra-red rearing beam lS.5-cm above floor level recorded rearing 
and PAS software intregrated and reported the results as ' ambulatory ' movement, 
'fine movement and rearing. 
Statistical analysis 
Two-way ANOV A followed by Bonferroni post hoc test, one-way ANOV A 
followed by Tukey' s post hoc test, unpaired Student t-test and one sample I-test 
were used where appropriate. P < 0.05 was considered as a significant 
difference. 
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4.1.3 Results 
(a) Locomotor activity before treatment 
Locomotor activity was observed 1 day before treatment to obtain an activity 
baseline for each group of rats. The three groups of rats (pre-saline, pre-
MDMA 3 x 3 mg/kg and pre-MDMA 3 x 6 mg/kg) exhibited similar 
ambulatory and fme movements which decreased across the 60 min period 
(Figure 4.3), such that two-way ANOV A showed a significant time effect on 
ambulatory activity (F(1l,231) = 91.24, P < 0.0001) and fine activity 
(F(11,231) = 20.9, P < 0.0001). Bonferronipost hoc test showed a significant 
difference in the ambulatory activity between pre-saline and pre-MDMA (3 x 6 
mg/kg) treated group in the first 5 min (p < 0.05) but there was no significant 
difference in either ambulatory or fme movement at any other time points. 
Thus although the pre-MDMA (3 x 6 mg/kg) were more active than the other 2 
groups at the beginning, overall all 3 groups of rats showed a similar pattern of 
activity before treatment (Figure 4.3). 
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Figure 4.3 A: Ambulatory and B: fine activity 1 day before treatment. Each point 
represents mean of number of beam breaks in 5-min ± SEM (n = 8 per group). * p < 
0.05 compared with saline in the same time point (Bonferroni post hoc test following 
two-way ANOV A). 
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(b) The acute effects of repeated administration of low doses of MDMA on 
ambulatory and fine activity 
During treatment each rat was placed in an individual infm-red activity 
chamber to measure acute effect of MDMA on activity. One hour before 
injection activity was recorded as a baseline and all group of rats showed a 
similar pattern of ambulation with ambulatory activity decreasing over time 
(Figure 4.4A). Then either MDMA (3 or 6 mg/kg) or saline (1 mllkg) was 
injected i.p. 3 times every 2 h. Both ambulatory and fine activity increased 
immediately after each injection of either MDMA (3 or 6 mg/kg) or saline (1 
mllkg), however, the activity of the rats treated with saline rapidly returned to 
baseline 40 min after each injection suggesting stressed-induced increase of 
locomotor activity following saline (Figure 4.4A and 4.5A). 
There was no difference in ambulatory activity between MDMA (3 mglkg) and 
saline control after the first injection. MDMA (3 mglkg) treatment however 
significantly increased activity compared to controls at 40 min after the second 
(p < 0.01) and the third (p < 0.05) injections (Figure 4.4A). Rats treated with 
MDMA (6 mgfkg) exhibited a high and prolonged increase in ambulatory 
, 
activity after each injection (p < 0.01 at t = 20, 100,220, P < 0.001 at t = 40-80, 
160-200, 280-360) (Figure 4.4A). Total activity showed a highly significant 
difference in ambulatory activity after each injection of MDMA (6 mglkg) 
compared to both saline and MDMA (3 mglkg) (Figure 4.4B). 
Interestingly although the lower dose of MDMA (3 mglkg) produced little 
significant difference in ambulatory activity, this dose of MDMA produced a 
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marked increase in fine movements after three injections of the drug (p < 0.05 
at t = 220, P < 0.01 at t = 40, 80, 320, p < 0.001 at t = 60, 160, 180,200,280, 
300) (Figure 4.5A). Total level of fine activity after all three injections of 
MDMA (3 mglkg) was significantly increased compared to saline control (p < 
0.001) (Figure 4.5B). The higher dose of MDMA (6 mglkg) produced an 
increase in fme activity which was prolonged after each injection compared to 
saline-treated controls (p < 0.001) (Figure 4.5A). 
127 
CHAPTER 4: Long-term effects of repeated MDMA administration 
(A) 
1500 
III 
.:.£ 
ns 
Q) 
.0 1000 
E 
ns 
Q) 
.c 500 
-0 
ci 
z 0 
I I I I I I i 1 
0 0 0 0 0 0 
<0 <0 N 00 '<t 
o 0 
o <0 
I ~ ~ ~ ~ N <") <") 
t t Time (min) t 
--.-- Saline ~ ~ MDMA (3 mg/kg) 
- MDMA (6 mg/kg) 
(B) 6000 $$$ 
*** 
5000 
III $$$ $$ .:.£ ns 
*** ~ ~ 400 
.c 
E 3000 ns 
Q) 
.c 
-
2000 * 0 
ci 
z 1000 
0 
c::::J saline c::::J MDMA (3 mg/kg) _ MDMA (6 mglkg) 
Figure 4.4 A: Ambulatory activity during treatment in the infra-red activity chambers. 
Rats were given either MDMA (3 or 6 mglkg) or saline (1 mglkg) i.p. 3 times every 2 
h as indicated by arrows. Each point represents mean of number of beam breaks in 20-
min time bins ± SEM (n = 8 per treatment). Two-way ANOVA revealed effects of 
time (F(20,420) = 6.99, p < 0.0001), treatment (F(2,420) = 47.90, p < 0.0001) and 
time x treatment interaction (F( 40,420) = 4.39, p < 0.0001) on ambulatory activity. 
The significant difference from Bonferroni post hoc test is not shown for the clarity of 
the figure. B: Total ambulatory activity in 2-h time bins after each injection. * p < 
0.05, ***p < 0.001 compared to saline at the same time period; ss p < 0.0 I, sssp < 
0.0001 compared to MDMA (3 mglkg)-treated at the same time period (Bonferroni 
post hoc test following 2-way ANOVA). 
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Figure 4.5 A: Fine activity during treatment in the infra-red activity chambers. ach 
point represents mean of number of beam breaks in 20-min time bins ± EM (n = 8 
per treahnent). Injections were indicated by arrows. Two-way AN V A revealed 
effects of time (F(20,420) = 16.82, P < 0.0001), treatment (F(2,420) = 67.90, p < 
0.0001) and time x treatment interaction (F(40,420) = 6.13, p < 0.0001) on fine 
activity. The significant difference from Bonferroni post hoc test is not shown for the 
clarity of the figure. B: Total fine activity in 2-h time bins after each injection. ***p < 
0.001 compared to saline at the same time period; ss p < 0.01, sssp < 0.001 compared 
to MDMA (3 mglkg)-treated at the same time period (Bonferroni post 110 test 
following 2-way ANOV A). 
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(c) The effect of repeated administration of low doses of MDMA on rectal 
temperature 
Rectal temperature was measured 2 h after the last injection of either MDMA 
or saline (t = 360). One-way ANOV A revealed an overall effect of treatment 
on rectal temperature (F = 3.75, P = 0.0406) (Figure 4.6A). The lower dose of 
MDMA (3 x 3 mg/kg) decreased rectal body temperature by -0.3 °c while the 
higher dose of MDMA (3 x 6 mglkg) increased rectal body temperature by 
+0.5 °c compared to saline, however these changes were not significant from 
saline control (Figure 4.6A). Three injections of the lower dose of MDMA (3 x 
3 mglkg) significantly reduced rectal temperature compared to the higher dose 
ofMDMA (3 x 6 mglkg) (p < 0.05) (Figure 4.6A) 
Figure 4.6 compares the results from the present experiment using a rectal 
probe thermometer (Figure 4.6A) and the experiment in the previous chapter 
when radiotelemetry (Figure 4.6B) was used to measure body temperature at 2 
h after the last injection. Data obtained from radiotelemetry showed that the 
higher dose of MDMA (3 x 6 mglkg) induced hyperthermia (+1.7 °C) and this 
is significantly higher than saline (p < 0.05). The lower dose of MDMA (3 x 3 
mglkg) decreased telemetric body temperature (-0.2 °C) compared to control at 
2 h after the last injection (t = 360) and this is significantly lower than MDMA 
(3 x 6 mglkg) treated group (p < 0.01) (Figure 4.6B). 
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Figure 4.6 A: The effect of repeated administration of MDMA (3 or 6 mglkg i.p 3 
injections every 2 h) on body temperature (mean ± SEM, n = 8 per treatment) 
measured using a rectal probe thermometer. Rectal temperature wa measured 2 h 
after the last injection (t = 360). B: Body temperature data obtained from the 
experiment in chapter 3 using radiotelemetry to compare the results from two 
experiments using the same treatment but different measuring devices. Data ar 
obtained from the same time point which is 2 h following the last injection (t = 360). 
*p < 0.05 compared to saline, S p < 0.05, ss p < 0.01 compared to MOMA (3 x 3 
mglkg) (Tukey's post hoc test following one-way ANOV A). 
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(d) Locomotor activity on day 14 
Rats were habituated in the infra-red activity monitor chamber 13 days after 
MDMA or saline treatment. All three groups of rats exhibited very similar 
ambulatory and fine movement profiles with activity decreasing across the 60 
min period of habituation (Figure 4.7). Two-way ANOVA showed a significant 
time effect on ambulatory activity (F(1l,231) = 64.73, P < 0.0001) and fine 
activity (F(1l,231) = 13.24, P < 0.0001). There was no effect of treatment on 
ambulatory activity as analysed by two-way ANDV A. However a significant 
treatment effect on fme activity was shown using two-way ANOV A (F(2,231) 
= 3.57, P = 0.0461). Data, calculated as total activity in 60-min test period, 
showed that rats treated with the higher dose of MDMA (3 x 6 mglkg) 
exhibited an increase of total fme activity which was significantly different 
from saline (p < 0.05; Tukey's post hoc test following one-way ANOVA) 
(Figure 4.7B). 
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Figure 4 .7 Effects of MDMA (3 or 6 mglkg i.p.) or saline (1 mllkg i.p.) x 3 on A: 
ambulatory movements and B: fine movements 13 days after treatment using a 
computer-controlled infra-red activity monitor chamber. Data are expressed as 5-min 
time bin and as total values over a 60 min test period (the inset figures) (mean ± SEM, 
n = 8 per group). * p < 0.05 compared to saline (Tukey' s post hoc test following one-
way ANOVA). 
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(e) Long-term effect of repeated administration of low doses of MDMA on 
novel object discrimination 
Novel object discrimination was performed 2 weeks after treatment. In the 
familiarisation trial (trial 1; Tt) rats explored two identical objects. All groups 
of rats showed no significant difference in the time spent exploring either of 
the objects and there was no preference for the location of the objects (Figure 
4.8A). Following a 2-h inter trial interval, one of the identical objects was 
replaced by a novel object as described in chapter 2. Two-way ANOV A 
revealed the overall effects of treatment (F(2,21) = 4.88, P = 0.0181) and 
objects (F(1,21) = 12.54, P = 0.0019) on time spent exploring the novel versus 
the familiar object. Rats treated with either saline or the lower dose MDMA (3 
x 3 mglkg) spent more time exploring the novel object than the familiar object 
(p < 0.05, Bonferroni post hoc test) indicating MDMA (3 x 3 mg/kg) has no 
long-term effect on novel object discrimination (Figure 4.8B). In contrast 
MDMA (3 x 6 mglkg)-treated rats failed to discriminate the novel from the 
familiar object as there was no significant difference of time exploring the 
novel versus the familiar objects (p > 0.05, Bonferroni post hoc test) 
suggesting that repeated administration of the higher dose of MDMA (3 x 6 
mg/kg) impaired novel object discrimination (Figure 4.8B). 
The time spent exploring the novel versus the familiar objects in the choice 
trial was converted into a preference index (PI) (e.g. [novel object! novel object 
+ familiar object] x 100) and shown in Figure 4.9. The PI value ofMDMA (3 x 
3 and 3 x 6 mglkg)-treated rats was not significantly different from saline-
treated rats (p > 0.05, unpaired Student t-test). The PI values of saline were 
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significantly greater than a PI value of 50% chance level (p = 0.0122, one 
sample t-test) (Figure 4.9). Although rats treated with MDMA (3 x 3 mg/kg) 
spent more time exploring the novel than the familiar object (p < 0.05, 
Bonferroni post hoc test) (Figure 4.8B), the PI value of MDMA (3 x 3 mglkg) 
treated rat was not significantly different from the 50% chance level (p = 
0.0519, one sample t-test) (Figure 4.9). Moreover the PI value ofMDMA (3 x 
6 mglkg) treated rats was not significantly different from 50% chance level (p 
= 0.4102, one sample t-test) (Figure 4.9). 
The total time spent by the rats exploring two identical objects in trial 1 (Total 
T1 time) and the total time rats spent exploring the novel and the familiar 
object in trial 2 (total T2 time) are presented in Table 4.1. While there was no 
significant difference in total T1 time between the three groups, rats treated 
with MDMA (3 x 6 mglkg) had significantly lower total T2 time activity 
compared to saline controls (p < 0.05; Tukey's post hoc test following one-way 
ANOV A) (Table 4.1). 
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Figure 4.8 Effects of MDMA on the time spent (s, means ± SEM) exploring A: each 
of the identical objects during trial I and B: the novel versus the familiar object during 
trial 2 which was 2 h after trial 1. Rats received either MDMA (3 or 6 mg/kg Lp.) or 
saline (1 ml/kg i.p.) 3 times every 2 h (n = 8 per treatment) . * p < 0.05 compar d with 
time spent at the familiar object in the same treatment group (Bonferroni post hoc 
test). 
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Figure 4.9 Time spent exploring the novel versus the familiar objects in the choice 
trial was converted into a preference index (PI) (e.g. [novel object! novel object + 
familiar object] x 100) (Bruel-Jungerman et aI., 2005). Data are presented as means of 
PI values ± SEM (n = 8 per group). Each experimental group was compared against a 
PI value of 50% chance level (dashed line) using one sample I-test. * p < 0.05 
compared to a PI value of 50% chance level (one-sample I-test) 
Table 4.1 Total time (s, means ± SEM) spent exploring two identical objects in trial 1 
and total time (s, means ± SEM) spent exploring the novel and the familiar objects in 
trial 2. 
Treatment Total Tl time Total T2 time 
(s, mean ± SEM) ( , mean ± SEM) 
saline 46 ± 6 39 ± 4 
MOM A (3 x 3 mglkg) 41 ± 6 37 ± 4 
MDMA (3 x 6 mglkg) 44 ± 5 25 ± 2* 
* p < 0.05 compared with saline in trial 2 (Tukey's po t 110 te t following one-way 
ANaVA) 
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(f) Long-term effects of repeated low doses of MDMA on 5-HT, dopamine and 
their metabolites in the hippocampus, frontal cortex and striatum 
5-HT, dopamine and their metabolites were measured using HPLC-ECD in 
three brain regions; hippocampus, frontal cortex and striatum 14 days after 
treatment. Repeated low dose MDMA treatment (3 or 6 mg/kg i.p. 3 injections 
every 2 h) tended to decrease 5-HT levels in the hippocampus however the 
effect was not significant and there was no change in the hippocampal 5-HlAA 
levels following MDMA treatment (Table 4.2). There were no significant 
differences in either 5-HT or 5-HIAA levels in the frontal cortex or the 
striatum (Table 4.2). Moreover MDMA tended to increase dopamine, DOPAC 
and HV A levels in the striatum however these effects were again not 
significant (Table 4.3). 
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Table 4.2 No long-tenn effect of repeated administration of low doses of MDMA on 
5-HT and 5-HlAA levels in the hippocampus, frontal cortex and striatum. Data are 
presented as mean of concentration (pmollmg of tissue) ± SEM (0 = 8 per group). 
Hippocampus Frontal cortex Striatum 
Treatment S-HT S-HIAA S-HT S-HIAA S-HT S-HIAA 
Saline 1.92±0.\3 1.94±O.14 2.80±0.32 1.44±O.09 3.81±0.29 2.7I±O.l4 
MDMA 1.82±0.08 1.92±0.08 2.90±0.23 I.3S±O.l3 3.60±0.32 2.37±0.19 
(3x3 mg/kg) 
MDMA 1.78±0.1I 1.94±0.09 2.74±0.29 1.4S±O.l4 3.62±0.32 2.47±0.12 
(3x6 mg/kg) 
Table 4.3 No long-tenn effect of repeated administration of low doses of MDMA on 
dopamine, OOPAC and HV A levels in the striatum. Data are presented as mean of 
concentration (pmol!mg of tissue) ± SEM (n = 8 per group). 
Treatment Dopamine 
Saline 27.27 ± 4.57 
MOMA (3x3 mg/kg) 31.34 ± 3.26 
MDMA (3x6 mg/kg) 37.64 ± 4.97 
DOPAC 
4.06 ± 0.58 
4.44±0.38 
5.61 ±0.55 
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2.09±0.37 
2.32 ±0.27 
2.85 ±0.38 
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4.1.4 Discussion 
The flrst experiment of this chapter aimed to determine the long-term effects of 
repeated administration of low doses of MDMA on novel object discrimination 
and changes in 5-HT, dopamine and their metabolites in the hippocampus, 
striatum and frontal cortex. The experimental procedure used in this 
experiment was similar to that used in the previous chapter as the rats were 
singly housed in a computer-controlled infra-red activity monitor chamber 
during treatment and the acute effect of the MDMA treatment on activity were 
measured. In addition rectal temperature was measured 2 h after the last 
injection of the drugs. Novel object discrimination and changes in amine 
neurotransmitters were measured 2 weeks after treatment. 
The activity response to MDMA was measured during treatment using the 
computer-controlled infra-red activity monitor chambers which provided data 
of 'ambulatory' and 'fme' movements. The ambulatory movement data 
represented locomotor activity of the rats and repeated administration of the 
higher dose of MDMA (3 x 6 mglkg) produced a marked and sustained 
hyperactivity, similar to that previously demonstrated in chapter 3 using 
radiotelemetry. The lower dose of MDMA (3 x 3 mglkg) produced little effect 
on locomotor activity after the second and third injections which was similar to 
the radiotelemetry measurement in chapter 3 when there was no effect on 
activity with lower dose of MDMA. 
Unlike the data from radiotelemetry, the computer-controlled infra-red activity 
monitor chamber provides data of 'fine' movements which were counted when 
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the rats repeatedly disrupted the same beam. It was demonstrated in the present 
study that both doses of MDMA markedly increased fine movement after each 
injection. MDMA-induced hyperactivity has been generally reported (Colado 
et aI., 1993, Shankaran and Gudelsky, 1999, Spanos and Yamamoto, 1989). 
The quality of hyperactivity produced by MDMA in rats is unique as MDMA 
produces both amphetamine-like hyperlocomotor activity together with the 
symptoms of the serotonin syndrome, which include low body posture, side-to-
side headweaving, lateral forepaw treading and the autonomic signs of 
piloerection and salivation (Gold et aI., 1988, Spanos and Yamamoto, 1989). In 
the present study the data for the fme movement was counted when the rats 
repeatedly disrupted the same beam and therefore probably represent the 
symptoms of the serotonin syndrome, especially side-to-side headweaving, 
which would be counted as fine movements. The increase in fme movements 
following both doses of MDMA is indicative of the serotonin syndrome 
following MDMA. Interestingly the increase in fine body movements with the 
higher dose persisted on day 14 after treatment suggesting MDMA treatment 
can have long-tenn effects on fine motor function. 
Body temperature was measured 2 h after the last injection showing that the 
higher dose of MDMA (3 x 6 mglkg) slightly increased body temperature by 
+0.5 °C while the lower dose of MDMA (3 x 3 mglkg) decreased body 
temperature by -0.3 °C compared to saline control. The pattern of body 
temperature change was comparable to those measured in the previous chapter 
using radiotelemetry but the magnitude of increase in the present study by the 
higher dose ofMDMA (6 mglkg) was lower (+0.5 °c using rectal thermometer 
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probe compared to + 1.7 °C by radiotelemetry). It might be due to the physical 
stress state of the rats in radiotelemetry experiment being higher as rats had 
been implanted with microdialysis probe the day before MDMA 
administration. This higher physical stress might have affected temperature 
response to the drug. 
The main fmding of the present study is that repeated administration of 6 but 
not 3 mg/kg MDMA (3 times every 2 h) disrupted novel object discrimination 
2 weeks after treatment (Figure 4.8). The effect at 3 mg/kg did not show in the 
novel object PI value (Figure 4.9) suggesting only a marginal novel object 
discrimination at this dose. The long-term effect of MDMA administration on 
novel object recognition seems to vary greatly across studies. McGregor et al 
(2003) showed a disruption of novel object recognition with a 1 hinter-trial 
interval 10-12 weeks following repeated MDMA administration (4 x 5 mglkg 
for 2 days) treatment while Morley et al (2001) reported a significant 
deleterious effect on novel object recognition with a 15 min but not 1 h inter-
trial interval 14 weeks after MDMA administration (4 x 5 mglkg for 2 days). 
On the other hand Able et al (2006) and Skelton et al (2008) gave MDMA (4 x 
15 mg/kg) to the rats and produced no impairment of novel object recognition 
with a 1 h inter-trial interval 4-6 weeks after treatment. 
The results from the previous studies are difficult to compare with the present 
study as there were differences in the doses used, dosage regimen and the 
experimental protocol. However the present study gave repeated low doses of 
MDMA (3 x 6 mg/kg accumulating to 18 mglkg over 4 h) and the studies by 
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Morley et al (2001) and McGregor et al (2003) also gave repeated low dose of 
MDMA (4 x 5 mg/kg for 2 days accumulating to 40 mglkg) and all these 
studies identified long-term disruption of novel object recognition while 
studies by Able et al (2006) and Skelton et al (2008) using repeated high dose 
of MDMA (4 x 15 mglkg accumulating to 60 mglkg) showed no impairment of 
novel object recognition. The experimental protocols including the inter-trial 
intervals and the duration of the novel object recognition task after treatment 
also vary across the studies. Morley et al (2001) showed that disruption of 
novel object recognition depended on the inter-trial interval with impairment 
with a 15 min delay but not 1 h delay while the present study with a 2 h delay 
found disruption. In addition novel object recognition was performed 2 weeks 
after MDMA treatment in the present study while others performed the novel 
object recognition task 4-6 weeks (Able et al., 2006, Skelton et al., 2008) or 
over 3 months (McGregor et aI., 2003, Morley et al., 2001) after MDMA 
treatment. Overall however the evidence suggests that "binge-type" repeated 
MDMA treatment in the rat can lead to long-term disruption to novel object 
discrimination indicating the impairment of working as well as recognition 
memory following repeated MDMA treatment in the rats. In humans there have 
been a number of studies showing impairments of working memory following 
MDMA use especially in heavy and chronic recreational users (Fox et al., 
2002, Gouzoulis-Mayfrank et al., 2000, McCann et al., 1999b, Morgan et aI., 
2002, Wareing et al., 2000). The present study suggests the risk of impairment 
of working memory following binge use of MDMA. 
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Rats treated with the higher dose of MDMA (3 x 6 mglkg) showed a 
significantly lower total exploratory time in trial 2 compared to saline and the 
lower dose of MDMA (3 x 3 mglkg) but a significant increase in fine 
movements as already discussed. This increase in fine movements might 
interfere with performance of the novel object recognition task however further 
investigation is required. 
The evidence for an involvement of 5-HT neurotoxicity on memory 
impairment following MDMA treatment is controversial. McGregor et al 
(2003) reported an impairment of novel object recognition with decreased 5-
HT in the hippocampus, striatum, amygdala and cortex. In contrast Able et al 
(2006) and Skelton et al (2008) found decreased 5-HT in the hippocampus, 
neostriatum and frontal cortex but no impairment of novel object recognition. 
The present study showed a disruption of novel object recognition 2 weeks 
following MDMA (3 x 6 mglkg) administration without changes in 5-HT in the 
hippocampus, striatum and frontal cortex, indicating that the long-term 
impairment of novel object discrimination caused by MDMA did not depend 
upon distribution of 5-HT function. 
The long-term depletion of brain 5-HT following MDMA administration has 
been well documented especially after high or repeated doses of MDMA to the 
rats (see review Capela et aI., 2009). There was however no change in S-HT 
and 5-HIAA in hippocampus, striatum and frontal cortex 2 weeks following 
repeated low doses of MDMA in the present study. A similar study by 
Baumann et al (2007) also showed that low dose of MDMA (3 x 1.5 mglkg) 
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had no effect on 5-HT in the frontal cortex and striatum 2 weeks after 
administration while a higher dose of MDMA (3 x 7.5 mg/kg) produced 50% 
reduction of 5-HT in those brain regions. The hyperthermic response has been 
previously shown to playa role in MDMA-induced neurotoxicity (Baumann et 
ai., 2008a, Green et ai., 2004, Malberg and Seiden, 1998, Sanchez et ai., 2004). 
Recently Baumann et al (2008a) showed a negative correlation between the 
acute hyperthermic response and 5-HT depletion 2 weeks after MDMA (3 x 
7.5 mg/kg). In the present study there was no increase in body temperature 2 h 
after the last injection of the lower dose of MDMA (3 x 3 mg/kg; -0.3 °C) and 
only a small increase after the higher dose (3 x 6 mglkg; +0.5 0c) and no 
consequent changes in 5-HT and 5-HIAA levels 2 weeks after treatment further 
suggesting 5-HT loss may have a link with the degree of hyperthermia 
produced by a given dose of MDMA. 
In summary, the present study provided evidence of long-term disruption of 
novel object discrimination following "binge-type" repeated MDMA 
administration (3 x 6 mg/kg) and that these impairments of recognition and 
working memory are not directly related to changes in brain region levels of 5-
HT or dopamine. The hyperthermic response is thought to be a factor 
influencing MDMA-induced 5-HT neurotoxicity but the doses given in this 
experiment did not produce significant hyperthermia. However it is known that 
single housing may influence the hyperthermic effect of MDMA as discussed 
in chapter 3. Thus the next experiment in this chapter compared the 
temperature response and MDMA-induced 5-HT neurotoxicity in singly and 
group housed rats. 
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4.2. Experiment 2: Acute effects of group housing on the MDMA-induced 
change in body temperature and the long-term effects on novel object 
discrimination and neurotoxicity 
4.2.1 Introduction 
It was demonstrated in the first experiment of this chapter that repeated 
administration of the higher dose of MDMA (3 x 6 mg/kg) slightly increased 
body temperature 2 h after the last injection. Studies using radiotelemetry in 
the previous chapter found that this dose of MDMA (3 x 6 mg/kg) impaired 
thermoregulation in the rats. However an increase in body temperature was not 
sufficient to produce neurotoxicity in the present study. In chapter 3 the 
importance of housing conditions on MDMA-induced hyperthermia and 
subsequent 5-HT neurotoxicity was discussed as aggregation has been 
previously reported to potentiate the behavioural and lethal effects of 
stimulants including amphetamine, methamphetamine, 3,4-
methylenedioxyamphetamine (MDA) and MDMA in animals (Chance, 1947, 
Davis and Borne, 1984, Fantegrossi et aI., 2003, Greenblatt and Osterberg, 
1961). The mechanism of toxicity has generally thought to be directly related 
to raised body temperature (Askew, 1961, Craig and Kupferberg, 1972) 
however no study has compared the effect of single and group housing 
condition on the body temperature response and subsequent neurotoxicity 
produced by MDMA. In addition investigation into the aggregate toxicity of 
MDMA is particularly relevant due to the common condition of social MDMA 
use by humans (Green et aI 2003). It is hypothesized in the present study that 
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the condition of crowding could produce greater hypertbennia and thus 
potentiate the neurotoxic effects of MDMA. 
The aims of the second experiment of this chapter were to compare the effects 
of single and group housing conditions on MDMA-induced hypertbennia and 
detennine the involvement of hypertbennia on MDMA-induced 5-HT 
neurotoxicity. The long-tenn effect of repeated MDMA administration on 
novel object discrimination was also examined. The higher dose of MDMA (3x 
6 mglkg) was selected as it had disrupted novel object discrimination in 
experiment 4.1. 
4.2.2 Materials and methods 
Animal 
Adult male Lister hooded rats (Biomedical Service Unit, University of 
Nottingham, UK) weighing 300-350 g were housed on a 12 h light/dark cycle 
(light on at 7.00h) in constant room temperature (21±2 °C) and humidity (45-
65%). Rats had free access to food and water. All experiments were perfonned 
in accordance with the UK Animals (Scientific Procedures) Act, 1986 under 
project license 40/2715 and approved by the University of Nottingham Local 
Ethical Review Committee. 
Experimental procedure 
Rats were housed in groups of 4 throughout the experiment. One day before 
treatment each rat was placed in an individual infra-red activity monitor 
chamber to measure activity baseline for each group as in experiment 4.1. On 
the treatment day rats were injected with either MDMA (6 mglkg i.p., (±)-
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MDMA Hel, Sigma, UK) or saline (1 mllkg i.p.) 3 times every 2 h while still 
group housed. Rectal temperature was measured 30, 60 min before the first 
injection then every 30 min until 2 h after the last injection using a digital 
thermocouple probe thermometer (Portec Instrumentation Ltd, P9005) inserted 
6-8 cm into the rectum. On day 14 each rat was habituated in the individual 
infra-red activity monitor chamber and activity recorded for 1 h. Novel object 
discrimination was performed on day 15. Brain tissue was dissected for later 
analysis of 5-HT, dopamine and their metabolites as previously described. 
Day 1 
o 14 15 
I ~ - - ~ - - - - - - - - - - - - - - - I - - - I I
I Habituation(1h) I 
• Treatment : 
- MDMA 6 mglkg Lp_ or 
- saline 1 mUkg Lp. 
3 Injections 2 h apart 
Experiment 42 
• Rats housed in group of 4 
during treatment 
• Rectal temperature recorded 
during treatment 
• Novel object discrimination (2 h 
inter-llial interval) 
• Brain dissected (fronlal cortex, 
hippocampus, slIiatum) 
1 
Analysis for 5-HT. 
dopamine and their metaboliles 
using HPl..C-ECD 
Figure 4.10 Experimental procedure to detennine the effects of repeated low dose 
MDMA administration while rats were group housed during treatment on body 
temperature, long-tenn effect of MDMA on novel object discrimination and changes 
in brain amiTIes. 
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Statistical analysis 
Two-way ANOV A followed by Bonferroni post hoc test, one-way ANOV A 
followed by Tukey's post hoc test, unpaired Student t-test and one sample t-test 
were used where appropriate. P < 0.05 was considered as a significant 
difference. 
4.2.3 Results 
(a) Locomotor activity before treatment 
Similar to the first experiment both pre-saline and pre-MDMA rats exhibited 
the similar ambulatory and fine movement which decreased across the 60 min 
period in the activity chamber, such that 2-way ANOV A showed a significant 
time effect on ambulatory (F(11,154) = 60.62, P < 0.0001) and fme activity 
(F(1l,154) = 16.64, p < 0.0001) indicating that both groups of rats performed 
normal activity before treatment (Figure 4.11). 
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Figure 4.11 A: Ambulatory and B: fine activity 1 day before treatment. Each point 
represents mean of number of beam breaks in 5-min ± SEM (n = 8 per group). 
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(b) The acute effect of repeated administration of low dose of MDMA on body 
temperature 
Rectal temperature was measured during treatment day as shown in Figure 
4.12A. Both groups of rats exhibited a decrease of rectal body temperature 
during the day. MDMA (6 mg/kg) decreased rectal body temperature by -0.3 ± 
0.1 DC following the first injection compared to saline however this effect was 
not significant different from saline controls. While rectal body temperature in 
saline-treated rats continuously decreased after the second and the third 
injections, MDMA (6 mg/kg) tended to increase body temperature. The 
average increase of body temperature following the third injection of MDMA 
was +0.4 ± 0.1 °C compared to saline controls. This increase however was not 
significantly different from saline. Two-way ANOV A showed a significant 
effect of time on body temperature (F(14,196) = 19.80, P < 0.0001) but there 
was no significant effect of treatment on body temperature. 
Figure 4.12 also shows the comparison between the results from the present 
experiment, using a rectal probe thermometer (Figure 4.12A), and the 
experiment in chapter 3 (Figure 4.12B) where radiotelemetry was used. Data 
obtained from radiotelemetry showed that repeated MDMA administration (3 x 
6 mglkg) decreased body temperature after the first injection then body 
temperature continuously increased after the second and the third injection 
(Figure 4.12B) with an average increase of +0.9 ± 0.3 °C after the last injection 
compared to saline controls (Figure 4.12B). 
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Figure 4.12 A: Effect of repeated administration of either MDMA (6 mglkg) or saline 
3 injections given 2 h intervals on body temperature (injections indicated by arrows). 
Rectal temperature was measured using a rectal probe every 30 min (means ± S ~ ~M, n 
= 8 per group). B: Body temperature data obtained from the experiment in chapter 3 
using radiotelemetry to compare the results from two experiments using the same 
treatment but different measuring devices. Data are presented as means of body 
temperature in 20-min time bins ± SEM (injections indicated by arrows, n = 6 per 
group). 
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(c) Locomotor activity on day 14 
Rats were habituated in the infra-red activity monitor chamber 13 days after 
MDMA or saline treatment. Two groups of rats exhibited the same ambulatory 
and fine movements which again decreased across the 60 min period. Two-way 
ANOVA showed a significant time effect on ambulatory (F(11,154) = 23.33, P 
< 0.0001) and fine activity (F(II,154) = 7.97, P < 0.0001) and there was no 
effect of treatment on activity on ambulatory and fme activity (Figure 4.13). 
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Figure 4.13 Effects of MDMA (3 x 6 mg/kg) or saline on A: ambulatory and B: fme 
movements 13 days after treatment. Data are expressed as 5-min time bins and as 
total values over 60 min test period (the inset figures) in the infra-red activity monitor 
chamber (mean ± SEM, n = 8 per group). 
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(d) Long-term effect of repeated low dose MDMA administration on memory 
using novel object discrimination in group housed rats 
Novel object discrimination was performed 14 days after treatment. In the 
familiarisation trial (trial 1; Tl) rats explored two identical objects and again 
there was no significant difference in time spent exploring two identical objects 
and no location preference (Figure 4.l4A). In the choice trail which was a 2 h 
after the familiarisation trial, two-way ANOV A showed no effect of either 
treatment or object on time spent exploring the novel versus the familiar object. 
However Bonferroni post hoc test showed that saline-treated rats spent more 
time exploring the novel than the familiar objects (p < 0.05) (Figure 4.14B), 
and the preference index (PI) value of saline-treated rats was significantly 
higher that a 50% chance level (p = 0.0260, one sample I-test) (Figure 4.15). In 
contrast MDMA (3 x 6 mglkg)-treated rats again failed to discriminate the 
novel from the familiar object and the PI value of MDMA-treated rats was not 
significantly different from a 50% chance level (p = 0.6683, one sample I-test) 
suggesting that repeated administration of MDMA (3 x 6 mglkg) impairs novel 
object discrimination (Figure 4.14B). 
Two-way ANOV A showed no effect of trial and treatment on total exploration 
time. However the total exploration time in trial 2 (total T2 time) was 
decreased in saline-treated rats compared to total exploration time in trial 1 
(total Tl time) (p < 0.05; Student unpaired t-test) (Table 4.4). 
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Figure 4.14 Effect of MDMA on the time spent (s, means ± SEM) exploring A: each 
of the identical objects during trial 1 and B: the novel versus the familiar objects 
during trial 2 which was 2 h after trial 1. Rats received either MDMA (6 mglkg Lp.) or 
saline (1 ml/kg i.p.) 3 times every 2 h (n = 8 per treatment) and performed novel 
object discrimination 14 days after treatment. * p < 0.05 compared with time spent at 
the familiar object in the same treatment group (Bonferroni post hoc test). 
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Figure 4.IS Time spent exploring the novel versus the familiar objects in the choice 
trial was converted into a preference index (PD (e.g. [novel object! novel object + 
familiar object] x 100) (Bruel-Jungerrnan et a!., 2005). Data are presented as means of 
PI values ± SEM (n = 8 per group). Each experimental group was compared against a 
PI value of SO% chance level (dashed line) using one sample t-test. * p < 0.05 
compared to a PI value of SO% chance level (one-sample t-test) 
Table 4.4 Total time spent exploring two identical objects in trial 1 (total T1 time) and 
total time spent exploring the novel and the familiar objects in trial 2 (total T2 time) 
(s, means ± SEM, n = 8 per group). 
Treatment Total Tl time Total T2 time 
(s, mean ± SEM) (s, mean ± SEM) 
saline 54 ± 6 41 ± 2* 
MDMA (3 x 6 mglkg) 45 ± 6 40 ± 4 
* p < O.OS compared to saline in trial 1 
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(e) Long-term effects of repeated low doses of MDMA on 5-HT, dopamine and 
their metabolites in the hippocampus, frontal cortex and striatum 
5-HT, dopamine and their metabolites in the hippocampus, frontal cortex and 
striatum were measured using HPLC-ECD 14 days after treatment. It was 
shown in experiment 4.1 that when given to singly housed rats MDMA had no 
effect on 5-HT levels in any brain regions examined however given MDMA (3 
x 6 mg/kg) to group housed rats significantly decreased 5-HT levels in the 
hippocampus (p = 0.0113, unpaired Student t-test) (Table 4.5). There was no 
change in hippocampal 5-HIAA levels following MDMA administration and 
also no significant difference of either 5-HT or 5-HIAA levels in the frontal 
cortex or the striatum (Table 4.5). MDMA tended to increase dopamine, 
DOP AC and HV A levels in the striatum however this was not significantly 
different from saline controls (Table 4.6). 
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Table 4.5 The long-term effects of repeated administration of low dose of MDMA on 
5-HT and 5-HlAA levels in the hippocampus, frontal cortex and striatum. Data are 
presented as mean of concentration (pmol/mg of tissue) ± SEM (n = 8 per group). 
Treatment 
Saline 
MDMA 
Hippocampus 
S-HT S-HIAA 
2. I 9±O.08 2.07±O.04 
I. 77±O.l1 * I. 95±O.12 
*p = 0.0113, unpaired Student I-test 
Frontal cortex Striatum 
S-HT S-HIAA 5-HT 5-HIAA 
2.52±O.08 1.34±O.06 3.1 I±O.17 2.S3±O.16 
2.34±O.19 1.29±O.08 2.80±0.27 2.24±O.08 
Table 4.6 Long-term effects of repeated administration of low dose of MDMA on 
dopamine, OOPAC and HV A levels in the striatum. Data are presented as mean of 
concentration (pmol/mg of tissue) ± SEM (n = 8 per group). 
Treatment 
Saline 
MDMA 
Dopamine 
26.81 ±4.11 
29.71 ± 2.36 
Concentration (pmoVmg of tissue) 
OOPAC 
3.38 ±O.SI 
3.61 ±O.27 
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4.2.4 Discussion 
The second experiment of this chapter aimed to determine the effect of the 
housing conditions on MDMA-induced changes in body temperature and long-
term 5-HT neurotoxicity. Rats were group housed during MDMA treatment to 
produce aggregation as it was previously reported that there was an increase in 
the behavioural and lethal effects of amphetamines, including MDMA, in 
group housed animals (Chance, 1947, Davis and Borne, 1984, Fantegrossi et 
aI., 2003). The main finding of the present study was that the pattern of body 
temperature change following repeated MDMA administration in the group 
housed rats, using a rectal probe, was similar to that seen in the singly housed 
rats in chapter 3, using radiotelemetry to measure body temperature (Figure 
4.12) indicating that there was no aggregation toxicity on hyperthermic effect 
of MDMA in rats. However although the pattern of hyperthermic response to 
MDMA of singly and group housed rats is not different, the present study 
showed that group housed rats significantly decreased 5-HT levels in the 
hippocampus 2 weeks after repeated MDMA administration (3 x 6 mglkg) 
(experiment 4.2) while the singly housed rats showed no long-term change in 
5-HT levels following repeated MDMA (experiment 4.1). Consistent to the 
results from experiment 4.1, the present study also showed that "binge-type" 
repeated administration of low dose MDMA (3 x 6 mglkg) caused long-term 
impairment of novel object discrimination. 
The effect of repeated MDMA administration {3 x 6 mglkg} on body 
temperature in the group housed rats was similar to that seen in the singly 
housed rats shown in chapter 3, using radiotelemetry to measure body 
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temperature, as decreased body temperature was found after the first injection 
of MDMA (3 x 6 mg/kg) and then body temperature continuously increased 
following the second and the third injections. However the magnitude of body 
temperature increase is different as in the present study, using a rectal probe 
thermometer, MDMA produced a small increase of body temperature after the 
second and third injections (+D.4 °c using a rectal probe compared to +D.9 °c 
using radiotelemetry after the last injection compared to saline controls) and 
the increase was not significant compared to saline controls. This is possibly 
due to the lower sensitivity of a rectal probe compared to radiotelemetry. In 
addition, using a rectal probe, both saline and MDMA-treated rats showed a 
marked decrease of body temperature during the treatment period and it is 
noticeable that the ftrst rectal temperature measured 1 h before treatment was 
as high as 39°C. Animal restraint stress might affect the results of changes in 
body temperature when using a rectal probe. Together with the results from 
chapter 3 it is likely that MDMA-induced changes in body temperature 
depends mainly on ambient temperature rather than the housing conditions. 
The influence of MDMA-induced acute hyperthermia on subsequent 5-HT 
neurotoxicity is unclear (Baumann et aI., 2008a, Green et al., 2004, Malberg 
and Seiden, 1998, Sanchez et al., 2004). Many studies showed that preventing 
MDMA-induced hyperthermia using several compounds such as a-methyl-p-
tyrosine, the tyrosine hydroxylase inhibitor, haloperidol, the dopamine receptor 
antagonist, and MDL 11939, the 5-HT2 receptor antagonist, can protect or 
attenuate MDMA-induced neurotoxicity (Broening et aI., 1995, Colado et aI., 
1999c, Hewitt and Green, 1994, MaIberg and Seiden, 1998). In contrast many 
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studies demonstrated that although rat body temperature was kept normal at the 
time of MDMA administration, MDMA can produce 5-HT neurotoxicity 
(Farfel and Seiden, 1995, Marston et aI., 1999, McGregor et aI., 2003). O'Shea 
et al (1998) also reported MDMA-induced hyperthermia without subsequent 5-
HT depletion. Similarly in the present study MDMA administration in the 
group housed rats produced a small but not significant increase in body 
temperature but long-term 5-HT depletion was found in the hippocampus. 
Comparing to experiment 4.1 in which MDMA treatment in singly housed rats 
produced a similar increase of body temperature with no long-term effect on 
brain 5-HT levels, it is indicated that hyperthermia is not an essential factor in 
MDMA-induced 5-HT neurotoxicity. 
In summary, both experiments in this chapter showed long-term disruption of 
novel object discrimination after "hinge-type" repeated MDMA administration 
indicating risk of long-term effect on working as well as recognition memory 
impairments in "binge" MDMA users. This memory impairment following 
repeated MDMA administration however did not depend on S-HT and 
dopamine function. In addition the present study provides evidence to show a 
lack of effect of aggregation on MDMA-induced changes in body temperature. 
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5.1. Introduction 
The precise mechanism underlying MDMA-induced 5-HT neurotoxicity is 
unknown; dopamine has been suggested to be involved. Sprague et al (1998) 
proposed that dopamine released following MDMA administration can be 
transported into 5-HT nerve terminals where oxidation of excessive dopamine 
produces free radicals which in turn induced the long-term damage to 5-HT 
terminals. Although administration of the tyrosine hydroxylase inhibitor, a-
methyl-p-tyrosine, the dopamine depleting agent, reserpine, the dopamine 
uptake inhibitors, GBR 12909 (Stone et aI., 1988) and mazindol (Shankaran et 
aI., 1999), or the dopamine receptor antagonist, haloperidol (Hewitt and Green, 
1994, Schmidt et aI., 1990), attenuate the MDMA-induced loss of 5-HT which 
appears to support the proposal, it is likely that all of these compounds do so by 
decreasing body temperature rather than because of a specific effect on 
dopamine function (Colado et aI., 1999b, Helanatpanah et aI., 1989, Yuan et 
al., 2002). Furthermore recent studies which examined the effect of depleting 
the cerebral dopamine content with a-methyl-p-tyrosine while keeping the 
animals normothermic (Yuan et aI., 2002) or enhancing dopamine content by 
administering L-DOPA (Colado et aI., 1999b) both failed to support a major 
role of dopamine in MDMA-induced neurotoxicity. 
There are questions as to how dopamine can be involved in the MDMA-
induced damage 5-HT neurons in several brain areas such as the hippocampus 
which are sparsely innervated by dopaminergic neurons. Recently Breier et al 
(2006) showed that MDMA increased the extracellular tyrosine concentration 
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in the striatum and hippocampus and demonstrated that this tyrosine could be 
converted to DOPA and dopamine via a tyrosine hydroxylase-independent 
mechanism. They also suggested that this increased dopamine concentration 
was primarily responsible for MDMA-induced 5-HT neurotoxicity 
The aim of the experiment in this chapter was to determine whether acute brain 
tyrosine depletion would influence the MDMA-induced immediate 5-HT 
depletion and/or the long-term 5-HT neurotoxicity. To reduce tyrosine 
availability in the brain and consequently alter dopamine synthesis and release, 
rats were administered a tyrosine- and phenylalanine-free amino acid mixture. 
As tyrosine is competitively transported into the brain and nerve terminals by 
the large neutral amino acid transporter (Fernstrom and Wurtmanm, 1972, 
Grahame-Smith and Parfitt, 1970), administration of a tyrosine- and 
phenylalanine-free amino acid mixture reduces brain tyrosine levels by up to 
70% within 2 hours (Biggio et aI., 1976, Fernstrom and Fernstrom, 1995, 
McTavish et aI., 1999). This experimental approach was therefore used to test 
the hypothesis that the brain tyrosine availability is involved in MDMA-
induced 5-HT neurotoxicity. 
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5.2. Acute effects of tyrosine depletion on brain tyrosine, dopamine, 5-HT 
and their metabolite levels 
5.2.1 Materials and methods 
Animals 
Male Dark Agouti rats weighing 165-200 g (Harlan-Olac, Bicester, UK) were 
housed on a 12h light/dark cycle (lights on at 07.00 h) and given food and 
water ad libitum. Room temperature (21 ± 2°C) and humidity (45-65%) were 
kept constant. All experiments were perfonned in accordance with the UK 
Animals (Scientific Procedures) Act, 1986 under project license 40/2715 and 
approval of the local ethical committee. The experimenter was blind to the 
treatment given in all parts of the study. 
Dark Agouti rats were used in the present study as this strain of rats is more 
sensitive to the acute and long-tenn effects of MDMA than other rat strains. It 
was shown that Dark Agouti rats required a single dose of MDMA (10-15 
mg/kg) to produce 30-50% loss of cerebral 5-HT content (Colado et aI., 1995, 
1999b, O'Shea et aI., 1998) while several doses ofMDMA (10-20 mg/kg) were 
required to produce similar loss in Lister hooded rats (Colado et aI., 1993, 
Sumnall et aI., 2004). 
Drugs and reagents 
The tyrosine- (and phenylalanine-) free amino acid mixture was prepared as 
previously described by McTavish et a1 (1999) and contained methionine (133 
mg), threonine (266 mg), tryptophan (67 mg), lysine (465 mg), isoleucine 
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methyl ester (399 mg), leucine methyl ester (599 mg) and valine methyl ester 
(465 mg) dissolved in 12 ml distilled water adjusted to pH 7.4 with 0.1 M 
NaOH and administered in a volume of 5 mllkg i.p. 
(±)-MDMA hydrochloride (Sigma) was dissolved in 0.154 M saline at 12.5 
mg/kg (calculated as base) and administered in a volume of 1 mllkg i.p. 
Experimental design 
Rats were divided into 4 groups (n = 5 per group) each housed by group. Two 
groups of rats received the tyrosine-free amino acid mixture (5 mllkg i.p. 
equivalent to 1 g/kg twice 1 h apart) and other two groups received saline (5 
ml/kg i.p. twice 1 h apart). One of the amino acid mixture-treated groups and 
one of the saline-treated groups received MDMA (12.5 mg/kg i.p.) 55 min after 
the first injection of the amino acid mixture (or saline) while the other two 
groups were given saline (1 mllkg Lp.) in place ofMDMA. Rats were killed by 
concussion and decapitated 2 h after MDMA administration. The 
hippocampus, striatum and frontal cortex were rapidly dissected on a cool tray 
at 4°C, snap frozen in liquid nitrogen and maintained at -80 °c prior to the 
analysis of tyrosine, 5-HT, dopamine and their metabolites (experimental 
design summarised in Figure 5.1. Measurement of 5-HT, dopamine and their 
metabolites was described in chapter 2. 
Measurement of tyrosine using HPLC-ECD 
For the measurement of tyrosine, high-performance liquid chromatography 
(HPLC) with pre-column derivatisation coupled with electrochemical detection 
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(ECD) was utilized as the method has high sensitivity and specificity. The 
HPLC-ECD method was modified from Bongiovanni et al (2001). The reaction 
of o-phthala1dehyde (OPA) with tyrosine in the presence of sulfite was used to 
produce N-alkyl-1-isoindole sulphonates which were detected using ECD. The 
derivatisation reaction is presented in Figure 5.2A. The optimum pH for the 
reaction is between 9 and 10.5 (Jacobs, 1987) which in this experiment was 
achieved using borate buffer pH 10.4 (see Derivatisation). 
The HPLC system consisted of a SphereClone column (4.6 x 100 mm, ODS 2, 
3-Jlm particles, Phenomenex, Macclesfield, GB), a PU-980 pump (Jasco, 
Essex, UK) and an Antec Cu-04 electrochemical controller and Antec VT -03 
electrochemical detector (Antec Leyden, Zoeterwoude, The Netherlands) fitted 
with a glassy carbon electrode set at +O.75V vs Ag/AgCl. The mobile phase 
consisting of 0.133 M disodium hydrogen phosphate (Na2HP04), 0.15 mM 
EDTA and 20% v/v methanol adjusted to pH 6.8 with o-phosphoric acid was 
pumped at 0.5 mllmin flow rate. During sample injection the system was run 
open-circuit but mobile phase was recycled overnight or when not in use. 
Tyrosine standard 
Tyrosine stock solution was prepared by dissolving 10 mg of tyrosine 
(calculated as base) into 9.5 ml of diluents (water-methanol, 75:50 v/v) and 0.5 
ml 30% NaOH. The 1 mg/m1 of tyrosine stock solution was diluted with 0.1 M 
perchloric acid containing 1 Jlg/ml norvaline (as internal standard) to make 
working standards in Jlglml. 
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Derivatising agent 
The derivatising reagent consisted of 10 mg o-phthalaldehyde, 30 mg sodium 
sulphite, 0.25 ml methanol and 0.25 ml H20 diluted to 5.0 ml with sodium 
borate buffer pH 10.4 (0.4 M boric acid adjusted to pH 10.4 with 6 M NaOH). 
The derivatising reagent was prepared once weekly and stored at room 
temperature in an amber bottle. 
Sample preparation 
One ml of ice-cold 0.1 M perchloric acid containing 1 Jlg/ml norvaline (as 
internal standard) was added to each brain region in an Eppendorf tube and 
samples sonicated for 30s and centrifuged at 16000 g for 4 min at 4 °c (Harrier 
18/80 refrigerated, MSE). The supernatants were stored at -80°C until analysis. 
Derivatisation 
To detect tyrosine, 100 J.lI of sample or working standard (1 J.lg/ml) was 
routinely reacted for 5 min at the room temperature with 100 J.lI of derivatising 
agent and 100 JlI of sodium borate buffer pH 10.4 (to buffer the perchloric acid 
used for the extraction). After 5 min the reaction samples or standards were 
made up to 1 ml with mobile phase before injection (20-JlI) into the HPLC 
system. The minimum level of detection was 0.5 ng injected onto the column. 
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Figure 5.1 Diagrammatic representation of experimental protocol for determining 
acute effects of tyrosine depletion and MDMA on tyrosine, 5-HT, dopamine and their 
metabolite levels in specific brain regions 
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+ Hp + OH-
Figure 5.2 (A) Reaction scheme to illustrate the derivatisation reaction between 0-
phthalaldehyde and primary alkyl amine (R'NH2) in the presence of sulfite ions ( S ~ 2 2
) producing N-alkyl-I-isoindole sulphonates. (B) The primary alkyl amine (R'NH2) 
reacted to o-phthalaldehyde in the present experiment is tyrosine. 
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Figure 5.3 An example of the chromatographic separation of A: tyrosine and norvaline 
mixed standard (1 /!g/ml each) and B: tyrosine in the striatum samples in percholic 
acid containing 1 )lg/ml norvaline (as internal standard) using mobile phase 0.133 M 
Na2HP04, 0.15 mM EDTA, 20 % v/vmethanol pH 6.8. 
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Figure 5.4 Linear relation between the concentrations of exogenous tyrosine injected 
onto the column and the detector response. 
Statistical analysis 
Statistical analysis of brain amines and tyrosine levels was perfonned using 
two-way ANOV A, with MDMA and tyrosine-free amino acid mixture as main 
factors followed by Bonferroni post hoc test if required. P < 0.05 was 
considered to be statistically significant. 
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5.2.2 Results 
(aJ Acute effect of the tyrosine-free amino acid mixture and MDMA on tyrosine 
levels in the hippocampus, striatum and frontal cortex 
Tyrosine levels in the hippocampus, striatum and frontal cortex were measured 
2 h after MDMA administration (Figure 5.5). Two-way ANOV A revealed a 
main effect of the tyrosine-free amino acid mixture on tyrosine levels in the 
hippocampus (F(l,16) = 92.08, P < 0.0001), striatum (F(l,16) = 76.92, P < 
0.0001) and frontal cortex (F(l,16) = 220.6, p < 0.0001). The tyrosine-free 
amino acid mixture (AA/Sal) decreased hippocampal tyrosine levels by 62% 
compared with saline controls (Sal/Sal) (p < 0.001) while combined tyrosine-
free amino acid mixture and MDMA (AAlMDMA) decreased hippocampal 
tyrosine levels by 53% compared with MDMA given alone (SallMDMA) (p < 
0.001) (Figure 5.5A). Tyrosine levels were similarly reduced in the striatum by 
the tyrosine-free amino acid mixture without MDMA (AA/Sal) (61%; p < 
0.001) compared with saline controls (Sal/Sal) and the tyrosine-free amino acid 
mixture given with MDMA (AAlMDMA) (51%; p < 0.001) compared with 
MDMA given alone group (AAlMDMA) (Figure 5.58). In the frontal cortex, 
tyrosine levels decreased by the tyrosine-free amino acid mixture alone 
(AA/Sal) by 58% compared to saline controls (Sal/Sal) while combining the 
tyrosine-free amino acid mixture with MDMA (AAlMDMA) decreased 
tyrosine levels by 49% compared with MDMA alone (SalIMDMA) (p < 0.001) 
(Figure 5.5C). 
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Two-way ANOV A also revealed that MDMA has an overall effect on tyrosine 
levels in the hippocampus, striatum and frontal cortex (F(I,16) = 6.26, p = 
0.0236; F(I,I6) = 5.56, P = 0.0314 and F(I,16) = 12.13, P = 0.0031 
respectively). Irrespective of whether rats received the tyrosine-free amino acid 
mixture or saline, MDMA caused a similar magnitude increase in CNS tyrosine 
content. Consequently, compared with saline controls (SaVSal) MDMA 
(SaVMDMA) increased tyrosine levels by 16% in the hippocampus, 15% in 
striatum and 11 % in frontal cortex and in the tyrosine-free amino acid mixture 
group administered MDMA (AAlMDMA) it was 42% higher in the 
hippocampus, 43% higher in the striatum and 36% higher in the frontal cortex 
compared with the tyrosine-free amino acid given alone (AA/Sal). 
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Figure 5.5 Effect of the tyrosine-free amino acid mixture given with or without 
MDMA on tyrosine levels (Ilg/mg tissue) in the bippocampus (A), striatum (B) and 
frontal cortex (C). Rats were administered either the tyrosine-free amino acid mixture 
(1 glkg i.p.) or saline (5 mllkg i.p.) twice I h apart and either MDMA (12.5 mg/kg i.p.) 
or saline (1 mglkg i.p.) was given 55 min after the first injection of either the tyrosine-
free amino acid mixture or saline. Brain regions were collected 2 h after MDMA 
administration. Data are presented as mean ± SEM (n = 5 per group) * p < 0.05; *** p 
< 0.0001 Bonferroni post hoc test following 2-way ANOVA (Sal = saline; AA = 
tyrosine-free amino acid mixture) 
177 
CHAPTER 5: Tyrosine depletion 
(b) Acute effects of the tyrosine-free amino acid mixture and MDMA on 5-HT 
and 5-HlAA levels in the hippocampus 
The acute effects of tyrosine depletion and MDMA administration on 
hippocampal 5-HTand 5-HIAA contents were measured 2 h after MDMA 
administration (Figure 5.6). There was a main effect of MDMA on 5-HT 
(F(1,15) = 114.6, P < 0.0001) and 5-HlAA (F(I,16) = 62.91, p < 0.0001) in the 
hippocampus. The magnitude of decrease of hippocampal 5-HT was similar 
irrespective of whether given the tyrosine-free amino acid or not, such that 
MDMA given alone (SallMDMA) decreased hippocampal 5-HT (68%; p < 
0.001) compared with saline-injected controls (SaVSal) (Figure 5.6A). 
Pretreatment with the tyrosine-free amino acid mixture (AAISal) did not alter 
5-HT levels and rats given MDMA with the tyrosine-free amino acid showed a 
5-HT depletion which was similarly reduced by 68% (p < 0.001) compared 
with the tyrosine-free amino acid mixture given alone (AAISal) (Figure S.6A). 
MDMA alone (SallMDMA) also decreased S-HIAA in the hippocampus by 
38% (p < 0.001) compared to saline controls while combining MDMA with the 
tyrosine-free amino acid (AAlMDMA) decreased S-HIAA by SI% compared 
with the tyrosine-free amino acid alone (AAlSal) (p < 0.001) (Figure S.6B). 
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Figure 5.6 Lack of acute effect of tyrosine depletion on 5-HT (A) and 5-HlAA (B) 
levels in the hippocampus 2 h after MDMA administration. Rats were treated with 
either tyrosine-free amino acid mixture (1 glkg i.p.) or saline (5 ml/kg i.p.) twice 1 h 
apart and then received either MDMA (12.5 mglkg i.p.) or saline (I mglkg i.p.) 55 min 
after the ftrst injection of the amino acid mixture or saline. Brain regions were 
collected 2 h after MDMA administration. Data are presented as mean ± M (n = 5 
per group). *** p < 0.001 Bonferroni post hoc test following 2-way AN VA ( a1 = 
saline; AA = tyrosine-free amino acid mixture). 
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(c) Acute effects of the tyrosine-free amino acid mixture and MDMA on 5-HT. 
dopamine and their metabolites in the striatum 
There was an overall effect of MDMA on 5-HT (F(1,16) = 17.43, P = 0.0007) 
and 5-HIAA (F(1,16) = 23.02, P = 0.0002) levels in the striatum. The MDMA-
induced 5-HT decrease in the striatum was smaller than that seen in the 
hippocampus being reduced by 29% (p < 0.05) compared with that in saline 
controls and the decrease was similar in the group given the tyrosine-free 
amino acid mixture with MDMA (ANMDMA) (25%, P < 0.05) compared 
with that in rats given the tyrosine-free amino acid mixture alone (AAlSal) 
(Figure 5.7A). MDMA alone (SallMDMA) did not significantly decrease 
striatal 5-HIAA compared with saline controls (Sal/Sal) while giving MDMA 
with the tyrosine-free amino acid mixture (AAlMDMA) significantly 
decreased 5-HIAA by 25% (p < 0.01) compared with the tyrosine-free amino 
acid mixture given alone (AAISal) (Figure 5.7B). 
Although tyrosine depletion had no effect on striatal5-HT, there was an overall 
effect of the tyrosine-free amino acid mixture on striatal 5-HIAA levels 
(F(1,16) = 6.49, p = 0.021), such that giving the tyrosine-free amino acid 
mixture alone (AAlSal) significantly increased 5-HIAA by 19% (p < 0.05) 
(Figure 5.7B). 
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Figure 5.7 Acute effect of tyrosine depletion on 5-HT (A) and 5-HIAA (B) levels in 
the striatum 2 h after MDMA administration. Rats were treated with either tyrosine-
free amino acid mixture (I glkg i.p.) or saline (5 mllkg i.p.) twice I b apart and then 
received either MDMA (12.5 mglkg i.p.) or saline (1 mglkg i.p.) 55 min after the first 
injection of the amino acid mixture or saline. Brain regions were collected 2 b aft r 
MDMA administration. Data are presented as mean ± SEM (n = 5 per group) * p < 
0.05; ** p < 0.0 I Bonferroni post hoc test following 2-way ANOVA (Sal = saline; AA 
= tyrosine-free amino acid mixture) 
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There was no acute effect of tyrosine-free amino acid mixture on striatal 
dopamine, DOP AC and HV A concentrations and also no effect of MDMA on 
striatal dopamine and HVA contents (2-way ANOVA) (Table 5.1). 
Interestingly there was an overall effect of the tyrosine-free amino acid mixture 
on DOPAC levels in the striatum (F(I,16) = 4.75, P = 0.045). However there 
was no significant difference between any of the groups following the 
Bonferroni post hoc test. 
Table 5.1 Acute effect of tyrosine depletion on dopamine, DOPAC and HV A levels in 
the striatum 2 h after treatment. Data are presented as means of concentration 
(pmol/mg tissue) ± SEM (n = 5 per group). (Sal = saline; AA = tyrosine-free amino 
acid mixture) 
Treatment Dopamine DOPAC· HVA 
Sal/Sal 32.78 ±2.85 5.83 ±0.64 5.22±0.38 
SallMDMA 32.66 ±4.85 4.13 ±0.38 4.96±0.68 
AAlSal 26.56 ±4.l6 4.54±0.66 4.50±0.94 
AAlMDMA 38.67 ± 3.93 3.77 ±0.53 5.38 ±0.38 
• There was an overall effect of the tyrosine-free amino acid mixture on OOPAC 
levels in the striatum (F(1,16) = 4.75, p = 0.045). 
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5.3. Effects of tyrosine depletion on MDMA-induced 5-HT neurotoxicity 
5.3.1 Materials and methods 
Animals 
Male Dark Agouti rats weighing 165-200 g (Harlan-Olac, Bicester, UK) were 
housed on a 12h light/dark cycle (lights on at 07.00 h) and given food and 
water ad libitum. Room temperature (21 ± 2°C) and humidity (45-65%) were 
kept constant. All experiments were performed in accordance with the UK 
Animals (Scientific Procedures) Act, 1986 under project license 40/2715 and 
approval of the local ethical committee. The experimenter was blind to the 
treatment given in all parts of the study. 
Experimental procedure 
A separate set of Dark Agouti rats were divided into 4 groups (n = 6 per group) 
and given one of the four treatments previously described in 5.2.1. On the day 
of treatment, the rectal temperature of all rats was measured in lightly 
restrained rats using a digital thermocouple probe thermometer (Portec 
Instrumentation Ltd, P9005), 30 min after the first injection of the amino acid 
mixture or saline and immediately before the MDMA or saline injection, and 
again at 30, 60, 120 and 180 min after the second injection of the amino acid 
mixture or saline. The room temperature was kept constant at 21-23 °C. Rats 
were killed 14 days later and selected brain regions (hippocampus, striatum and 
frontal cortex) were dissected on a cool tray, snap frozen in liquid nitrogen and 
stored at - 80°C until subsequent neurochemical analysis. 
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Figure 5.8 Treatment (black arrows) and rectal temperature measurement (red arrows) 
time on the treatment day. Either the tyrosine-free amino acid mixture (1 glkg i.p.) or 
saline (5 mllkg i.p.) was given twice I h apart (t = 0 and t = 60) and either MDMA 
(12.5 mg/kg i.p.) or saline (I mIlkg i.p.) was given at t = 55 . Rectal temperature was 
measured at the time indicated by red arrows. 
Statistical analysis 
Statistical analysis of 5-HT, dopamine and their metabolite levels was 
performed using two-way ANOVA, with MDMA and tyrosine-free amino acid 
mixture as main factors followed by Bonferroni post hoc test if required. 
Statistical analysis of rectal temperature was performed using two-way 
ANOV A, with time and treatment as main factors followed by Bonferroni post 
hoc test if required P < 0.05 was considered to be statistically significant. 
184 
CHAPTER 5: Tyrosine depletion 
5.3.2 Results 
(a) Effect of the tyrosine-free amino acid mixture and/or MDMA on rectal 
temperature 
On the treatment day the temporal changes in rectal temperature were 
measured after the first injection of the tyrosine-free amino acid mixture and 
for a further 180 min (see Methods). Two-way ANOVA revealed main effects 
of treatment (F(3, 120) = 29.43, P < 0.0001), time (F(5,120) = 15.12, P < 
0.0001) and a treatment x time interaction (F(15,120) = 6.84, p < 0.0001) on 
rectal temperature. MDMA increased rectal temperature when given either 
with or without the tyrosine-free amino acid mixture while the tyrosine-free 
amino acid mixture alone had no effect on body temperature at any time point 
measured (Figure 5.9). It appears that MDMA given with the tyrosine-free 
amino acid mixture (AAlMDMA) increased body temperature more rapidly 
than when MDMA was given alone (SalIMDMA) as the maximal hyperthermia 
in the tyrosine-free amino acid plus MDMA (ANMDMA)-treated animals 
occurred at 30 min compared with 60 min after MDMA in saline plus MDMA 
(SallMDMA)-treated animals although the absolute peak rectal temperature 
was similar (+ 1.53 °c in ANMDMA and + 1.70 °c in SaVMDMA) (Figure 
5.9). In addition, MDMA given alone caused a more prolonged increase of 
body temperature such that at 180 min after MDMA body temperature in the 
MDMA-treated animals was significantly greater than that in saline controls (p 
< 0.01) while the body temperature of MDMA plus tyrosine-free amino acid 
mixture-treated animals had returned to that observed in its appropriate control 
groups (Figure 5.9). 
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Figure 5.9 Effects of the tyrosine-free amino acid mixture given with or without 
MDMA on rectal temperature (OC, mean ± SEM, n = 6 per group). Rats were treated 
with either tyrosine-free amino acid mixture (1 glkg i.p.) or saline (5 mllkg i.p.) twice 
I h apart and given either MDMA (12.5 mglkg i.p.) or saline (1 mglkg i.p.) 55 min 
after the first injection of the amino acid mixture or saline. Rectal temperature was 
measured 30 min after the first injection of the amino acid mixture or saline and for 
further 180 min (see Methods).Two-way ANOVA revealed main effects of treatment 
(F(3, 120) = 29.43, p < 0.0001), time (F(5,120) = 15.12, p < 0.0001) and a treatment x 
time interaction (F( IS , 120) = 6.84, p < 0.0001) on rectal temperature. At 30 min after 
the first injection of the amino acid mixture, there was a significant difference in rectal 
temperature between ANMDMA group and saline controls (p < 0.05) . MDMA alone 
produced a significant increase in rectal temperature at 30 (p < 0.001), 60 (p < 0.001), 
120 (p < 0.01) and 180 (p < 0.01) min compared with that in saline controls. In 
addition MDMA given with the tyrosine-free amino acid mixture showed a 
significantly different change in rectal temperature from controls at 30 (p < 0.001), 60 
(p < 0.001) and 120 (p < 0.05) min after the second injection of tyrosine-free amino 
acid mixture. 
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(b) Long-term effects of tyrosine depletion and MDMA on MDMA-induced 5-
HT neurotoxicity in the hippocampus 
Two-way ANOV A showed a main effect of MDMA on hippocampal 5-HT 
levels (F(1,19) = 23.58, P = 0.0001) such that 5-HT was reduced by 28% (p < 
0.01) in MDMA treated rats (SaVMDMA) compared with saline controls 
(Sal/Sal) and combined MDMA and tyrosine-free amino acid mixture 
administration (AAlMDMA) decreased 5-HT by 27% (p < 0.01) compared 
with the tyrosine-free amino acid mixture alone (AA/Sal) (Figure 5.10A). 
There were MDMA (F( 1 ,20) = 11.58, P = 0.0028) and MDMA x AA 
interaction effects (F(I,20) = 5.97, p = 0.024) on 5-HIAA levels in the 
hippocampus. MDMA alone (SallMDMA) significantly decreased 5-HIAA 
levels in the hippocampus by 24% (p < 0.01) compared with saline controls 
(Sal/Sal) while pretreatment with tyrosine-free amino acid mixture showed no 
significant difference of 5-HIAA levels in the hippocampus when given either 
with or without MDMA (Figure 5.10B). 
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Figure 5.10 Long-term effect of tyrosine depletion on 5-HT (A) and 5-HIAA (B) 
levels in the hippocampus 2 weeks after MDMA administration. Rats were treated 
with either tyrosine-free amino acid mixture (1 glkg i.p.) or saline (5 ml/kg i.p.) twice 
1 h apart and then received either MDMA (12.5 mglkg i.p.) or saline (1 mglkg i.p.) 55 
mjn after the first injection of the amino acid mixture or saline. Data are presented as 
mean ± SEM (n = 6 per group). ** p < 0.01 Bonferroni po t hoc test following 2-way 
ANOVA (Sal = saline; AA = tyrosine-free amino acid mixture) 
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(c) Long-term effects o/tyrosine depletion and MDMA on 5-HT, dopamine and 
their metabolites in the striatum 
In contrast to long-tenn effect of tyrosine depletion and MDMA in the 
hippocampus, two weeks after MDMA treatment there were no clear long-tenn 
losses of either 5-HT or 5-HIAA irrespective of the drug combination and there 
was no significant difference in the 5-HT and 5-HIAA levels in any treatment 
groups (Table 5.2). In the same brain region there was an MDMA x tyrosine-
free amino acid mixture interaction effect on the dopamine levels in tyrosine-
free amino acid mixture treated group (F(I,19) = 9.28, p = 0.0067). The 
tyrosine-free amino acid mixture MDMA combination (AAlMDMA) 
significantly decreased dopamine (p < 0.05) compared with that in rats either 
given tyrosine-free amino acid alone (ANSal) or MDMA alone (SallMDMA) 
(Figure 5.lIA). Two-way ANOVA also showed an overall effect of tyrosine-
free amino acid mixture treatment on DOPAC (F(1,20) = 8.49; P = 0.0086) and 
HVA (F(I,20) = 8.82; p = 0.0076) levels in the striatum. MDMA with tyrosine-
free amino acid mixture (AAlMDMA) significantly decreased DOPAC and 
HV A levels (p < 0.05) compared with MDMA treatment alone (SalIMDMA) 
(Figure 5.IIB,C). 
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Table 5.2 Lack of long-tenn effect of tyrosine depletion and MDMA on 5-HT and 5-
HIAA levels in the striatum 2 weeks after treatment. Data are presented as means of 
concentration (pmol/mg tissue) ± SEM (n = 6 per group). 
Treatment 5-HT 
Sal/Sal 2.38 ± 0.16 
Sal/MDMA 2.26 ± 0.18 
AAlSal 2.38 ± 0.07 
AAlMDMA 2.72 ± 0.25 
(A) Striatal dopamine levels 
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Figure 5.11 Long-term effect of tyrosine depletion on dopamine (A) DOPAC (B) and 
HVA (C) levels in the hippocampus 2 weeks after MDMA administration. Rats were 
treated with either tyrosine-free amino acid mixture (1 glkg i.p.) or saline (5 ml/kg 
i.p.) twice 1 h apart and then received either MDMA (12.5 mglkg i.p.) or saline (1 
mglkg i.p.) 55 min after the first injection of the amino acid mixture. Data are 
presented as mean ± SEM (n = 6 per group). * p < 0.05 Bonferroni post hoc test 
following 2-way ANOVA (Sal = saline; AA = tyrosine-free amino acid mixture). 
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(d) Long-term effects of tyrosine depletion and MDMA 5-HT and 5-HlAA 
levels in the frontal cortex 
There was no significant effect of either MDMA or tyrosine-free amino acid 
mixture on long-tenn 5-HT and 5-HIAA levels in the frontal cortex (2-way 
ANOVA) (Figure 5.3). However Bonferroni post hoc test following ANOVA 
showed a significant decrease of 5-HIAA levels following MDMA treatment 
(SallMDMA) (p < 0.05) compared with saline controls (SaVSal). 
Table 5.3 Long-tenn effects of tyrosine depletion on 5-HT and 5-HIAA levels in the 
frontal cortex 2 weeks after treatment. Data are presented as means of concentration 
(pmol/mg tissue) ± SEM (n = 6 per group). 
Treatment 5-HT 5-HIAA 
SaVSal 2.S4± 0.27 1.36 ± 0.09 
SallMDMA 2.40 ± 0.25 1.05 ± O.OS* 
AAlSal 2.60± 0.27 1.15 ± 0.09 
AA/MDMA 2.48 ± 0.24 1.13 ± 0.07 
• p < 0.05 compared with Sal/Sal (Bonferroni post hoc test follOwing 2-way ANOV A) 
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5.4. Discussion 
The experiments in this chapter investigated the contribution of tyrosine 
availability to the mechanisms underlying MDMA-induced brain 5-HT 
depletions. For this, brain tyrosine levels were depleted during MDMA 
administration by giving a tyrosine-free amino acid mixture. It was 
demonstrated that acute administration of the tyrosine-free amino acid mixture 
with and without MDMA produced a greater than 50% reduction of tyrosine in 
the hippocampus, striatum and frontal cortex 2 h after MDMA administration, 
confIrming the fmding of others (Biggio et aI., 1976, Fernstrom and Fernstrom, 
1995, McTavish et aI., 1999). Despite acute tyrosine depletion in rats treated 
with a combination of the tyrosine-free amino acid mixture and MDMA, the 
tyrosine-free amino acid mixture did not attenuate MDMA-induced acute 5-HT 
and 5-HIAA loss in the hippocampus and striatum observed 2 h after MDMA 
administration. 
Regardless of the effect of a tyrosine-free amino acid mixture, systemic 
MDMA administration has an overall effect on the brain tyrosine 
concentrations, such that MDMA alone produced a small increase in tyrosine 
levels (11-16 %) compared to saline controls and MDMA given with the 
tyrosine-free amino acid mixture increased the tyrosine levels (36-42 %) 
compared to the tyrosine-free amino acid mixture given alone (see J.2. 2a). 
This observation is consistent with the finding of Breier et al (2006) in that the 
extracellular concentration of tyrosine increased following MDMA 
administration. However Breier et al (2006) administered 4 doses of MDMA 
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(10 mg/kg, 2 h apart) while a single 12.5 mg/kg dose of MDMA was given in 
the present study. The question arises as to the origin of the tyrosine. Breier et 
a1. (2006) suggested a peripheral origin. Recently Gom-AHo et al (2008) also 
reported that MDMA administration increased the serum tyrosine 
concentration which suggests that the rise in the brain may be the consequence 
of a preceding peripheral elevation. 
At the doses given to Sprague Dawley rats, Breier et a1. (2006) produced a 
decrease in 5-HT content of 60% in the hippocampus and 40% in the striatum 1 
week after treatment. In the present study, using Dark Agouti rats and a dose of 
MDMA of 12.5 mg/kg i.p., there was a 28% decrease of 5-HT in the 
hippocampus. In contrast to the finding of Breier et a1. (2006) the present study 
was unable to show that altering tissue free tyrosine influenced the long-term 
(2 weeks) effect ofMDMA in the hippocampus in the present study. The 5-HT 
content in the striatum and frontal cortex however was not decreased following 
MDMA in this study. O'Shea et al (2006) have previously demonstrated that 
the striatum is less sensitive to the long-term effects of MDMA. Surprisingly 
there was no loss in 5-HT and 5-HIAA in the frontal cortex 2 weeks after 
MDMA. 
Although microdiaIysis studies have shown that MDMA administration acutely 
increases dopamine release (Colado et aI., 1999, Mechan et aI., 2002a, 
Shankaran and Gudelsky, 1998), tissue dopamine levels in the striatum are 
generally reported to be either increased or unchanged (Colado and Green, 
1994, Gough et aI., 1991, Logan et aI., 1988, Schmidt et aI., 1987, Schmidt et 
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aI., 1991, Yamamoto and Spanos, 1988) and in the present study no acute 
change of dopamine and its metabolites in the striatum was seen 2 h after 
MDMA. Acute tyrosine depletion also had no effect on striatal dopamine, 
DOPAC and HV A levels 2 h after the second injection of the tyrosine-free 
amino acid mixture, in agreement with previous studies showing that a 
tyrosine-free amino acid mixture failed to alter basal dopamine levels even 
though it attenuated amphetamine- and haloperidol-induced dopamine release 
(Jaskiw and Bongiovanni, 2004, McTavish et aI., 1999). In addition the present 
study conftrmed previous studies which have shown that MDMA alone does 
not produce long-term dopaminergic neurotoxicity in rats (Battaglia et aI., 
1987, Colado et aI., 1997, Colado et aI., 1999b). Administration of the 
tyrosine-free amino acid mixture together with MDMA however did produce a 
long-term decrease in striatal dopamine and its metabolites, an observation that 
needs further investigation and there is no explanation for this change at 
present. 
What was altered by administration of the tyrosine-free amino acid mixture 
was the MDMA-induced hyperthermic response. While the peak temperature 
rise was comparable, the duration of the elevated rectal temperature was 
attenuated. Interestingly GoDi-AIlo et al (2008) noted a modest enhancement of 
the MDMA-induced hyperthermic response when they pretreated rats with 
tyrosine. Together these observations suggest that increased cerebral tyrosine 
can enhance the MDMA-induced temperature response while tyrosine 
depletion can attenuate the hyperthermia duration. The mechanisms involved in 
this interaction are unclear at present. However the study of Mechan et al 
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(2002a) indicated that the hyperthennic effect of MDMA in animals kept at 
nonnal ambient room temperature was primarily the result of dopamine release 
and subsequent dopamine DJ receptor activation. Since the tyrosine-free amino 
acid mixture has previously been shown to decrease amphetamine-induced 
dopamine release (McTavish et aI., 1999) one might expect it to have the same 
effect on dopamine release induced by the substituted amphetamine, MDMA, 
thereby attenuating the temperature response. The modest attenuation of 
MDMA-induced hyperthennia seen in the current study therefore supports the 
notion that dopamine is associated with MDMA-induced hyperthennia. 
In conclusion, this study shows that reducing brain tyrosine levels during 
MDMA administration does not have an indirect effect on either MDMA-
induced immediate or long-tenn 5-HT loss. However the study does support 
the observation that MDMA increases the cerebral free tyrosine concentration 
and the proposal that dopamine is involved in MDMA-induced hyperthennia. 
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CHAPTER 6: General discussion 
6.1 Introduction 
The principle aim of this thesis was to detennine the acute and long-tenn 
functional and phannacological effects of single and 'binge type' repeated 
administration of low doses of MDMA in rats. The work focused on the effects 
of MDMA on memory and the possible association between 5-HT and these 
effects of MDMA. 
The main findings of this thesis were as follows: 
1. Single administration of a low dose of MDMA (3 mglkg) produced an acute 
disruption of novel object discrimination indicating an acute impairment of 
recognition as well as working memory following MDMA (Chapter 2). 
2. 'Binge type' repeated administration of low doses of MDMA increased 
locomotor activity (3 x 6 mglkg), impaired thennoregulation (3 x 6 mglkg) and 
increased 5-HT release in the hippocampus (3 x 3 mglkg and 3 x 6 mglkg) 
(Chapter 3). 
3. The acute disruption of novel object discrimination following a single low 
dose MDMA administration (3 mglkg) was associated with 5-HT release in the 
hippocampus (Chapter 2 and 3). 
4. 'Binge type' repeated low dose MDMA administration produced long-term 
impairment of novel object discrimination indicating a long-term effect of 
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MDMA on recognition and working memory (Chapter 4). This long-term 
effect of MDMA is consistent with several studies in humans which report 
long-term recognition and working memory impairments in MDMA users. 
However the present study found no long-term effect of repeated low dose 
MDMA administration on 5-HT levels in the hippocampus, frontal cortex or 
striatum indicating 5-HT loss did not contribute to MDMA-induced memory 
impairment (Chapter 4). 
5. MDMA increased brain tyrosine levels. However depletion of brain tyrosine, 
by giving a tyrosine-free amino acid mixture both before and after MDMA 
administration, did not protect against MDMA-induced immediate and long-
term loss of 5-HT suggesting there was no involvement of tyrosine in MDMA-
induced 5-HT neurotoxicity (Chapter 5). In addition the tyrosine-free amino 
acid mixture reduced onset and duration of MDMA-induced hyperthermia 
suggesting a possible association between dopamine and the hyperthermic 
response following MDMA. 
Overall the results of the present study provide extensive evidence showing 
that low doses of MDMA can produce both acute and long-term memory 
impairments and these effects of MDMA do not correlate with changes in brain 
5-HT. Three main topics will be discussed in this chapter. The fllSt is how 
effectively data obtained from animal studies can be interpreted in terms of 
potential effects in humans. Secondly what is the evidence for 5-HT 
neurotoxicity following low doses MDMA administration and finally what are 
the possible mechanisms underlying MDMA-induced memory impairments. 
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6.2 The interpretation of animal data to humans 
The study of functional and pharmacological effects of MDMA in this thesis 
attempted to relate the findings in rats to the possible consequences of MDMA 
use in humans therefore low doses and 'binge type' repeated administration of 
MDMA were applied. Green et al (2009) reviewed the pharmacokinetics of 
MDMA in rats and humans and produced MDMA dose-plasma concentration 
response curve for rats and humans and therefore suggested that "a fourfold 
higher dose is required in rats to produce a similar peak blood plasma exposure 
to that seen in human" (Green et aI., 2009). Thus, doses of MDMA used in this 
thesis, 1,3 and 6 mglkg are equivalent to 0.25, 0.75 and 1.5 mglkg in humans 
respectively which are in the range of doses used by humans (0.75-4 mglkg) 
(Morgan, 2000). 'Binge' use ofMDMA has been described recently as MDMA 
users reportedly taking on average 2-3 tablets during a single session (Parrott, 
2005, Soar et aI., 2006, Winstock et aI., 2001). The experiments in this thesis 
used a dose regime of 3 injections of low dose MDMA every 2 h to imitate 
binge use in humans. Thus in tenns of the doses and dosage regimen used in 
this thesis, every effort was made to use conditions in the rat that closely 
resemble use in humans. 
The review by Green et at (2009) however did not detail other pharmacokinetic 
factors including route of administration, plasma protein binding and especially 
metabolism of MDMA. The differences in the MDMA metabolic pathways 
between rats and humans have been a concern as a limitation in the translation 
of animal data to humans as toxic metabolites rather than MDMA itself 
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produce neurotoxicity (Escobedo et aI., 2005, Esteban et aI., 2001). Although 
the metabolites of MDMA in rats and humans are qualitatively similar, the 
major metabolic pathways are different. In rats MDMA is mainly N-
demethylated to MDA (3,4-methylenedioxyamphetamine) whereas MDMA is 
mainly metabolized to HHMA (3,4-dihydroxymethamphetamine) via 0-
demethylation in humans (De la Torre and Farre, 2004). Moreover human 
MDMA metabolism shows non-linear pharmacokinetics as MDMA acts as a 
CYP 2D6, an enzyme important in MDMA metabolism, inhibitor and 
consequently decreases MDMA metabolism (Delaforge et aI., 1999, Farre et 
aI., 2004) while there was no enzyme inhibition in rats (Capela et aI., 2009, De 
la Torre and Farre, 2004). Therefore repeated administration of MDMA to rats 
might produce different effects from binge MDMA ingestion in humans. The 
influence of metabolism of MDMA on 'hinge' use of MDMA needs further 
investigation. 
6.3 Does low dose MDMA administration produce long-term 5-HT 
neurotoxicity? 
Lack of evidence for MDMA-induced 5-HT neurotoxicity in rats following 
repeated low doses of MDMA administration (3 and 6 mglkg i.p. 3 injections 
every 2 h) was presented in this thesis. The dosage regimen used in this thesis 
represents 'binge' use in a single occasion and the results indicate no long-term 
effect of this dosage regimen of MDMA on brain 5-HT in rats. There have 
been a few studies on long-term 5-HT neurotoxicity following repeated low 
doses MDMA administration. Studies by Baumann et al (2007, 2008b) using a 
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similar dosage regimen showed that the lower dose of MDMA (1.5 mg/kg i.p. 
3 injections every 2 h) did not produce a long-term effect on 5-HT levels while 
the higher dose of MDMA (7.5 mg/kg i.p. 3 injections every 2 h) decreased 5-
HT levels by -50% in the frontal cortex, striatum, olfactory tubercle, nucleus 
accumbens and hypothalamus of the rats. A more intensive dosage regimen to 
rats (MDMA 5 mg/kg 4 injections for 2 days) decreased 5-HT in the prefrontal 
cortex, striatum, hippocampus and amygdala 20 weeks after treatment 
(McGregor et aI., 2003). Similarly MDMA (4 mg/kg x 2 for 4 days) decreased 
5-HT levels and eH]paroxetine binding to presynaptic 5-HT terminals 7 days 
after treatment in rat cortex, hippocampus and striatum (O'Shea et aI., 1998). 
Finally a study by Kindlundh-Hogberg et al (2007), using 'binge' dosage 
regimen on several occasions (MDMA 3x 5 mg/kg every 3 h once a week for 4 
weeks), showed a decrease of SERT density in the rat nucleus accumbens. 
Taken together, there is evidence for MDMA-induced 5-HT neurotoxicity 
following binge low doses of MDMA especially when using more intensive 
regimens or on repeated occasions. These results indicate that the frequency 
and duration of dosing influence the effects of MDMA on 5-HT neurotoxicity. 
The influence of the amounts of MDMA used on 5-HT neurotoxicity have also 
been reported in humans as there was a decrease of SERT binding in heavy 
MDMA users while normal SERT binding was found in moderate MDMA 
users (see reviews Cowan, 2007, de Win et aI., 2004, Reneman et al., 2001a, 
200Ib). In summary it is likely that there is no long-term S-HT neurotoxicity 
following low dose MDMA administration to rats and possibly in mild MDMA 
human users. 
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6.4 Mechanisms for memory impairments produced by MDMA 
This thesis showed no contribution of 5-HT on the MDMA-produced long-
tenn memory impainnents following repeated low dose administration (binge). 
Although 5-HT appears to play important roles in learning and memory, 
several neurotransmitter systems have been implicated in the memory process 
including dopamine, acetylcholine and glutamate (see review Riedel et a1., 
2003, Vakalopoulos, 2006). Therefore changes in 5-HT might not be the only 
explanation for MDMA-induced memory impainnents. 
Recently adult neurogenesis in hippocampal dentate gyrus has been one of the 
factors linked with learning and memory (see review Suzuki and Clayton, 
2000). Bruel-Jungennan et al (2005) showed that an increase in the number of 
adult-generated neurons in rat dentate gyrus contributed to improvement of 
long-tenn recognition memory using the novel object recognition task. 
Stimulants such as cocaine and methamphetamine were shown to reduce cell 
proliferation in the hippocampal dentate gyrus (Teuchert-Noodt et aI., 2000, 
Yamaguchi et a1., 2004, Dominguez-Escriba et aI., 2006). Similarly 
Hemandez-Rabaza et aI (2006) demonstrated that binge MDMA administration 
(5 mg/kg i.p. 8 injections every 6 h) has deleterious effects on adult 
neurogenesis by impairing the survival of newly generated neurons in the 
dentate gyrus while there was no effect on cell proliferation. In addition 
chronic MDMA administration (1.25, 5, 20 or 40 mglkg p.o. for 30 days) to 
C57BU6 mice decreased cell proliferation (Cho et aI., 2007). Recently Cho et 
al (2008) showed a decrease of cell proliferation and survival in adult mouse 
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dentate gyrus following exposure to MDMA during early development. 
Therefore a decrease in adult neurogenesis following MDMA may possibly 
influence the memory impairments produced by MDMA. In addition 5-HT is 
one of the factors involved in the regulation of adult hippocampal neurogenesis 
(Brezun and Daszuta, 1999, Djavadian, 2004, Malberg et aI., 2000). It is likely 
that an indirect effect of an MDMA-induced decrease in 5-HT is to decrease 
neurogenesis and thus might be implicated in the mechanism of memory 
impairments produced by MDMA. 
6.S Summary 
MDMA use has increased dramatically and more intensive patterns of use such 
as binging have become general. MDMA is thought by some to be a safe drug 
(Nutt, 2009) and there are several studies showing no 5-HT neurotoxicity 
following mild or moderate use. In addition loss of 5-HT is reversed following 
long term abstinence in rats and humans. However the psychological 
consequences of MDMA use have been intensively reported especially the 
impairments of memory and learning abilities which persist in MDMA users. 
Although specific studies in humans are limited due to several factors 
including ethical issues concerning drug administration, history of drug use and 
polydrug use, studies in animals have demonstrated learning and memory 
impairments caused by MDMA. The translation of these preclinical data to 
humans is a problem due to issues raised by irrelevant dose administration and 
dosage regimens between animal and human studies. The results from this 
thesis provide strong evidence for acute and long-term. memory impairments 
204 
CHAPTER 6: General discussion 
caused by low dose MDMA administration in rats and that these effects may 
translate effectively to human conditions. Consistent with studies in humans, 
low dose MDMA administration appears to have no long-term effect on brain 
5-HT in the rat indicating no contribution of 5-HT to MDMA-induced memory 
impainnents obsetved with these low dose regimens. Therefore it is important 
to focus on factors other than 5-HT when studying the mechanism involved in 
MDMA-induced memory impainnents for example to determine whether the 
memory impairment involves the attenuation of neurogenesis by MDMA. 
Further studies also need to address the effect of MDMA metabolism, which 
differs between rat and human, on the 'binge' effects ofMDMA. 
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APPENDIX I 
Solution preparation for analysis of brain tissue amines 
(A) Mobile Phase (SOO ml) 
0.1 mM EOTA 
0.16 mM Sodium octanylsulfonate 
13.5 % v/v Methanol 
3.4023 g 
0.0186 g 
0.0173 g 
67.5 ml 
Made up to 500 ml by HPLC grade water and adjust pH to 3.0 with 0-
phosphoric acid 
(B) Perchloric acid (PCA) stock solution (1 M) (2S0 mI) 
0.2 % w/v Sodium metabisulfite 0.5 g 
1 % w/v EOTA 0.25 g 
PCA(60%) 21.6 ml 
Made up to 250 ml by HPLC grade water 
(e) Amines standard stock solution (10-1 M) 
Dopamine 
OOPAC 
HVA 
S-HT 
5-HIAA 
0.0095 g/5 ml 
0.0084 g/Sml 
0.0091 g/S ml 
0.0194 g/5 ml 
0.0096 g/S ml 
Aliquot 100 JoLl into 1.5 ml eppendorf tubes and keep in - 80°C freezer 
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APPENDIX II 
Mobile phase for analysis of S-HT in microdialysis samples 
All chemicals used in HPLC analysis were of HPLC grade. pH was adjusted to 
3.0 with a-phosphoric acid. The mobile phase was filtered with 45 mM 
millipore flask filter and sonicated for 15 min before using. 
Table AI Chemical compositions of the mobile phase for HPLC 
Compounds Concentration gIlitre 
KH2P04 0.05M 6.8046 
EDTA O.lmM 0.0372 
Sodium octanylsulfonate 120 mgIL 0.120 
KCI 8mM 0.5964 
Methanol 15% 150ml 
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APPENDIX III 
Artificial cerebrospinal Fluid Solution (aCSF) 
All chemicals, except CaCho were dissolved together with distilled millipore 
water. CaCh was separately dissolved in distilled water before added to the 
aCSF solution. pH was adjusted to 7.4 with o-phosphoric acid. aCSF solution 
was filtered twice with 45 mM millipore flask filter and sonicated for 15 min 
before using. 
Table All Chemical compositions of the aCSF for in vivo microdialysis 
Compounds Concentration (mM) g/litre 
NaCI 125 7.30 
NaHC03 27.0 2.268 
KCI 2.5 0.186 
NaH2P04 0.5 0.069 
Na2HP04 1.2 0.32 
NaS04 0.5 0.072 
MgCh 1.0 0.204 
CaCh.2H2O 1.0 0.148 
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APPENDIX IV 
Solution preparations for analysis of brain tissue tyrosine 
For the measurement of tyrosine, HPLC with pre-column derivatisation 
coupled with electrochemical detection (ECD) was utilized. The HPLC-ECD 
method was modified from Bongiovanni et al (2001). 
(A) Mobile phase 
All chemicals used in HPLC analysis were of HPLC grade. pH was adjusted to 
6.8 with o-phosphoric acid. The mobile phase was filtered with 45 mM 
millipore flask filter and sonicated for 15 min before using. 
Table AlII Chemical compositions of the mobile phase for HPLC 
Compounds Concentration gIlitre 
Na2HP04 0.133 M 47.6326 
EDTA 0.15 mM 0.0558 
Methanol 20% 200ml 
250 
Appendix 
(B) Tyrosine stock solution (1 mg/ml) 
1. Weighing Tyrosine HCI (Sigma) 10 mg into a 10-ml amber 
volumetric flask 
2. Add 9.5 ml of diluent (H20: MeOH 75:50 v/v) and 0.5 ml of 30% 
w/v NaOH (3 mg NaOH + 10 ml H20) to make to-ml of 1 mg/ml tyrosine 
stock solution 
3. Aliquot 50 III of the tyrosine stock solution into 0.5 ml amber 
eppendorf tube and keep in -80°C freezer 
(C) Derivatising agent (OPA-S) 
1. Weighing o-phthaldehyde (OPA) 10 mg and 30 mg sodium sulfite 
into 50-ml volumetric flask 
2. Add 0.25 ml water (HPLC grade) and 0.25 ml Methanol 
3. Vortex-mixed 
4. Add 4.5 ml Sodium borate buffer (0.4 M Boric acid pH 10.4 with 6 
MNaOH) 
0.4 M Boric acid (H3B03 , MW 61.83) 
Boric acid 2.4732 gin 100 ml H20 
6 M NaOH (MW 40) 
NaOH 2.4 g in 10 ml H20 
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(D) Perchloric acid (0.1 M) containing 1.0 f.1g1ml norvaline 
1. Make 1 M PCA by 
60% Perchloric acid (PCA) 21.6 ml in HPLC grade water made up to 250 ml 
2. Dilute 1 M PCA to 0.1 M PCA 
3. Make 100 Ilglml norvaline in 0.1 M PCA by 
11 mg norvaline + 10 ml of 0.1 M PCA 
4. Dilute 100 Ilglml norvaline to I Ilglml norvaline using 0.1 M PCA 
(E) Tissue sample preparation 
I. Weighing brain tissue into 5-ml plastic tube 
2. Add 1 ml of ice-cold 0.1 M PCA containing 1 Ilglml norvaline 
3. Sonicate 20-30 s 
4. Centrifuge at 16000 g 4°C 4 min 
5. Keep supernatant in -80°C for later analysis 
(F) Derivatisation 
1. Pipette 100 III of sample or standard into the 1.5-ml eppebdorf 
centrifuge tube 
2. Add 100 III derivatising agent (OPA-S) and 100 J.ll sodium borate 
buffer 
3. Sample or standard react to OPA-S for 5 min at room temperature 
4. Made the reaction samples or standard up to 1 ml with mobile phase 
and injected 20 Jll onto column 
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